US20230250062A9 - Substituted Heterocyclyl Derivatives as CDK Inhibitors - Google Patents
Substituted Heterocyclyl Derivatives as CDK Inhibitors Download PDFInfo
- Publication number
- US20230250062A9 US20230250062A9 US17/496,452 US202117496452A US2023250062A9 US 20230250062 A9 US20230250062 A9 US 20230250062A9 US 202117496452 A US202117496452 A US 202117496452A US 2023250062 A9 US2023250062 A9 US 2023250062A9
- Authority
- US
- United States
- Prior art keywords
- amino
- pyrazol
- cyclopropyl
- oxopropan
- enamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000623 heterocyclic group Chemical group 0.000 title claims abstract description 23
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 title abstract description 5
- 150000001875 compounds Chemical class 0.000 claims abstract description 217
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 53
- 230000002103 transcriptional effect Effects 0.000 claims abstract description 35
- 108091007914 CDKs Proteins 0.000 claims abstract description 31
- 150000003839 salts Chemical class 0.000 claims abstract description 22
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 166
- 125000000217 alkyl group Chemical group 0.000 claims description 92
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 61
- 229910052739 hydrogen Inorganic materials 0.000 claims description 54
- 239000001257 hydrogen Substances 0.000 claims description 54
- 238000000034 method Methods 0.000 claims description 54
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 51
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 50
- 229910001868 water Inorganic materials 0.000 claims description 46
- 125000003545 alkoxy group Chemical group 0.000 claims description 36
- NQQRXZOPZBKCNF-NSCUHMNNSA-N (e)-but-2-enamide Chemical compound C\C=C\C(N)=O NQQRXZOPZBKCNF-NSCUHMNNSA-N 0.000 claims description 32
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 32
- 201000010099 disease Diseases 0.000 claims description 32
- 125000005843 halogen group Chemical group 0.000 claims description 32
- 230000008569 process Effects 0.000 claims description 26
- 125000003118 aryl group Chemical group 0.000 claims description 25
- 239000002904 solvent Substances 0.000 claims description 25
- -1 (E)-4-((5-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2- yl)phenyl)pyridin-2-yl)amino)-4-oxobut-2-en-1-yl Chemical group 0.000 claims description 24
- 125000001188 haloalkyl group Chemical group 0.000 claims description 24
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 claims description 23
- ZMANZCXQSJIPKH-UHFFFAOYSA-N N,N-Diethylethanamine Substances CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 22
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 22
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 claims description 22
- 229910052701 rubidium Inorganic materials 0.000 claims description 22
- 206010028980 Neoplasm Diseases 0.000 claims description 20
- 229910052757 nitrogen Inorganic materials 0.000 claims description 20
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 19
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 18
- 125000001072 heteroaryl group Chemical group 0.000 claims description 18
- 125000005842 heteroatom Chemical group 0.000 claims description 17
- 229910052717 sulfur Inorganic materials 0.000 claims description 17
- 210000004027 cell Anatomy 0.000 claims description 16
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 16
- 229910052760 oxygen Inorganic materials 0.000 claims description 16
- SNRCKKQHDUIRIY-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloromethane;dichloropalladium;iron(2+) Chemical compound [Fe+2].ClCCl.Cl[Pd]Cl.C1=C[CH-]C(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.C1=C[CH-]C(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 SNRCKKQHDUIRIY-UHFFFAOYSA-L 0.000 claims description 15
- 229910003827 NRaRb Inorganic materials 0.000 claims description 14
- 229910000024 caesium carbonate Inorganic materials 0.000 claims description 13
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 claims description 13
- ZNHSMYOYLFQLTL-ZZXKWVIFSA-N (E)-N-[5-[3-[1-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-1-oxopropan-2-yl]phenyl]pyridin-2-yl]-4-morpholin-4-ylbut-2-enamide Chemical compound C1(CC1)C1=CC(=NN1)NC(C(C)C=1C=C(C=CC=1)C=1C=CC(=NC=1)NC(\C=C\CN1CCOCC1)=O)=O ZNHSMYOYLFQLTL-ZZXKWVIFSA-N 0.000 claims description 12
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 12
- 125000001424 substituent group Chemical group 0.000 claims description 12
- 229910052799 carbon Inorganic materials 0.000 claims description 11
- 230000003197 catalytic effect Effects 0.000 claims description 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 11
- 125000006413 ring segment Chemical group 0.000 claims description 11
- IPWKHHSGDUIRAH-UHFFFAOYSA-N bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 claims description 10
- MXUFWRPGQWGALR-VMPITWQZSA-N (E)-N-[4-[3-[1-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-1-oxopropan-2-yl]phenyl]phenyl]-4-(dimethylamino)but-2-enamide Chemical compound C1(CC1)C1=CC(=NN1)NC(C(C)C=1C=C(C=CC=1)C1=CC=C(C=C1)NC(\C=C\CN(C)C)=O)=O MXUFWRPGQWGALR-VMPITWQZSA-N 0.000 claims description 9
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 9
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 9
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 9
- 201000011510 cancer Diseases 0.000 claims description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 8
- YNHIGQDRGKUECZ-UHFFFAOYSA-L PdCl2(PPh3)2 Substances [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 claims description 7
- 125000002252 acyl group Chemical group 0.000 claims description 7
- 125000004966 cyanoalkyl group Chemical group 0.000 claims description 7
- 230000001404 mediated effect Effects 0.000 claims description 7
- YQOLEILXOBUDMU-KRWDZBQOSA-N (4R)-5-[(6-bromo-3-methyl-2-pyrrolidin-1-ylquinoline-4-carbonyl)amino]-4-(2-chlorophenyl)pentanoic acid Chemical compound CC1=C(C2=C(C=CC(=C2)Br)N=C1N3CCCC3)C(=O)NC[C@H](CCC(=O)O)C4=CC=CC=C4Cl YQOLEILXOBUDMU-KRWDZBQOSA-N 0.000 claims description 6
- FTHWKDSNIHXRKG-VMPITWQZSA-N (E)-N-[5-[3-[1-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-1-oxopropan-2-yl]phenyl]pyridin-2-yl]-4-pyrrolidin-1-ylbut-2-enamide Chemical compound C1(CC1)C1=CC(=NN1)NC(C(C)C=1C=C(C=CC=1)C=1C=CC(=NC=1)NC(\C=C\CN1CCCC1)=O)=O FTHWKDSNIHXRKG-VMPITWQZSA-N 0.000 claims description 6
- DEVSOMFAQLZNKR-RJRFIUFISA-N (z)-3-[3-[3,5-bis(trifluoromethyl)phenyl]-1,2,4-triazol-1-yl]-n'-pyrazin-2-ylprop-2-enehydrazide Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(C2=NN(\C=C/C(=O)NNC=3N=CC=NC=3)C=N2)=C1 DEVSOMFAQLZNKR-RJRFIUFISA-N 0.000 claims description 6
- PXIACUPZCJZCBF-UHFFFAOYSA-N N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-[3-[6-(prop-2-enoylamino)pyridin-3-yl]phenyl]propanamide Chemical compound C1(CC1)C1=CC(=NN1)NC(C(C)C=1C=C(C=CC=1)C=1C=CC(=NC=1)NC(C=C)=O)=O PXIACUPZCJZCBF-UHFFFAOYSA-N 0.000 claims description 6
- SPXSEZMVRJLHQG-XMMPIXPASA-N [(2R)-1-[[4-[(3-phenylmethoxyphenoxy)methyl]phenyl]methyl]pyrrolidin-2-yl]methanol Chemical compound C(C1=CC=CC=C1)OC=1C=C(OCC2=CC=C(CN3[C@H](CCC3)CO)C=C2)C=CC=1 SPXSEZMVRJLHQG-XMMPIXPASA-N 0.000 claims description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 6
- 229940125904 compound 1 Drugs 0.000 claims description 6
- 229940125810 compound 20 Drugs 0.000 claims description 6
- 108010041382 compound 20 Proteins 0.000 claims description 6
- 229940125844 compound 46 Drugs 0.000 claims description 6
- 229940127271 compound 49 Drugs 0.000 claims description 6
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 6
- 206010025323 Lymphomas Diseases 0.000 claims description 5
- 229940125773 compound 10 Drugs 0.000 claims description 5
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 claims description 5
- 125000002950 monocyclic group Chemical group 0.000 claims description 5
- 235000011056 potassium acetate Nutrition 0.000 claims description 5
- YQDHRHYFLKUTQX-UHFFFAOYSA-N tert-butyl 3-amino-5-cyclopropylpyrazole-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1N=C(N)C=C1C1CC1 YQDHRHYFLKUTQX-UHFFFAOYSA-N 0.000 claims description 5
- KPJHJQSGMGJQHF-KPKJPENVSA-N (E)-4-(dimethylamino)-N-[4-[3-[1-(1H-indazol-3-ylamino)-1-oxopropan-2-yl]phenyl]phenyl]but-2-enamide Chemical compound N1N=C(C2=CC=CC=C12)NC(C(C)C=1C=C(C=CC=1)C1=CC=C(C=C1)NC(\C=C\CN(C)C)=O)=O KPJHJQSGMGJQHF-KPKJPENVSA-N 0.000 claims description 4
- JLSUNTPGMCLMPI-OWOJBTEDSA-N (E)-N-(5-bromopyridin-2-yl)-4-morpholin-4-ylbut-2-enamide Chemical compound BrC=1C=CC(=NC=1)NC(\C=C\CN1CCOCC1)=O JLSUNTPGMCLMPI-OWOJBTEDSA-N 0.000 claims description 4
- ZNHSMYOYLFQLTL-NAASZUNDSA-N (E)-N-[5-[3-[(2S)-1-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-1-oxopropan-2-yl]phenyl]pyridin-2-yl]-4-morpholin-4-ylbut-2-enamide Chemical compound C1(CC1)C1=CC(=NN1)NC([C@@H](C)C=1C=C(C=CC=1)C=1C=CC(=NC=1)NC(\C=C\CN1CCOCC1)=O)=O ZNHSMYOYLFQLTL-NAASZUNDSA-N 0.000 claims description 4
- HLJDDFGBLSZCEP-VMPITWQZSA-N (E)-N-[6-[3-[1-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-1-oxopropan-2-yl]phenyl]pyrazin-2-yl]-4-pyrrolidin-1-ylbut-2-enamide Chemical compound C1(CC1)C1=CC(=NN1)NC(C(C)C=1C=C(C=CC=1)C1=CN=CC(=N1)NC(\C=C\CN1CCCC1)=O)=O HLJDDFGBLSZCEP-VMPITWQZSA-N 0.000 claims description 4
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 claims description 4
- RTFSYHAIVUXTEI-IZZDOVSWSA-N 4-[[(E)-4-(dimethylamino)but-2-enoyl]amino]-N-[3-(1H-indazol-3-ylamino)phenyl]benzamide Chemical compound N1N=C(C2=CC=CC=C12)NC=1C=C(C=CC=1)NC(C1=CC=C(C=C1)NC(\C=C\CN(C)C)=O)=O RTFSYHAIVUXTEI-IZZDOVSWSA-N 0.000 claims description 4
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 4
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 4
- ITWZGLISPPKPSI-UHFFFAOYSA-N N-(1H-indazol-3-yl)-2-[3-[4-(prop-2-enoylamino)phenyl]phenyl]propanamide Chemical compound N1N=C(C2=CC=CC=C12)NC(C(C)C=1C=C(C=CC=1)C1=CC=C(C=C1)NC(C=C)=O)=O ITWZGLISPPKPSI-UHFFFAOYSA-N 0.000 claims description 4
- KAPLPYXIOOIIAU-QPJJXVBHSA-N N-(5-cyclopropyl-1H-pyrazol-3-yl)-1-[3-[6-[[(E)-4-pyrrolidin-1-ylbut-2-enoyl]amino]pyridin-3-yl]phenyl]cyclopropane-1-carboxamide Chemical compound C1(CC1)C1=CC(=NN1)NC(=O)C1(CC1)C1=CC(=CC=C1)C=1C=NC(=CC=1)NC(\C=C\CN1CCCC1)=O KAPLPYXIOOIIAU-QPJJXVBHSA-N 0.000 claims description 4
- IYGKACUPABBHDX-VMPITWQZSA-N N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-[3-[1-[(E)-4-(dimethylamino)but-2-enoyl]-3,6-dihydro-2H-pyridin-4-yl]phenyl]propanamide Chemical compound C1(CC1)C1=CC(=NN1)NC(C(C)C1=CC(=CC=C1)C=1CCN(CC=1)C(\C=C\CN(C)C)=O)=O IYGKACUPABBHDX-VMPITWQZSA-N 0.000 claims description 4
- JDYQFGCWGWMKSX-VMPITWQZSA-N N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-[3-[1-[(E)-4-(dimethylamino)but-2-enoyl]piperidin-4-yl]phenyl]propanamide Chemical compound C1(CC1)C1=CC(=NN1)NC(C(C)C1=CC(=CC=C1)C1CCN(CC1)C(\C=C\CN(C)C)=O)=O JDYQFGCWGWMKSX-VMPITWQZSA-N 0.000 claims description 4
- XOXUBALWXREHEV-RMKNXTFCSA-N N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-methyl-2-[3-[6-[[(E)-4-pyrrolidin-1-ylbut-2-enoyl]amino]pyridin-3-yl]phenyl]propanamide Chemical compound C1(CC1)C1=CC(=NN1)NC(C(C)(C)C=1C=C(C=CC=1)C=1C=CC(=NC=1)NC(\C=C\CN1CCCC1)=O)=O XOXUBALWXREHEV-RMKNXTFCSA-N 0.000 claims description 4
- CVAXNGIXLUILFO-QPJJXVBHSA-N N-(5-cyclopropyl-1H-pyrazol-3-yl)-3-methyl-2-[3-[6-[[(E)-4-morpholin-4-ylbut-2-enoyl]amino]pyridin-3-yl]phenyl]butanamide Chemical compound C1(CC1)C1=CC(=NN1)NC(C(C(C)C)C=1C=C(C=CC=1)C=1C=CC(=NC=1)NC(\C=C\CN1CCOCC1)=O)=O CVAXNGIXLUILFO-QPJJXVBHSA-N 0.000 claims description 4
- NCJFRNDCMJMAFJ-UHFFFAOYSA-N N-[3-[(5-ethyl-1H-pyrazol-3-yl)amino]phenyl]-4-(prop-2-enoylamino)benzamide Chemical compound C(C=C)(=O)NC1=CC=C(C(=O)NC2=CC(=CC=C2)NC2=NNC(=C2)CC)C=C1 NCJFRNDCMJMAFJ-UHFFFAOYSA-N 0.000 claims description 4
- UADWXWRNCKWWNR-UHFFFAOYSA-N N-[4-[3-[2-[(5-methyl-1H-pyrazol-3-yl)amino]-2-oxoethyl]phenyl]phenyl]prop-2-enamide Chemical compound CC1=CC(=NN1)NC(CC=1C=C(C=CC=1)C1=CC=C(C=C1)NC(C=C)=O)=O UADWXWRNCKWWNR-UHFFFAOYSA-N 0.000 claims description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 4
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 4
- 201000005787 hematologic cancer Diseases 0.000 claims description 4
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 4
- 210000001685 thyroid gland Anatomy 0.000 claims description 4
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 claims description 3
- 229910002666 PdCl2 Inorganic materials 0.000 claims description 3
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 3
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 claims description 3
- AMJGJBCDROPOGP-ZZXKWVIFSA-N (E)-4-(3-cyanopyrrolidin-1-yl)-N-[5-[3-[1-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-1-oxopropan-2-yl]phenyl]pyridin-2-yl]but-2-enamide Chemical compound C(#N)C1CN(CC1)C/C=C/C(=O)NC1=NC=C(C=C1)C1=CC(=CC=C1)C(C(=O)NC1=NNC(=C1)C1CC1)C AMJGJBCDROPOGP-ZZXKWVIFSA-N 0.000 claims description 2
- XLFLDHATWQIKPP-JXMROGBWSA-N (E)-4-(dimethylamino)-N-[4-[3-[1-[(5-ethyl-1H-pyrazol-3-yl)amino]-1-oxopropan-2-yl]phenyl]phenyl]but-2-enamide Chemical compound CN(C/C=C/C(=O)NC1=CC=C(C=C1)C1=CC(=CC=C1)C(C(=O)NC1=NNC(=C1)CC)C)C XLFLDHATWQIKPP-JXMROGBWSA-N 0.000 claims description 2
- JKRQEZUHCSFNMK-VMPITWQZSA-N (E)-4-[[6-[3-[1-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-1-oxopropan-2-yl]phenyl]pyridin-3-yl]amino]-N,N-dimethylbut-2-enamide Chemical compound C1(CC1)C1=CC(=NN1)NC(C(C)C=1C=C(C=CC=1)C1=CC=C(C=N1)NC/C=C/C(=O)N(C)C)=O JKRQEZUHCSFNMK-VMPITWQZSA-N 0.000 claims description 2
- PBXDGJCKKDXXQB-RUDMXATFSA-N (E)-N-[3-[3-[1-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-1-oxopropan-2-yl]phenyl]phenyl]-4-morpholin-4-ylbut-2-enamide Chemical compound CC(C(=O)NC1=NNC(=C1)C1CC1)C1=CC=CC(=C1)C1=CC(NC(=O)\C=C\CN2CCOCC2)=CC=C1 PBXDGJCKKDXXQB-RUDMXATFSA-N 0.000 claims description 2
- MWQKAIKIEHUSGL-IZZDOVSWSA-N (E)-N-[4-[3-[1-[(5-cyclobutyl-1H-pyrazol-3-yl)amino]-1-oxopropan-2-yl]phenyl]phenyl]-4-(dimethylamino)but-2-enamide Chemical compound C1(CCC1)C1=CC(=NN1)NC(C(C)C=1C=C(C=CC=1)C1=CC=C(C=C1)NC(\C=C\CN(C)C)=O)=O MWQKAIKIEHUSGL-IZZDOVSWSA-N 0.000 claims description 2
- GUKWPWBWSGIXJS-KPKJPENVSA-N (E)-N-[4-[3-[1-[(5-cyclopentyl-1H-pyrazol-3-yl)amino]-1-oxopropan-2-yl]phenyl]-2-fluorophenyl]-4-(dimethylamino)but-2-enamide Chemical compound CC(C(=O)NC1=NNC(=C1)C1CCCC1)C1=CC=CC(=C1)C1=CC(F)=C(NC(=O)\C=C\CN(C)C)C=C1 GUKWPWBWSGIXJS-KPKJPENVSA-N 0.000 claims description 2
- VXEHWKXHDMNAIH-SNAWJCMRSA-N (E)-N-[4-[3-[1-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-1-oxopropan-2-yl]-4-fluorophenyl]phenyl]-4-(dimethylamino)but-2-enamide Chemical compound CC(C(=O)NC1=NNC(=C1)C1CC1)C1=C(F)C=CC(=C1)C1=CC=C(NC(=O)\C=C\CN(C)C)C=C1 VXEHWKXHDMNAIH-SNAWJCMRSA-N 0.000 claims description 2
- QEXRKGOKBACTRG-JXMROGBWSA-N (E)-N-[4-[3-[1-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-1-oxopropan-2-yl]phenyl]-2-fluorophenyl]-4-(diethylamino)but-2-enamide Chemical compound C1(CC1)C1=CC(=NN1)NC(C(C)C=1C=C(C=CC=1)C1=CC(=C(C=C1)NC(\C=C\CN(CC)CC)=O)F)=O QEXRKGOKBACTRG-JXMROGBWSA-N 0.000 claims description 2
- LKYLFMPULYPUET-VMPITWQZSA-N (E)-N-[4-[3-[1-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-1-oxopropan-2-yl]phenyl]-2-fluorophenyl]-4-(dimethylamino)but-2-enamide Chemical compound CC(C(=O)NC1=NNC(=C1)C1CC1)C1=CC=CC(=C1)C1=CC(F)=C(NC(=O)\C=C\CN(C)C)C=C1 LKYLFMPULYPUET-VMPITWQZSA-N 0.000 claims description 2
- VCBLQGZFCBQQQX-ZZXKWVIFSA-N (E)-N-[4-[3-[1-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-1-oxopropan-2-yl]phenyl]-2-fluorophenyl]-4-morpholin-4-ylbut-2-enamide Chemical compound CC(C(=O)NC1=NNC(=C1)C1CC1)C1=CC=CC(=C1)C1=CC(F)=C(NC(=O)\C=C\CN2CCOCC2)C=C1 VCBLQGZFCBQQQX-ZZXKWVIFSA-N 0.000 claims description 2
- WEZUISMDDVGNCM-VMPITWQZSA-N (E)-N-[4-[3-[1-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-1-oxopropan-2-yl]phenyl]-2-fluorophenyl]-4-pyrrolidin-1-ylbut-2-enamide Chemical compound C1(CC1)C1=CC(=NN1)NC(C(C)C=1C=C(C=CC=1)C1=CC(=C(C=C1)NC(\C=C\CN1CCCC1)=O)F)=O WEZUISMDDVGNCM-VMPITWQZSA-N 0.000 claims description 2
- ODCUIHBFFKIENB-VMPITWQZSA-N (E)-N-[4-[3-[1-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-1-oxopropan-2-yl]phenyl]-3-fluorophenyl]-4-(dimethylamino)but-2-enamide Chemical compound CC(C(=O)NC1=NNC(=C1)C1CC1)C1=CC=CC(=C1)C1=C(F)C=C(NC(=O)\C=C\CN(C)C)C=C1 ODCUIHBFFKIENB-VMPITWQZSA-N 0.000 claims description 2
- JQLASICYXWOLAZ-DHZHZOJOSA-N (E)-N-[4-[3-[1-[(5-tert-butyl-1H-pyrazol-3-yl)amino]-1-oxopropan-2-yl]phenyl]phenyl]-4-(dimethylamino)but-2-enamide Chemical compound C(C)(C)(C)C1=CC(=NN1)NC(C(C)C=1C=C(C=CC=1)C1=CC=C(C=C1)NC(\C=C\CN(C)C)=O)=O JQLASICYXWOLAZ-DHZHZOJOSA-N 0.000 claims description 2
- RDIXRPLZSJLFTI-QPJJXVBHSA-N (E)-N-[4-[3-[2-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-oxoethyl]phenyl]phenyl]-4-(dimethylamino)but-2-enamide Chemical compound CN(C)C\C=C\C(=O)NC1=CC=C(C=C1)C1=CC(CC(=O)NC2=NNC(=C2)C2CC2)=CC=C1 RDIXRPLZSJLFTI-QPJJXVBHSA-N 0.000 claims description 2
- KLVOWXFWNDEZSV-SNAWJCMRSA-N (E)-N-[4-[5-[1-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-1-oxopropan-2-yl]-2-fluorophenyl]phenyl]-4-(dimethylamino)but-2-enamide Chemical compound CC(C(=O)NC1=NNC(=C1)C1CC1)C1=CC(=C(F)C=C1)C1=CC=C(NC(=O)\C=C\CN(C)C)C=C1 KLVOWXFWNDEZSV-SNAWJCMRSA-N 0.000 claims description 2
- CUBDFKPNPMKIJA-ZZXKWVIFSA-N (E)-N-[5-[3-[1-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-1-oxopropan-2-yl]phenyl]-3-fluoropyridin-2-yl]-4-morpholin-4-ylbut-2-enamide Chemical compound C1(CC1)C1=CC(=NN1)NC(C(C)C=1C=C(C=CC=1)C=1C=C(C(=NC=1)NC(\C=C\CN1CCOCC1)=O)F)=O CUBDFKPNPMKIJA-ZZXKWVIFSA-N 0.000 claims description 2
- KVOMOZYLJKQEDA-ZZXKWVIFSA-N (E)-N-[5-[3-[1-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-1-oxopropan-2-yl]phenyl]-6-fluoropyridin-2-yl]-4-morpholin-4-ylbut-2-enamide Chemical compound C1(CC1)C1=CC(=NN1)NC(C(C)C=1C=C(C=CC=1)C=1C=CC(=NC=1F)NC(\C=C\CN1CCOCC1)=O)=O KVOMOZYLJKQEDA-ZZXKWVIFSA-N 0.000 claims description 2
- DGWRKYUYWBECQL-XBXARRHUSA-N (E)-N-[5-[3-[1-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-1-oxopropan-2-yl]phenyl]pyridin-2-yl]-4-(3-fluoropiperidin-1-yl)but-2-enamide Chemical compound C1(CC1)C1=CC(=NN1)NC(C(C)C=1C=C(C=CC=1)C=1C=CC(=NC=1)NC(\C=C\CN1CC(CCC1)F)=O)=O DGWRKYUYWBECQL-XBXARRHUSA-N 0.000 claims description 2
- FELGDXDUEDTBOE-ZZXKWVIFSA-N (E)-N-[5-[3-[1-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-1-oxopropan-2-yl]phenyl]pyridin-2-yl]-4-(3-fluoropyrrolidin-1-yl)but-2-enamide Chemical compound C1(CC1)C1=CC(=NN1)NC(C(C)C=1C=C(C=CC=1)C=1C=CC(=NC=1)NC(\C=C\CN1CC(CC1)F)=O)=O FELGDXDUEDTBOE-ZZXKWVIFSA-N 0.000 claims description 2
- ILWXRPGNXYTZIP-JXMROGBWSA-N (E)-N-[5-[3-[1-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-1-oxopropan-2-yl]phenyl]pyridin-2-yl]-4-(diethylamino)but-2-enamide Chemical compound C1(CC1)C1=CC(=NN1)NC(C(C)C=1C=C(C=CC=1)C=1C=CC(=NC=1)NC(\C=C\CN(CC)CC)=O)=O ILWXRPGNXYTZIP-JXMROGBWSA-N 0.000 claims description 2
- BGEKDDQVUQNTLG-VMPITWQZSA-N (E)-N-[5-[3-[1-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-1-oxopropan-2-yl]phenyl]pyridin-2-yl]-4-(dimethylamino)but-2-enamide Chemical compound C1(CC1)C1=CC(=NN1)NC(C(C)C=1C=C(C=CC=1)C=1C=CC(=NC=1)NC(\C=C\CN(C)C)=O)=O BGEKDDQVUQNTLG-VMPITWQZSA-N 0.000 claims description 2
- RMTHHMQLXQDQPP-WGRJZYJMSA-N (E)-N-[5-[3-[1-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-1-oxopropan-2-yl]phenyl]pyridin-2-yl]-4-[(2S,4S)-4-fluoro-2-(methoxymethyl)pyrrolidin-1-yl]but-2-enamide Chemical compound C1(CC1)C1=CC(=NN1)NC(C(C)C=1C=C(C=CC=1)C=1C=CC(=NC=1)NC(\C=C\CN1[C@@H](C[C@@H](C1)F)COC)=O)=O RMTHHMQLXQDQPP-WGRJZYJMSA-N 0.000 claims description 2
- CFAQELNWSAYXAP-VMPITWQZSA-N (E)-N-[5-[3-[1-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-1-oxopropan-2-yl]phenyl]pyridin-2-yl]-4-[methoxy(methyl)amino]but-2-enamide Chemical compound C1(CC1)C1=CC(=NN1)NC(C(C)C=1C=C(C=CC=1)C=1C=CC(=NC=1)NC(\C=C\CN(C)OC)=O)=O CFAQELNWSAYXAP-VMPITWQZSA-N 0.000 claims description 2
- BOBOCYVCAPAGSR-ZZXKWVIFSA-N (E)-N-[5-[3-[1-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-1-oxopropan-2-yl]phenyl]pyridin-2-yl]-4-imidazol-1-ylbut-2-enamide Chemical compound C1(CC1)C1=CC(=NN1)NC(C(C)C=1C=C(C=CC=1)C=1C=CC(=NC=1)NC(\C=C\CN1C=NC=C1)=O)=O BOBOCYVCAPAGSR-ZZXKWVIFSA-N 0.000 claims description 2
- SISWNQFWTSKWLM-QPJJXVBHSA-N (E)-N-[5-[3-[1-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-1-oxopropan-2-yl]phenyl]pyridin-2-yl]-4-methoxybut-2-enamide Chemical compound C1(CC1)C1=CC(=NN1)NC(C(C)C=1C=C(C=CC=1)C=1C=CC(=NC=1)NC(\C=C\COC)=O)=O SISWNQFWTSKWLM-QPJJXVBHSA-N 0.000 claims description 2
- QYHNACRNROAGBW-RMKNXTFCSA-N (E)-N-[5-[3-[1-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-1-oxopropan-2-yl]phenyl]pyridin-2-yl]-4-piperidin-1-ylbut-2-enamide Chemical compound C1(CC1)C1=CC(=NN1)NC(C(C)C=1C=C(C=CC=1)C=1C=CC(=NC=1)NC(\C=C\CN1CCCCC1)=O)=O QYHNACRNROAGBW-RMKNXTFCSA-N 0.000 claims description 2
- ZFDZFQZUFROCDW-ZZXKWVIFSA-N (E)-N-[5-[3-[1-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-1-oxopropan-2-yl]phenyl]pyridin-3-yl]-4-morpholin-4-ylbut-2-enamide Chemical compound C1(CC1)C1=CC(=NN1)NC(C(C)C=1C=C(C=CC=1)C=1C=C(C=NC=1)NC(\C=C\CN1CCOCC1)=O)=O ZFDZFQZUFROCDW-ZZXKWVIFSA-N 0.000 claims description 2
- FSLNKEPUUKBMOR-ZZXKWVIFSA-N (E)-N-[6-[3-[1-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-1-oxopropan-2-yl]phenyl]-2-fluoropyridin-3-yl]-4-(3-fluoropyrrolidin-1-yl)but-2-enamide Chemical compound C1(CC1)C1=CC(=NN1)NC(C(C)C=1C=C(C=CC=1)C1=CC=C(C(=N1)F)NC(\C=C\CN1CC(CC1)F)=O)=O FSLNKEPUUKBMOR-ZZXKWVIFSA-N 0.000 claims description 2
- YLAFDLZUXMDTQR-VMPITWQZSA-N (E)-N-[6-[3-[1-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-1-oxopropan-2-yl]phenyl]-2-fluoropyridin-3-yl]-4-(dimethylamino)but-2-enamide Chemical compound C1(CC1)C1=CC(=NN1)NC(C(C)C=1C=C(C=CC=1)C1=CC=C(C(=N1)F)NC(\C=C\CN(C)C)=O)=O YLAFDLZUXMDTQR-VMPITWQZSA-N 0.000 claims description 2
- JADXDCWRGVSHHM-ZZXKWVIFSA-N (E)-N-[6-[3-[1-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-1-oxopropan-2-yl]phenyl]-2-fluoropyridin-3-yl]-4-morpholin-4-ylbut-2-enamide Chemical compound C1(CC1)C1=CC(=NN1)NC(C(C)C=1C=C(C=CC=1)C1=CC=C(C(=N1)F)NC(\C=C\CN1CCOCC1)=O)=O JADXDCWRGVSHHM-ZZXKWVIFSA-N 0.000 claims description 2
- BXERJFWRHNGYKW-VMPITWQZSA-N (E)-N-[6-[3-[1-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-1-oxopropan-2-yl]phenyl]pyridin-3-yl]-4-(dimethylamino)but-2-enamide Chemical compound C1(CC1)C1=CC(=NN1)NC(C(C)C=1C=C(C=CC=1)C1=CC=C(C=N1)NC(\C=C\CN(C)C)=O)=O BXERJFWRHNGYKW-VMPITWQZSA-N 0.000 claims description 2
- AVYVWHSDHOMIFK-ZZXKWVIFSA-N (E)-N-[6-[3-[1-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-1-oxopropan-2-yl]phenyl]pyridin-3-yl]-4-morpholin-4-ylbut-2-enamide Chemical compound C1(CC1)C1=CC(=NN1)NC(C(C)C=1C=C(C=CC=1)C1=CC=C(C=N1)NC(\C=C\CN1CCOCC1)=O)=O AVYVWHSDHOMIFK-ZZXKWVIFSA-N 0.000 claims description 2
- JDQAABVCOXYLAL-RMKNXTFCSA-N (E)-N-[6-[3-[1-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-1-oxopropan-2-yl]phenyl]pyridin-3-yl]-4-piperidin-1-ylbut-2-enamide Chemical compound C1(CC1)C1=CC(=NN1)NC(C(C)C=1C=C(C=CC=1)C1=CC=C(C=N1)NC(\C=C\CN1CCCCC1)=O)=O JDQAABVCOXYLAL-RMKNXTFCSA-N 0.000 claims description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 2
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 claims description 2
- 206010003571 Astrocytoma Diseases 0.000 claims description 2
- 208000003950 B-cell lymphoma Diseases 0.000 claims description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 2
- 201000009030 Carcinoma Diseases 0.000 claims description 2
- 201000008808 Fibrosarcoma Diseases 0.000 claims description 2
- 208000032612 Glial tumor Diseases 0.000 claims description 2
- 206010018338 Glioma Diseases 0.000 claims description 2
- 208000017604 Hodgkin disease Diseases 0.000 claims description 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 208000007766 Kaposi sarcoma Diseases 0.000 claims description 2
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims description 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 2
- MPCBRTRKWFIMPP-UHFFFAOYSA-N N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-[3-(1-prop-2-enoyl-2,3-dihydroindol-5-yl)phenyl]propanamide Chemical compound C(C=C)(=O)N1CCC2=CC(=CC=C12)C=1C=C(C=CC=1)C(C(=O)NC1=NNC(=C1)C1CC1)C MPCBRTRKWFIMPP-UHFFFAOYSA-N 0.000 claims description 2
- DUFMHAYNJSTFNP-VMPITWQZSA-N N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-[3-[1-[(E)-4-(dimethylamino)but-2-enoyl]-2,3-dihydroindol-5-yl]phenyl]propanamide Chemical compound C1(CC1)C1=CC(=NN1)NC(C(C)C1=CC(=CC=C1)C=1C=C2CCN(C2=CC=1)C(\C=C\CN(C)C)=O)=O DUFMHAYNJSTFNP-VMPITWQZSA-N 0.000 claims description 2
- ZWJSNJVUWYOJQS-UHFFFAOYSA-N N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-[3-[2-methoxy-4-(prop-2-enoylamino)phenyl]phenyl]propanamide Chemical compound C1(CC1)C1=CC(=NN1)NC(C(C)C=1C=C(C=CC=1)C1=C(C=C(C=C1)NC(C=C)=O)OC)=O ZWJSNJVUWYOJQS-UHFFFAOYSA-N 0.000 claims description 2
- VNCOUMJGTILENW-UHFFFAOYSA-N N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-[3-[2-methyl-4-(prop-2-enoylamino)phenyl]phenyl]propanamide Chemical compound C1(CC1)C1=CC(=NN1)NC(C(C)C=1C=C(C=CC=1)C1=C(C=C(C=C1)NC(C=C)=O)C)=O VNCOUMJGTILENW-UHFFFAOYSA-N 0.000 claims description 2
- CYGIXPCVOXQQFT-UHFFFAOYSA-N N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-[3-[3,5-dimethyl-4-(prop-2-enoylamino)phenyl]phenyl]propanamide Chemical compound C1(CC1)C1=CC(=NN1)NC(C(C)C=1C=C(C=CC=1)C1=CC(=C(C(=C1)C)NC(C=C)=O)C)=O CYGIXPCVOXQQFT-UHFFFAOYSA-N 0.000 claims description 2
- QRHXYRZCHFIWGD-UHFFFAOYSA-N N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-[3-[3-fluoro-4-(prop-2-enoylamino)phenyl]phenyl]-3-methylbutanamide Chemical compound C(C=C)(=O)NC1=C(C=C(C=C1)C1=CC(=CC=C1)C(C(=O)NC1=NNC(=C1)C1CC1)C(C)C)F QRHXYRZCHFIWGD-UHFFFAOYSA-N 0.000 claims description 2
- GALFFUXCRBJGEU-UHFFFAOYSA-N N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-[3-[3-fluoro-4-(prop-2-enoylamino)phenyl]phenyl]butanamide Chemical compound CCC(C(=O)NC1=NNC(=C1)C1CC1)C1=CC=CC(=C1)C1=CC(F)=C(NC(=O)C=C)C=C1 GALFFUXCRBJGEU-UHFFFAOYSA-N 0.000 claims description 2
- JXTNBBXDHFAGLE-UHFFFAOYSA-N N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-[3-[3-fluoro-4-(prop-2-enoylamino)phenyl]phenyl]propanamide Chemical compound CC(C(=O)NC1=NNC(=C1)C1CC1)C1=CC=CC(=C1)C1=CC(F)=C(NC(=O)C=C)C=C1 JXTNBBXDHFAGLE-UHFFFAOYSA-N 0.000 claims description 2
- UIAAGQZTUVOBEG-UHFFFAOYSA-N N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-[3-[3-methoxy-4-(prop-2-enoylamino)phenyl]phenyl]propanamide Chemical compound C1(CC1)C1=CC(=NN1)NC(C(C)C=1C=C(C=CC=1)C1=CC(=C(C=C1)NC(C=C)=O)OC)=O UIAAGQZTUVOBEG-UHFFFAOYSA-N 0.000 claims description 2
- BOEJCOGAHAQURG-UHFFFAOYSA-N N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-[3-[3-methyl-4-(prop-2-enoylamino)phenyl]phenyl]propanamide Chemical compound C1(CC1)C1=CC(=NN1)NC(C(C)C=1C=C(C=CC=1)C1=CC(=C(C=C1)NC(C=C)=O)C)=O BOEJCOGAHAQURG-UHFFFAOYSA-N 0.000 claims description 2
- OGXMJWWUYDHCJO-UHFFFAOYSA-N N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-[3-[4-(prop-2-enoylamino)phenyl]phenyl]propanamide Chemical compound C1(CC1)C1=CC(=NN1)NC(C(C)C=1C=C(C=CC=1)C1=CC=C(C=C1)NC(C=C)=O)=O OGXMJWWUYDHCJO-UHFFFAOYSA-N 0.000 claims description 2
- XTFHGMCOJLLLQQ-RMKNXTFCSA-N N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-[3-[4-[[(E)-4-(dimethylamino)but-2-enoyl]amino]-3-fluorophenyl]phenyl]butanamide Chemical compound CCC(C(=O)NC1=NNC(=C1)C1CC1)C1=CC=CC(=C1)C1=CC(F)=C(NC(=O)\C=C\CN(C)C)C=C1 XTFHGMCOJLLLQQ-RMKNXTFCSA-N 0.000 claims description 2
- SIGAKCXGEQAVJE-RMKNXTFCSA-N N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-[3-[4-[[(E)-4-(dimethylamino)but-2-enoyl]amino]phenyl]phenyl]butanamide Chemical compound CCC(C(=O)NC1=NNC(=C1)C1CC1)C1=CC=CC(=C1)C1=CC=C(NC(=O)\C=C\CN(C)C)C=C1 SIGAKCXGEQAVJE-RMKNXTFCSA-N 0.000 claims description 2
- FBGLMGGQRUIUMR-UHFFFAOYSA-N N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-[3-[5-(prop-2-enoylamino)pyridin-2-yl]phenyl]butanamide Chemical compound CCC(C(=O)NC1=NNC(=C1)C1CC1)C1=CC(=CC=C1)C1=NC=C(NC(=O)C=C)C=C1 FBGLMGGQRUIUMR-UHFFFAOYSA-N 0.000 claims description 2
- ZGNFJXHNIRUYHS-UHFFFAOYSA-N N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-[3-[5-(prop-2-enoylamino)pyridin-2-yl]phenyl]propanamide Chemical compound C1(CC1)C1=CC(=NN1)NC(C(C)C=1C=C(C=CC=1)C1=CC=C(C=N1)NC(C=C)=O)=O ZGNFJXHNIRUYHS-UHFFFAOYSA-N 0.000 claims description 2
- KMUMKQADBDLOOD-RMKNXTFCSA-N N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-[3-[5-[[(E)-4-(dimethylamino)but-2-enoyl]amino]pyridin-2-yl]phenyl]-3-methylbutanamide Chemical compound C1(CC1)C1=CC(=NN1)NC(C(C(C)C)C=1C=C(C=CC=1)C1=CC=C(C=N1)NC(\C=C\CN(C)C)=O)=O KMUMKQADBDLOOD-RMKNXTFCSA-N 0.000 claims description 2
- GMNVYRVFOCFQPC-UHFFFAOYSA-N N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-[3-[6-(prop-2-enoylamino)pyrazin-2-yl]phenyl]propanamide Chemical compound C1(CC1)C1=CC(=NN1)NC(C(C)C=1C=C(C=CC=1)C1=CN=CC(=N1)NC(C=C)=O)=O GMNVYRVFOCFQPC-UHFFFAOYSA-N 0.000 claims description 2
- HSNXQARRVZPWKH-UHFFFAOYSA-N N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-[3-[6-[(prop-2-enoylamino)methyl]pyridin-3-yl]phenyl]propanamide Chemical compound C1(CC1)C1=CC(=NN1)NC(C(C)C=1C=C(C=CC=1)C=1C=CC(=NC=1)CNC(C=C)=O)=O HSNXQARRVZPWKH-UHFFFAOYSA-N 0.000 claims description 2
- SRWPGRUPJNPGRS-RMKNXTFCSA-N N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-[3-[6-[[(E)-4-(dimethylamino)but-2-enoyl]amino]pyridin-3-yl]phenyl]-3-methylbutanamide Chemical compound C1(CC1)C1=CC(=NN1)NC(C(C(C)C)C=1C=C(C=CC=1)C=1C=CC(=NC=1)NC(\C=C\CN(C)C)=O)=O SRWPGRUPJNPGRS-RMKNXTFCSA-N 0.000 claims description 2
- CFQMBAKFNZEINV-UHFFFAOYSA-N N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-[4-fluoro-3-[3-fluoro-4-(prop-2-enoylamino)phenyl]phenyl]propanamide Chemical compound C1(CC1)C1=CC(=NN1)NC(C(C)C=1C=CC(=C(C=1)C1=CC(=C(C=C1)NC(C=C)=O)F)F)=O CFQMBAKFNZEINV-UHFFFAOYSA-N 0.000 claims description 2
- MZHGPDHKECGCPC-UHFFFAOYSA-N N-(5-cyclopropyl-4-methyl-1H-pyrazol-3-yl)-2-[3-[4-(prop-2-enoylamino)phenyl]phenyl]propanamide Chemical compound C1(CC1)C1=C(C(=NN1)NC(C(C)C=1C=C(C=CC=1)C1=CC=C(C=C1)NC(C=C)=O)=O)C MZHGPDHKECGCPC-UHFFFAOYSA-N 0.000 claims description 2
- RRUWFPWAJURWDR-UHFFFAOYSA-N N-(5-ethyl-1H-pyrazol-3-yl)-2-[3-[4-(prop-2-enoylamino)phenyl]phenyl]propanamide Chemical compound C(C)C1=CC(=NN1)NC(C(C)C=1C=C(C=CC=1)C1=CC=C(C=C1)NC(C=C)=O)=O RRUWFPWAJURWDR-UHFFFAOYSA-N 0.000 claims description 2
- XTHLXHUYTGEKEA-UHFFFAOYSA-N N-(5-tert-butyl-1H-pyrazol-3-yl)-2-[3-[4-(prop-2-enoylamino)phenyl]phenyl]propanamide Chemical compound C(C)(C)(C)C1=CC(=NN1)NC(C(C)C=1C=C(C=CC=1)C1=CC=C(C=C1)NC(C=C)=O)=O XTHLXHUYTGEKEA-UHFFFAOYSA-N 0.000 claims description 2
- 206010029260 Neuroblastoma Diseases 0.000 claims description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 2
- 201000010208 Seminoma Diseases 0.000 claims description 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 2
- 206010042971 T-cell lymphoma Diseases 0.000 claims description 2
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims description 2
- 230000001154 acute effect Effects 0.000 claims description 2
- 125000002619 bicyclic group Chemical group 0.000 claims description 2
- 210000000481 breast Anatomy 0.000 claims description 2
- 150000001721 carbon Chemical group 0.000 claims description 2
- 210000003169 central nervous system Anatomy 0.000 claims description 2
- 210000003679 cervix uteri Anatomy 0.000 claims description 2
- 210000001072 colon Anatomy 0.000 claims description 2
- 210000003238 esophagus Anatomy 0.000 claims description 2
- 230000003325 follicular Effects 0.000 claims description 2
- 210000000232 gallbladder Anatomy 0.000 claims description 2
- 210000003128 head Anatomy 0.000 claims description 2
- 210000003734 kidney Anatomy 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 210000003739 neck Anatomy 0.000 claims description 2
- 208000007538 neurilemmoma Diseases 0.000 claims description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 2
- 201000008968 osteosarcoma Diseases 0.000 claims description 2
- 210000001672 ovary Anatomy 0.000 claims description 2
- 210000000496 pancreas Anatomy 0.000 claims description 2
- 210000001428 peripheral nervous system Anatomy 0.000 claims description 2
- 210000002307 prostate Anatomy 0.000 claims description 2
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims description 2
- 210000003491 skin Anatomy 0.000 claims description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 2
- 210000002784 stomach Anatomy 0.000 claims description 2
- 208000001608 teratocarcinoma Diseases 0.000 claims description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 2
- 210000003932 urinary bladder Anatomy 0.000 claims description 2
- FELGDXDUEDTBOE-XRIOEKHQSA-N (E)-N-[5-[3-[1-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-1-oxopropan-2-yl]phenyl]pyridin-2-yl]-4-[(3R)-3-fluoropyrrolidin-1-yl]but-2-enamide Chemical compound C1(CC1)C1=CC(=NN1)NC(C(C)C=1C=C(C=CC=1)C=1C=CC(=NC=1)NC(\C=C\CN1C[C@@H](CC1)F)=O)=O FELGDXDUEDTBOE-XRIOEKHQSA-N 0.000 claims 3
- 230000008878 coupling Effects 0.000 claims 3
- 238000010168 coupling process Methods 0.000 claims 3
- 238000005859 coupling reaction Methods 0.000 claims 3
- KRKRAOXTGDJWNI-DMTCNVIQSA-L (2s,4r)-2-amino-4-methylpentanedioate Chemical compound [O-]C(=O)[C@H](C)C[C@H](N)C([O-])=O KRKRAOXTGDJWNI-DMTCNVIQSA-L 0.000 claims 2
- FELGDXDUEDTBOE-NEKWBUCNSA-N (E)-N-[5-[3-[1-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-1-oxopropan-2-yl]phenyl]pyridin-2-yl]-4-[(3S)-3-fluoropyrrolidin-1-yl]but-2-enamide Chemical compound C1(CC1)C1=CC(=NN1)NC(C(C)C=1C=C(C=CC=1)C=1C=CC(=NC=1)NC(\C=C\CN1C[C@H](CC1)F)=O)=O FELGDXDUEDTBOE-NEKWBUCNSA-N 0.000 claims 2
- KDCKKNHYXJQMRS-LGDADKFGSA-N (E)-4-[(2S)-2-(cyanomethyl)pyrrolidin-1-yl]-N-[5-[3-[1-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-1-oxopropan-2-yl]phenyl]pyridin-2-yl]but-2-enamide Chemical compound C(#N)C[C@H]1N(CCC1)C/C=C/C(=O)NC1=NC=C(C=C1)C1=CC(=CC=C1)C(C(=O)NC1=NNC(=C1)C1CC1)C KDCKKNHYXJQMRS-LGDADKFGSA-N 0.000 claims 1
- MDUXNMZMPCMACK-VMPITWQZSA-N (E)-N-[5-[3-[1-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-1-oxopropan-2-yl]phenyl]pyridin-2-yl]-4-[2-methoxyethyl(methyl)amino]but-2-enamide Chemical compound C1(CC1)C1=CC(=NN1)NC(C(C)C=1C=C(C=CC=1)C=1C=CC(=NC=1)NC(\C=C\CN(C)CCOC)=O)=O MDUXNMZMPCMACK-VMPITWQZSA-N 0.000 claims 1
- 125000001989 1,3-phenylene group Chemical group [H]C1=C([H])C([*:1])=C([H])C([*:2])=C1[H] 0.000 claims 1
- BHLNGAPPKDGQSQ-RMKNXTFCSA-N N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-[3-[4-[[(E)-4-(dimethylamino)but-2-enoyl]amino]-3-fluorophenyl]phenyl]-3-methylbutanamide Chemical compound CC(C)C(C(=O)NC1=NNC(=C1)C1CC1)C1=CC=CC(=C1)C1=CC(F)=C(NC(=O)\C=C\CN(C)C)C=C1 BHLNGAPPKDGQSQ-RMKNXTFCSA-N 0.000 claims 1
- 102100026810 Cyclin-dependent kinase 7 Human genes 0.000 abstract description 52
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 22
- 102100024457 Cyclin-dependent kinase 9 Human genes 0.000 abstract description 19
- 101000980930 Homo sapiens Cyclin-dependent kinase 9 Proteins 0.000 abstract description 19
- 102100038111 Cyclin-dependent kinase 12 Human genes 0.000 abstract description 18
- 102100038114 Cyclin-dependent kinase 13 Human genes 0.000 abstract description 18
- 101000884345 Homo sapiens Cyclin-dependent kinase 12 Proteins 0.000 abstract description 18
- 101000884348 Homo sapiens Cyclin-dependent kinase 13 Proteins 0.000 abstract description 18
- 102100033144 Cyclin-dependent kinase 18 Human genes 0.000 abstract description 17
- 108010039798 PCTAIRE-3 protein kinase Proteins 0.000 abstract description 17
- 238000011282 treatment Methods 0.000 abstract description 15
- 239000003112 inhibitor Substances 0.000 abstract description 5
- 238000002360 preparation method Methods 0.000 abstract description 5
- 241000124008 Mammalia Species 0.000 abstract description 2
- 230000006806 disease prevention Effects 0.000 abstract description 2
- 101000911952 Homo sapiens Cyclin-dependent kinase 7 Proteins 0.000 abstract 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 190
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 137
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 132
- 238000006243 chemical reaction Methods 0.000 description 109
- 238000004128 high performance liquid chromatography Methods 0.000 description 97
- 238000005160 1H NMR spectroscopy Methods 0.000 description 95
- 230000015572 biosynthetic process Effects 0.000 description 67
- 239000000243 solution Substances 0.000 description 67
- 238000003786 synthesis reaction Methods 0.000 description 67
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 58
- 101710106276 Cyclin-dependent kinase 7 Proteins 0.000 description 50
- 235000019439 ethyl acetate Nutrition 0.000 description 47
- 108090000266 Cyclin-dependent kinases Proteins 0.000 description 42
- 102000003903 Cyclin-dependent kinases Human genes 0.000 description 42
- 230000002829 reductive effect Effects 0.000 description 38
- 229910052938 sodium sulfate Inorganic materials 0.000 description 35
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 34
- 239000011541 reaction mixture Substances 0.000 description 30
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 28
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 27
- 239000012044 organic layer Substances 0.000 description 24
- 238000010898 silica gel chromatography Methods 0.000 description 24
- 239000010410 layer Substances 0.000 description 23
- 239000012267 brine Substances 0.000 description 21
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 21
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 20
- 208000035475 disorder Diseases 0.000 description 20
- 235000011152 sodium sulphate Nutrition 0.000 description 19
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- 230000000694 effects Effects 0.000 description 18
- 239000000203 mixture Substances 0.000 description 18
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- 239000007832 Na2SO4 Substances 0.000 description 16
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 16
- 239000012074 organic phase Substances 0.000 description 16
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 14
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 14
- 108091000080 Phosphotransferase Proteins 0.000 description 14
- 102000020233 phosphotransferase Human genes 0.000 description 14
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 14
- 239000003153 chemical reaction reagent Substances 0.000 description 13
- 238000004296 chiral HPLC Methods 0.000 description 13
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 12
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 12
- 238000002953 preparative HPLC Methods 0.000 description 12
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 11
- 230000001594 aberrant effect Effects 0.000 description 10
- 239000005457 ice water Substances 0.000 description 10
- 230000002401 inhibitory effect Effects 0.000 description 10
- 238000003756 stirring Methods 0.000 description 10
- 230000005764 inhibitory process Effects 0.000 description 9
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 8
- 239000007821 HATU Substances 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- 125000004429 atom Chemical group 0.000 description 8
- 230000022131 cell cycle Effects 0.000 description 8
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 239000000546 pharmaceutical excipient Substances 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 229910052786 argon Inorganic materials 0.000 description 7
- 238000012512 characterization method Methods 0.000 description 7
- 229910000027 potassium carbonate Inorganic materials 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 229940086542 triethylamine Drugs 0.000 description 7
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- DOTGZROJTAUYFQ-OWOJBTEDSA-N (e)-4-bromobut-2-enoic acid Chemical compound OC(=O)\C=C\CBr DOTGZROJTAUYFQ-OWOJBTEDSA-N 0.000 description 5
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 5
- HFBMWMNUJJDEQZ-UHFFFAOYSA-N acryloyl chloride Chemical compound ClC(=O)C=C HFBMWMNUJJDEQZ-UHFFFAOYSA-N 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 239000006196 drop Substances 0.000 description 5
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 5
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 5
- 230000002062 proliferating effect Effects 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 239000011593 sulfur Chemical group 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 5
- 238000004809 thin layer chromatography Methods 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 4
- 102100032857 Cyclin-dependent kinase 1 Human genes 0.000 description 4
- 239000012300 argon atmosphere Substances 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 239000000460 chlorine Substances 0.000 description 4
- HZLAWYIBLZNRFZ-VXGBXAGGSA-N cphpc Chemical compound OC(=O)[C@H]1CCCN1C(=O)CCCCC(=O)N1[C@@H](C(O)=O)CCC1 HZLAWYIBLZNRFZ-VXGBXAGGSA-N 0.000 description 4
- 238000007872 degassing Methods 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 239000001301 oxygen Chemical group 0.000 description 4
- 230000026731 phosphorylation Effects 0.000 description 4
- 238000006366 phosphorylation reaction Methods 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- YYPSLRSXKISVBU-UHFFFAOYSA-N tert-butyl 3-[2-(3-bromophenyl)propanoylamino]-5-cyclopropylpyrazole-1-carboxylate Chemical compound BrC=1C=C(C=CC=1)C(C(=O)NC1=NN(C(=C1)C1CC1)C(=O)OC(C)(C)C)C YYPSLRSXKISVBU-UHFFFAOYSA-N 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- QLHMQZFTSIHQIT-UHFFFAOYSA-N 2-(3-bromophenyl)propanoic acid Chemical compound OC(=O)C(C)C1=CC=CC(Br)=C1 QLHMQZFTSIHQIT-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- VNQPDARRIJKZSD-UHFFFAOYSA-N CC(C(=O)NC1=NN(C(=O)OC(C)(C)C)C(=C1)C1CC1)C1=CC(=CC=C1)B1OC(C)(C)C(C)(C)O1 Chemical compound CC(C(=O)NC1=NN(C(=O)OC(C)(C)C)C(=C1)C1CC1)C1=CC(=CC=C1)B1OC(C)(C)C(C)(C)O1 VNQPDARRIJKZSD-UHFFFAOYSA-N 0.000 description 3
- 101710106279 Cyclin-dependent kinase 1 Proteins 0.000 description 3
- 230000033616 DNA repair Effects 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- ZJPKYZMGUIDCBM-UHFFFAOYSA-N NC1=CC=C(C=C1)C1=CC(=CC=C1)C(C(=O)NC1=NN(C2=CC=CC=C12)COCC[Si](C)(C)C)C Chemical compound NC1=CC=C(C=C1)C1=CC(=CC=C1)C(C(=O)NC1=NN(C2=CC=CC=C12)COCC[Si](C)(C)C)C ZJPKYZMGUIDCBM-UHFFFAOYSA-N 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- AUALQMFGWLZREY-UHFFFAOYSA-N acetonitrile;methanol Chemical compound OC.CC#N AUALQMFGWLZREY-UHFFFAOYSA-N 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 235000011114 ammonium hydroxide Nutrition 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000006369 cell cycle progression Effects 0.000 description 3
- 230000032823 cell division Effects 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 3
- 238000010511 deprotection reaction Methods 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 239000012458 free base Substances 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 125000002757 morpholinyl group Chemical group 0.000 description 3
- 125000004193 piperazinyl group Chemical group 0.000 description 3
- 125000003386 piperidinyl group Chemical group 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000004224 protection Effects 0.000 description 3
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 3
- 239000000376 reactant Substances 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- PRLJUNODMBDWED-UHFFFAOYSA-N tert-butyl 4-[3-[1-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-1-oxopropan-2-yl]phenyl]-3,6-dihydro-2H-pyridine-1-carboxylate Chemical compound C1(CC1)C1=CC(=NN1)NC(C(C)C=1C=C(C=CC=1)C=1CCN(CC=1)C(=O)OC(C)(C)C)=O PRLJUNODMBDWED-UHFFFAOYSA-N 0.000 description 3
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 2
- DMWSJNCDNJGSHD-OWOJBTEDSA-N (E)-4-bromo-N-(5-bromopyridin-2-yl)but-2-enamide Chemical compound BrC/C=C/C(=O)NC1=NC=C(C=C1)Br DMWSJNCDNJGSHD-OWOJBTEDSA-N 0.000 description 2
- VWXOURURGZGUQO-ONEGZZNKSA-N (E)-N-(5-bromopyridin-2-yl)-4-pyrrolidin-1-ylbut-2-enamide Chemical compound BrC=1C=CC(=NC=1)NC(\C=C\CN1CCCC1)=O VWXOURURGZGUQO-ONEGZZNKSA-N 0.000 description 2
- ITGIYLMMAABTHC-ONEGZZNKSA-N (e)-4-(dimethylazaniumyl)but-2-enoate Chemical compound CN(C)C\C=C\C(O)=O ITGIYLMMAABTHC-ONEGZZNKSA-N 0.000 description 2
- HNUXOZWKZHPUCT-UHFFFAOYSA-N 1-(2-trimethylsilylethoxymethyl)indazol-3-amine Chemical compound C1=CC=C2N(COCC[Si](C)(C)C)N=C(N)C2=C1 HNUXOZWKZHPUCT-UHFFFAOYSA-N 0.000 description 2
- KYNNBXCGXUOREX-UHFFFAOYSA-N 2-(3-bromophenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC(Br)=C1 KYNNBXCGXUOREX-UHFFFAOYSA-N 0.000 description 2
- GRPBHLGZLKGRHT-UHFFFAOYSA-N 2-[3-(4-aminophenyl)phenyl]-N-(5-cyclopropyl-1H-pyrazol-3-yl)propanamide Chemical compound NC1=CC=C(C=C1)C1=CC(=CC=C1)C(C(=O)NC1=NNC(=C1)C1CC1)C GRPBHLGZLKGRHT-UHFFFAOYSA-N 0.000 description 2
- XWYWRJSCJVJOMX-UHFFFAOYSA-N 2-[3-(6-aminopyrazin-2-yl)phenyl]-N-(5-cyclopropyl-1H-pyrazol-3-yl)propanamide Chemical compound NC1=CN=CC(=N1)C=1C=C(C=CC=1)C(C(=O)NC1=NNC(=C1)C1CC1)C XWYWRJSCJVJOMX-UHFFFAOYSA-N 0.000 description 2
- LZOGXDBVTFWJLD-UHFFFAOYSA-N 3-N-[1-(oxan-2-yl)indazol-3-yl]benzene-1,3-diamine Chemical compound O1C(CCCC1)N1N=C(C2=CC=CC=C12)NC1=CC(=CC=C1)N LZOGXDBVTFWJLD-UHFFFAOYSA-N 0.000 description 2
- QWLOLRJEKXVXBN-UHFFFAOYSA-N 3-bromo-1-(oxan-2-yl)indazole Chemical compound C12=CC=CC=C2C(Br)=NN1C1CCCCO1 QWLOLRJEKXVXBN-UHFFFAOYSA-N 0.000 description 2
- HTKXRTUKPXEALT-UHFFFAOYSA-N 3-bromo-2h-indazole Chemical compound C1=CC=CC2=C(Br)NN=C21 HTKXRTUKPXEALT-UHFFFAOYSA-N 0.000 description 2
- MNIDYHCRWJBKLX-UHFFFAOYSA-N 4-(prop-2-enoylamino)benzoic acid Chemical compound OC(=O)C1=CC=C(NC(=O)C=C)C=C1 MNIDYHCRWJBKLX-UHFFFAOYSA-N 0.000 description 2
- DFCNILIWBHWXSC-MDWZMJQESA-N 4-[[(E)-4-(dimethylamino)but-2-enoyl]amino]-N-[3-[[1-(oxan-2-yl)indazol-3-yl]amino]phenyl]benzamide Chemical compound CN(C/C=C/C(=O)NC1=CC=C(C(=O)NC2=CC(=CC=C2)NC2=NN(C3=CC=CC=C23)C2OCCCC2)C=C1)C DFCNILIWBHWXSC-MDWZMJQESA-N 0.000 description 2
- GDLBSCLVNXCZJX-UHFFFAOYSA-N 4-amino-N-[3-[[1-(oxan-2-yl)indazol-3-yl]amino]phenyl]benzamide Chemical compound NC1=CC=C(C(=O)NC2=CC(=CC=C2)NC2=NN(C3=CC=CC=C23)C2OCCCC2)C=C1 GDLBSCLVNXCZJX-UHFFFAOYSA-N 0.000 description 2
- WGOLHUGPTDEKCF-UHFFFAOYSA-N 5-bromopyridin-2-amine Chemical compound NC1=CC=C(Br)C=N1 WGOLHUGPTDEKCF-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- LKQWRCGTSGZYJB-UHFFFAOYSA-N BrC=1C=C(C=CC=1)C(C(=O)NC1=NN(C2=CC=CC=C12)COCC[Si](C)(C)C)C Chemical compound BrC=1C=C(C=CC=1)C(C(=O)NC1=NN(C2=CC=CC=C12)COCC[Si](C)(C)C)C LKQWRCGTSGZYJB-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- YGYHZLUZEFFRCW-UHFFFAOYSA-N CC(C)(C)OC(=O)N1N=C(NC(=O)C(C)(C)C2=CC(=CC=C2)B2OC(C)(C)C(C)(C)O2)C=C1C1CC1 Chemical compound CC(C)(C)OC(=O)N1N=C(NC(=O)C(C)(C)C2=CC(=CC=C2)B2OC(C)(C)C(C)(C)O2)C=C1C1CC1 YGYHZLUZEFFRCW-UHFFFAOYSA-N 0.000 description 2
- NFSCRNSPAOLWAF-UHFFFAOYSA-N CC(C)(C)OC(=O)N1N=C(NC(=O)C2(CC2)C2=CC(=CC=C2)B2OC(C)(C)C(C)(C)O2)C=C1C1CC1 Chemical compound CC(C)(C)OC(=O)N1N=C(NC(=O)C2(CC2)C2=CC(=CC=C2)B2OC(C)(C)C(C)(C)O2)C=C1C1CC1 NFSCRNSPAOLWAF-UHFFFAOYSA-N 0.000 description 2
- OPPUCCIAUQMSNJ-XNTDXEJSSA-N CN(C/C=C/C(=O)NC1=CC=C(C=C1)C1=CC(=CC=C1)C(C(NC1=NN(C2=CC=CC=C12)COCC[Si](C)(C)C)=O)C)C Chemical compound CN(C/C=C/C(=O)NC1=CC=C(C=C1)C1=CC(=CC=C1)C(C(NC1=NN(C2=CC=CC=C12)COCC[Si](C)(C)C)=O)C)C OPPUCCIAUQMSNJ-XNTDXEJSSA-N 0.000 description 2
- VNQPDARRIJKZSD-INIZCTEOSA-N C[C@H](C(=O)NC1=NN(C(=O)OC(C)(C)C)C(=C1)C1CC1)C1=CC(=CC=C1)B1OC(C)(C)C(C)(C)O1 Chemical compound C[C@H](C(=O)NC1=NN(C(=O)OC(C)(C)C)C(=C1)C1CC1)C1=CC(=CC=C1)B1OC(C)(C)C(C)(C)O1 VNQPDARRIJKZSD-INIZCTEOSA-N 0.000 description 2
- 102100040428 Chitobiosyldiphosphodolichol beta-mannosyltransferase Human genes 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 102000016736 Cyclin Human genes 0.000 description 2
- 108050006400 Cyclin Proteins 0.000 description 2
- 102000002435 Cyclin T Human genes 0.000 description 2
- 108010068106 Cyclin T Proteins 0.000 description 2
- 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 description 2
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 2
- 108010025468 Cyclin-Dependent Kinase 6 Proteins 0.000 description 2
- 102100036883 Cyclin-H Human genes 0.000 description 2
- 102100036876 Cyclin-K Human genes 0.000 description 2
- 102100036239 Cyclin-dependent kinase 2 Human genes 0.000 description 2
- 102100036252 Cyclin-dependent kinase 4 Human genes 0.000 description 2
- 102100026804 Cyclin-dependent kinase 6 Human genes 0.000 description 2
- 101710177611 DNA polymerase II large subunit Proteins 0.000 description 2
- 101710184669 DNA polymerase II small subunit Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- 101000891557 Homo sapiens Chitobiosyldiphosphodolichol beta-mannosyltransferase Proteins 0.000 description 2
- 101000713127 Homo sapiens Cyclin-K Proteins 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- CLCVYSFZMWDHJK-UHFFFAOYSA-N N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3-piperidin-4-ylphenyl)propanamide Chemical compound C1(CC1)C1=CC(=NN1)NC(C(C)C1=CC(=CC=C1)C1CCNCC1)=O CLCVYSFZMWDHJK-UHFFFAOYSA-N 0.000 description 2
- IAZHDFAVJSTASS-UHFFFAOYSA-N N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-[3-(1,2,3,6-tetrahydropyridin-4-yl)phenyl]propanamide Chemical compound C1(CC1)C1=CC(=NN1)NC(C(C)C1=CC(=CC=C1)C=1CCNCC=1)=O IAZHDFAVJSTASS-UHFFFAOYSA-N 0.000 description 2
- ZTCLCSCHTACERP-AWEZNQCLSA-N N-[(1S)-1-[3-chloro-5-fluoro-2-[[2-methyl-4-(2-methyl-1,2,4-triazol-3-yl)quinolin-8-yl]oxymethyl]phenyl]ethyl]-2-(difluoromethoxy)acetamide Chemical compound C1=C(C=C(C(=C1Cl)COC1=CC=CC2=C(C=3N(N=CN=3)C)C=C(C)N=C12)[C@@H](NC(=O)COC(F)F)C)F ZTCLCSCHTACERP-AWEZNQCLSA-N 0.000 description 2
- BXRHVYDXPSMTOP-UHFFFAOYSA-N O=C(C(C)C=1C=C(C=CC=1)C1=CC=C(C=C1)NC(C=C)=O)NC1=NN(C2=CC=CC=C12)COCC[Si](C)(C)C Chemical compound O=C(C(C)C=1C=C(C=CC=1)C1=CC=C(C=C1)NC(C=C)=O)NC1=NN(C2=CC=CC=C12)COCC[Si](C)(C)C BXRHVYDXPSMTOP-UHFFFAOYSA-N 0.000 description 2
- 238000006069 Suzuki reaction reaction Methods 0.000 description 2
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 2
- BIIVYFLTOXDAOV-YVEFUNNKSA-N alvocidib Chemical compound O[C@@H]1CN(C)CC[C@@H]1C1=C(O)C=C(O)C2=C1OC(C=1C(=CC=CC=1)Cl)=CC2=O BIIVYFLTOXDAOV-YVEFUNNKSA-N 0.000 description 2
- 229950010817 alvocidib Drugs 0.000 description 2
- 229960004050 aminobenzoic acid Drugs 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000001028 anti-proliverative effect Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 108010089576 carboxy-terminal domain kinase Proteins 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 101150059448 cdk7 gene Proteins 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000013058 crude material Substances 0.000 description 2
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- VCRUFOUHDAQOIF-UHFFFAOYSA-N n-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]prop-2-enamide Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=C(NC(=O)C=C)C=C1 VCRUFOUHDAQOIF-UHFFFAOYSA-N 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 230000022983 regulation of cell cycle Effects 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- FNKJIONLRYGAKE-UHFFFAOYSA-N tert-butyl 3-(3-aminoanilino)-5-ethylpyrazole-1-carboxylate Chemical compound NC=1C=C(C=CC=1)NC1=NN(C(=C1)CC)C(=O)OC(C)(C)C FNKJIONLRYGAKE-UHFFFAOYSA-N 0.000 description 2
- YYPSLRSXKISVBU-LBPRGKRZSA-N tert-butyl 3-[[(2S)-2-(3-bromophenyl)propanoyl]amino]-5-cyclopropylpyrazole-1-carboxylate Chemical compound BrC=1C=C(C=CC=1)[C@@H](C(=O)NC1=NN(C(=C1)C1CC1)C(=O)OC(C)(C)C)C YYPSLRSXKISVBU-LBPRGKRZSA-N 0.000 description 2
- JGAXMKPOQHAEIY-UHFFFAOYSA-N tert-butyl 3-[[1-(3-bromophenyl)cyclopropanecarbonyl]amino]-5-cyclopropylpyrazole-1-carboxylate Chemical compound BrC=1C=C(C=CC=1)C1(CC1)C(=O)NC1=NN(C(=C1)C1CC1)C(=O)OC(C)(C)C JGAXMKPOQHAEIY-UHFFFAOYSA-N 0.000 description 2
- KDYJVYQVSICTBA-UHFFFAOYSA-N tert-butyl 3-[[2-(3-bromophenyl)-2-methylpropanoyl]amino]-5-cyclopropylpyrazole-1-carboxylate Chemical compound BrC=1C=C(C=CC=1)C(C(=O)NC1=NN(C(=C1)C1CC1)C(=O)OC(C)(C)C)(C)C KDYJVYQVSICTBA-UHFFFAOYSA-N 0.000 description 2
- OZOPOBMLTTZFRI-UHFFFAOYSA-N tert-butyl 3-[[2-(3-bromophenyl)acetyl]amino]-5-methylpyrazole-1-carboxylate Chemical compound BrC=1C=C(C=CC=1)CC(=O)NC1=NN(C(=C1)C)C(=O)OC(C)(C)C OZOPOBMLTTZFRI-UHFFFAOYSA-N 0.000 description 2
- GJDCNROAKOCYIQ-UHFFFAOYSA-N tert-butyl 3-amino-5-methylpyrazole-1-carboxylate Chemical compound CC1=CC(N)=NN1C(=O)OC(C)(C)C GJDCNROAKOCYIQ-UHFFFAOYSA-N 0.000 description 2
- INPOTOSFBLCFAP-UHFFFAOYSA-N tert-butyl 4-[3-[1-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-1-oxopropan-2-yl]phenyl]piperidine-1-carboxylate Chemical compound C1(CC1)C1=CC(=NN1)NC(C(C)C=1C=C(C=CC=1)C1CCN(CC1)C(=O)OC(C)(C)C)=O INPOTOSFBLCFAP-UHFFFAOYSA-N 0.000 description 2
- NGMMIVKZBHOAJW-UHFFFAOYSA-N tert-butyl 5-ethyl-3-(3-nitroanilino)pyrazole-1-carboxylate Chemical compound C(C)C1=CC(=NN1C(=O)OC(C)(C)C)NC1=CC(=CC=C1)[N+](=O)[O-] NGMMIVKZBHOAJW-UHFFFAOYSA-N 0.000 description 2
- FYGRDZFBHRJAMX-UHFFFAOYSA-N tert-butyl 5-ethyl-3-[3-[[4-(prop-2-enoylamino)benzoyl]amino]anilino]pyrazole-1-carboxylate Chemical compound C(C=C)(=O)NC1=CC=C(C(=O)NC=2C=C(C=CC=2)NC2=NN(C(=C2)CC)C(=O)OC(C)(C)C)C=C1 FYGRDZFBHRJAMX-UHFFFAOYSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- 238000010626 work up procedure Methods 0.000 description 2
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 2
- BIIBYWQGRFWQKM-JVVROLKMSA-N (2S)-N-[4-(cyclopropylamino)-3,4-dioxo-1-[(3S)-2-oxopyrrolidin-3-yl]butan-2-yl]-2-[[(E)-3-(2,4-dichlorophenyl)prop-2-enoyl]amino]-4,4-dimethylpentanamide Chemical compound CC(C)(C)C[C@@H](C(NC(C[C@H](CCN1)C1=O)C(C(NC1CC1)=O)=O)=O)NC(/C=C/C(C=CC(Cl)=C1)=C1Cl)=O BIIBYWQGRFWQKM-JVVROLKMSA-N 0.000 description 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- QLHMQZFTSIHQIT-LURJTMIESA-N (2s)-2-(3-bromophenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(Br)=C1 QLHMQZFTSIHQIT-LURJTMIESA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- QIVUCLWGARAQIO-OLIXTKCUSA-N (3s)-n-[(3s,5s,6r)-6-methyl-2-oxo-1-(2,2,2-trifluoroethyl)-5-(2,3,6-trifluorophenyl)piperidin-3-yl]-2-oxospiro[1h-pyrrolo[2,3-b]pyridine-3,6'-5,7-dihydrocyclopenta[b]pyridine]-3'-carboxamide Chemical compound C1([C@H]2[C@H](N(C(=O)[C@@H](NC(=O)C=3C=C4C[C@]5(CC4=NC=3)C3=CC=CN=C3NC5=O)C2)CC(F)(F)F)C)=C(F)C=CC(F)=C1F QIVUCLWGARAQIO-OLIXTKCUSA-N 0.000 description 1
- AUIXMWKVLPXKGC-UHFFFAOYSA-N (5-bromopyridin-2-yl)methanamine Chemical compound NCC1=CC=C(Br)C=N1 AUIXMWKVLPXKGC-UHFFFAOYSA-N 0.000 description 1
- CEYDLJSYGCLBDD-YRNVUSSQSA-N (E)-4-(dimethylamino)-N-[4-[3-[1-oxo-1-(pyrazolo[1,5-a]pyridin-2-ylamino)propan-2-yl]phenyl]phenyl]but-2-enamide Chemical compound CN(C/C=C/C(=O)NC1=CC=C(C=C1)C1=CC(=CC=C1)C(C(NC1=NN2C(C=CC=C2)=C1)=O)C)C CEYDLJSYGCLBDD-YRNVUSSQSA-N 0.000 description 1
- FWGXKFXAMWYOFD-VMPITWQZSA-N (E)-N-[1-[3-[1-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-1-oxopropan-2-yl]phenyl]piperidin-4-yl]-4-(dimethylamino)but-2-enamide Chemical compound C1(CC1)C1=CC(=NN1)NC(C(C)C=1C=C(C=CC=1)N1CCC(CC1)NC(\C=C\CN(C)C)=O)=O FWGXKFXAMWYOFD-VMPITWQZSA-N 0.000 description 1
- KJBPYAKLYFALDJ-RMKNXTFCSA-N (E)-N-[2-[1-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-1-oxopropan-2-yl]phenyl]-4-(dimethylamino)but-2-enamide Chemical compound C1(CC1)C1=CC(=NN1)NC(C(C)C1=C(C=CC=C1)NC(\C=C\CN(C)C)=O)=O KJBPYAKLYFALDJ-RMKNXTFCSA-N 0.000 description 1
- FKHPYIDNBJTYPT-BJMVGYQFSA-N (E)-N-[2-[3-[1-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-1-oxopropan-2-yl]phenyl]phenyl]-4-morpholin-4-ylbut-2-enamide Chemical compound CC(C(=O)NC1=NNC(=C1)C1CC1)C1=CC=CC(=C1)C1=C(NC(=O)\C=C\CN2CCOCC2)C=CC=C1 FKHPYIDNBJTYPT-BJMVGYQFSA-N 0.000 description 1
- IAKQXFOWZYIWAR-VMPITWQZSA-N (E)-N-[3-[1-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-1-oxopropan-2-yl]phenyl]-4-(dimethylamino)but-2-enamide Chemical compound C1(CC1)C1=CC(=NN1)NC(C(C)C=1C=C(C=CC=1)NC(\C=C\CN(C)C)=O)=O IAKQXFOWZYIWAR-VMPITWQZSA-N 0.000 description 1
- LICPUNVECJAMLO-IZZDOVSWSA-N (E)-N-[3-[3-[1-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-1-oxopropan-2-yl]phenyl]cyclohexyl]-4-(dimethylamino)but-2-enamide Chemical compound C1(CC1)C1=CC(=NN1)NC(C(C)C=1C=C(C=CC=1)C1CC(CCC1)NC(\C=C\CN(C)C)=O)=O LICPUNVECJAMLO-IZZDOVSWSA-N 0.000 description 1
- SKCISWTTYHUOJV-ZZXKWVIFSA-N (E)-N-[3-[3-[1-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-1-oxopropan-2-yl]phenyl]pyridin-4-yl]-4-morpholin-4-ylbut-2-enamide Chemical compound C1(CC1)C1=CC(=NN1)NC(C(C)C=1C=C(C=CC=1)C=1C=NC=CC=1NC(\C=C\CN1CCOCC1)=O)=O SKCISWTTYHUOJV-ZZXKWVIFSA-N 0.000 description 1
- QNCNPNBQICFOQU-SNAWJCMRSA-N (E)-N-[4-[1-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-1-oxopropan-2-yl]phenyl]-4-(dimethylamino)but-2-enamide Chemical compound C1(CC1)C1=CC(=NN1)NC(C(C)C1=CC=C(C=C1)NC(\C=C\CN(C)C)=O)=O QNCNPNBQICFOQU-SNAWJCMRSA-N 0.000 description 1
- QEXRKGOKBACTRG-VQFGERMISA-N (E)-N-[4-[3-[(2S)-1-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-1-oxopropan-2-yl]phenyl]-2-fluorophenyl]-4-(diethylamino)but-2-enamide Chemical compound C1(CC1)C1=CC(=NN1)NC([C@@H](C)C=1C=C(C=CC=1)C1=CC(=C(C=C1)NC(\C=C\CN(CC)CC)=O)F)=O QEXRKGOKBACTRG-VQFGERMISA-N 0.000 description 1
- GROHULHQWVAWLJ-SNAWJCMRSA-N (E)-N-[4-[3-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-4-methylisoquinolin-6-yl]phenyl]-4-(dimethylamino)but-2-enamide Chemical compound C1(CC1)C1=CC(=NN1)NC=1N=CC2=CC=C(C=C2C=1C)C1=CC=C(C=C1)NC(\C=C\CN(C)C)=O GROHULHQWVAWLJ-SNAWJCMRSA-N 0.000 description 1
- QSUMZLIWNJJRBG-VMPITWQZSA-N (E)-N-[4-[3-[(5-cyclopropyl-1H-pyrazol-3-yl)carbamoyl-methylamino]phenyl]phenyl]-4-(dimethylamino)but-2-enamide Chemical compound C1(CC1)C1=CC(=NN1)NC(N(C)C=1C=C(C=CC=1)C1=CC=C(C=C1)NC(\C=C\CN(C)C)=O)=O QSUMZLIWNJJRBG-VMPITWQZSA-N 0.000 description 1
- GMJMRCHMMFEFBX-MDWZMJQESA-N (E)-N-[4-[3-[1-[(5-cyclohexyl-1H-pyrazol-3-yl)amino]-1-oxopropan-2-yl]phenyl]phenyl]-4-(dimethylamino)but-2-enamide Chemical compound C1(CCCCC1)C1=CC(=NN1)NC(C(C)C=1C=C(C=CC=1)C1=CC=C(C=C1)NC(\C=C\CN(C)C)=O)=O GMJMRCHMMFEFBX-MDWZMJQESA-N 0.000 description 1
- PKPZOVXBACPJRX-KPKJPENVSA-N (E)-N-[4-[3-[1-[(5-cyclopentyl-1H-pyrazol-3-yl)amino]-1-oxopropan-2-yl]phenyl]phenyl]-4-(dimethylamino)but-2-enamide Chemical compound C1(CCCC1)C1=CC(=NN1)NC(C(C)C=1C=C(C=CC=1)C1=CC=C(C=C1)NC(\C=C\CN(C)C)=O)=O PKPZOVXBACPJRX-KPKJPENVSA-N 0.000 description 1
- IXTBIXXAAKDVJL-RMKNXTFCSA-N (E)-N-[4-[3-[1-[(5-cyclopropyl-1-methylpyrazol-3-yl)amino]-1-oxopropan-2-yl]phenyl]phenyl]-4-(dimethylamino)but-2-enamide Chemical compound CC(C(=O)NC1=NN(C)C(=C1)C1CC1)C1=CC=CC(=C1)C1=CC=C(NC(=O)\C=C\CN(C)C)C=C1 IXTBIXXAAKDVJL-RMKNXTFCSA-N 0.000 description 1
- LPJSXNSIPAVWKC-VMPITWQZSA-N (E)-N-[4-[3-[1-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-1-oxopropan-2-yl]phenyl]cyclohexyl]-4-(dimethylamino)but-2-enamide Chemical compound C1(CC1)C1=CC(=NN1)NC(C(C)C=1C=C(C=CC=1)C1CCC(CC1)NC(\C=C\CN(C)C)=O)=O LPJSXNSIPAVWKC-VMPITWQZSA-N 0.000 description 1
- BUQVXVCGNFEHJR-RMKNXTFCSA-N (E)-N-[4-[3-[1-[(5-cyclopropyl-4-methyl-1H-pyrazol-3-yl)amino]-1-oxopropan-2-yl]phenyl]phenyl]-4-(dimethylamino)but-2-enamide Chemical compound C1(CC1)C1=C(C(=NN1)NC(C(C)C=1C=C(C=CC=1)C1=CC=C(C=C1)NC(\C=C\CN(C)C)=O)=O)C BUQVXVCGNFEHJR-RMKNXTFCSA-N 0.000 description 1
- ANFBWWOTFWYFSY-SNAWJCMRSA-N (E)-N-[4-[4-[1-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-1-oxopropan-2-yl]pyridin-2-yl]phenyl]-4-(dimethylamino)but-2-enamide Chemical compound C1(CC1)C1=CC(=NN1)NC(C(C)C1=CC(=NC=C1)C1=CC=C(C=C1)NC(\C=C\CN(C)C)=O)=O ANFBWWOTFWYFSY-SNAWJCMRSA-N 0.000 description 1
- FJOBJVJWOHUJPA-RMKNXTFCSA-N (E)-N-[5-[3-[1-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-1-oxopropan-2-yl]phenyl]-2-methylpyrazol-3-yl]-4-(dimethylamino)but-2-enamide Chemical compound C1(CC1)C1=CC(=NN1)NC(C(C)C=1C=C(C=CC=1)C1=NN(C(=C1)NC(\C=C\CN(C)C)=O)C)=O FJOBJVJWOHUJPA-RMKNXTFCSA-N 0.000 description 1
- MDBVQMQRYOOKPI-VMPITWQZSA-N (E)-N-[5-[3-[1-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-1-oxopropan-2-yl]phenyl]-6-fluoropyridin-2-yl]-4-(dimethylamino)but-2-enamide Chemical compound C1(CC1)C1=CC(=NN1)NC(C(C)C=1C=C(C=CC=1)C=1C=CC(=NC=1F)NC(\C=C\CN(C)C)=O)=O MDBVQMQRYOOKPI-VMPITWQZSA-N 0.000 description 1
- WZCQRUWWHSTZEM-UHFFFAOYSA-N 1,3-phenylenediamine Chemical compound NC1=CC=CC(N)=C1 WZCQRUWWHSTZEM-UHFFFAOYSA-N 0.000 description 1
- MYDCJGVBYNDHIC-UHFFFAOYSA-N 1-(3-bromophenyl)cyclopropane-1-carboxylic acid Chemical compound C=1C=CC(Br)=CC=1C1(C(=O)O)CC1 MYDCJGVBYNDHIC-UHFFFAOYSA-N 0.000 description 1
- GFSRKGXIDBTJBQ-UHFFFAOYSA-N 1-(5-bromo-2,3-dihydroindol-1-yl)prop-2-en-1-one Chemical compound BrC1=CC=C2N(CCC2=C1)C(=O)C=C GFSRKGXIDBTJBQ-UHFFFAOYSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- CBRJPFGIXUFMTM-WDEREUQCSA-N 1-[(2S,5R)-2-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)piperidin-1-yl]prop-2-en-1-one Chemical compound N1=CN=C(C2=C1NC=C2)N[C@@H]2CC[C@@H](N(C2)C(C=C)=O)C CBRJPFGIXUFMTM-WDEREUQCSA-N 0.000 description 1
- FWIROFMBWVMWLB-UHFFFAOYSA-N 1-bromo-3-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC(Br)=C1 FWIROFMBWVMWLB-UHFFFAOYSA-N 0.000 description 1
- YDTDKKULPWTHRV-UHFFFAOYSA-N 1H-indazol-3-amine Chemical compound C1=CC=C2C(N)=NNC2=C1 YDTDKKULPWTHRV-UHFFFAOYSA-N 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- PZQVCFYGWRPVLE-UHFFFAOYSA-N 2-(3-bromophenyl)-2-methylpropanoic acid Chemical compound OC(=O)C(C)(C)C1=CC=CC(Br)=C1 PZQVCFYGWRPVLE-UHFFFAOYSA-N 0.000 description 1
- BPXKZEMBEZGUAH-UHFFFAOYSA-N 2-(chloromethoxy)ethyl-trimethylsilane Chemical compound C[Si](C)(C)CCOCCl BPXKZEMBEZGUAH-UHFFFAOYSA-N 0.000 description 1
- DWKNOLCXIFYNFV-HSZRJFAPSA-N 2-[[(2r)-1-[1-[(4-chloro-3-methylphenyl)methyl]piperidin-4-yl]-5-oxopyrrolidine-2-carbonyl]amino]-n,n,6-trimethylpyridine-4-carboxamide Chemical compound CN(C)C(=O)C1=CC(C)=NC(NC(=O)[C@@H]2N(C(=O)CC2)C2CCN(CC=3C=C(C)C(Cl)=CC=3)CC2)=C1 DWKNOLCXIFYNFV-HSZRJFAPSA-N 0.000 description 1
- JTPXVCKCLBROOJ-UHFFFAOYSA-N 2-amino-6-chloropyrazine Chemical compound NC1=CN=CC(Cl)=N1 JTPXVCKCLBROOJ-UHFFFAOYSA-N 0.000 description 1
- DFRAKBCRUYUFNT-UHFFFAOYSA-N 3,8-dicyclohexyl-2,4,7,9-tetrahydro-[1,3]oxazino[5,6-h][1,3]benzoxazine Chemical compound C1CCCCC1N1CC(C=CC2=C3OCN(C2)C2CCCCC2)=C3OC1 DFRAKBCRUYUFNT-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- SDARMQNRQJBGQE-UHFFFAOYSA-N 3-cyclopropyl-3-oxopropanenitrile Chemical compound N#CCC(=O)C1CC1 SDARMQNRQJBGQE-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- ZANPJXNYBVVNSD-UHFFFAOYSA-N 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=C(N)C=C1 ZANPJXNYBVVNSD-UHFFFAOYSA-N 0.000 description 1
- UXHQLGLGLZKHTC-CUNXSJBXSA-N 4-[(3s,3ar)-3-cyclopentyl-7-(4-hydroxypiperidine-1-carbonyl)-3,3a,4,5-tetrahydropyrazolo[3,4-f]quinolin-2-yl]-2-chlorobenzonitrile Chemical compound C1CC(O)CCN1C(=O)C1=CC=C(C=2[C@@H]([C@H](C3CCCC3)N(N=2)C=2C=C(Cl)C(C#N)=CC=2)CC2)C2=N1 UXHQLGLGLZKHTC-CUNXSJBXSA-N 0.000 description 1
- HFGHRUCCKVYFKL-UHFFFAOYSA-N 4-ethoxy-2-piperazin-1-yl-7-pyridin-4-yl-5h-pyrimido[5,4-b]indole Chemical compound C1=C2NC=3C(OCC)=NC(N4CCNCC4)=NC=3C2=CC=C1C1=CC=NC=C1 HFGHRUCCKVYFKL-UHFFFAOYSA-N 0.000 description 1
- FYTLHYRDGXRYEY-UHFFFAOYSA-N 5-Methyl-3-pyrazolamine Chemical compound CC=1C=C(N)NN=1 FYTLHYRDGXRYEY-UHFFFAOYSA-N 0.000 description 1
- VKLKXFOZNHEBSW-UHFFFAOYSA-N 5-[[3-[(4-morpholin-4-ylbenzoyl)amino]phenyl]methoxy]pyridine-3-carboxamide Chemical compound O1CCN(CC1)C1=CC=C(C(=O)NC=2C=C(COC=3C=NC=C(C(=O)N)C=3)C=CC=2)C=C1 VKLKXFOZNHEBSW-UHFFFAOYSA-N 0.000 description 1
- QEDCHCLHHGGYBT-UHFFFAOYSA-N 5-bromo-2,3-dihydro-1h-indole Chemical compound BrC1=CC=C2NCCC2=C1 QEDCHCLHHGGYBT-UHFFFAOYSA-N 0.000 description 1
- FMIAELJMRNMQHT-UHFFFAOYSA-N 5-cyclopropyl-1-methylpyrazol-3-amine Chemical compound CN1N=C(N)C=C1C1CC1 FMIAELJMRNMQHT-UHFFFAOYSA-N 0.000 description 1
- GDUANFXPOZTYKS-UHFFFAOYSA-N 6-bromo-8-[(2,6-difluoro-4-methoxybenzoyl)amino]-4-oxochromene-2-carboxylic acid Chemical compound FC1=CC(OC)=CC(F)=C1C(=O)NC1=CC(Br)=CC2=C1OC(C(O)=O)=CC2=O GDUANFXPOZTYKS-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 102000051485 Bcl-2 family Human genes 0.000 description 1
- 108700038897 Bcl-2 family Proteins 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 125000005915 C6-C14 aryl group Chemical group 0.000 description 1
- 229940126074 CDK kinase inhibitor Drugs 0.000 description 1
- 102100030933 CDK-activating kinase assembly factor MAT1 Human genes 0.000 description 1
- 101150012716 CDK1 gene Proteins 0.000 description 1
- 101150059217 CDK12 gene Proteins 0.000 description 1
- 101150035324 CDK9 gene Proteins 0.000 description 1
- 101100533230 Caenorhabditis elegans ser-2 gene Proteins 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 108010068192 Cyclin A Proteins 0.000 description 1
- 102000002427 Cyclin B Human genes 0.000 description 1
- 108010068150 Cyclin B Proteins 0.000 description 1
- 108010068237 Cyclin H Proteins 0.000 description 1
- 102100025191 Cyclin-A2 Human genes 0.000 description 1
- 102100034770 Cyclin-dependent kinase inhibitor 3 Human genes 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000583935 Homo sapiens CDK-activating kinase assembly factor MAT1 Proteins 0.000 description 1
- 101000713120 Homo sapiens Cyclin-H Proteins 0.000 description 1
- 101000868333 Homo sapiens Cyclin-dependent kinase 1 Proteins 0.000 description 1
- 101000945639 Homo sapiens Cyclin-dependent kinase inhibitor 3 Proteins 0.000 description 1
- 101000909198 Homo sapiens DNA polymerase delta catalytic subunit Proteins 0.000 description 1
- 101001056180 Homo sapiens Induced myeloid leukemia cell differentiation protein Mcl-1 Proteins 0.000 description 1
- 102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- JJSFPFCJNRKLIC-VMPITWQZSA-N N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-[3-[4-[(E)-4-(dimethylamino)but-2-enoyl]piperazin-1-yl]phenyl]propanamide Chemical compound C1(CC1)C1=CC(=NN1)NC(C(C)C1=CC(=CC=C1)N1CCN(CC1)C(\C=C\CN(C)C)=O)=O JJSFPFCJNRKLIC-VMPITWQZSA-N 0.000 description 1
- LOIPTYCVEFXVQC-DHZHZOJOSA-N N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-[3-[6-[[(E)-4-(diethylamino)but-2-enoyl]amino]pyridin-3-yl]phenyl]-3-methylbutanamide Chemical compound C1(CC1)C1=CC(=NN1)NC(C(C(C)C)C=1C=C(C=CC=1)C=1C=CC(=NC=1)NC(\C=C\CN(CC)CC)=O)=O LOIPTYCVEFXVQC-DHZHZOJOSA-N 0.000 description 1
- VZBAXFZRGOVLCW-JXMROGBWSA-N N-(5-cyclopropyl-1H-pyrazol-3-yl)-3-methyl-2-[3-[6-[[(E)-4-piperidin-1-ylbut-2-enoyl]amino]pyridin-3-yl]phenyl]butanamide Chemical compound C1(CC1)C1=CC(=NN1)NC(C(C(C)C)C=1C=C(C=CC=1)C=1C=CC(=NC=1)NC(\C=C\CN1CCCCC1)=O)=O VZBAXFZRGOVLCW-JXMROGBWSA-N 0.000 description 1
- NQVGHBBUAYANPC-RMKNXTFCSA-N N-(5-cyclopropyl-1H-pyrazol-3-yl)-3-methyl-2-[3-[6-[[(E)-4-pyrrolidin-1-ylbut-2-enoyl]amino]pyridin-3-yl]phenyl]butanamide Chemical compound C1(CC1)C1=CC(=NN1)NC(C(C(C)C)C=1C=C(C=CC=1)C=1C=CC(=NC=1)NC(\C=C\CN1CCCC1)=O)=O NQVGHBBUAYANPC-RMKNXTFCSA-N 0.000 description 1
- RAHCCLAZVPIUKT-UHFFFAOYSA-N N-[(5-bromopyridin-2-yl)methyl]prop-2-enamide Chemical compound BrC=1C=CC(=NC=1)CNC(C=C)=O RAHCCLAZVPIUKT-UHFFFAOYSA-N 0.000 description 1
- GFKYGHONKWFMDQ-YRNVUSSQSA-N N-[3-[1-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-1-oxopropan-2-yl]phenyl]-1-[(E)-4-(dimethylamino)but-2-enoyl]piperidine-2-carboxamide Chemical compound C1(CC1)C1=CC(=NN1)NC(C(C)C=1C=C(C=CC=1)NC(=O)C1N(CCCC1)C(\C=C\CN(C)C)=O)=O GFKYGHONKWFMDQ-YRNVUSSQSA-N 0.000 description 1
- LSJOQACXADDVKU-UXBLZVDNSA-N N-[3-[1-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-1-oxopropan-2-yl]phenyl]-1-[(E)-4-(dimethylamino)but-2-enoyl]piperidine-3-carboxamide Chemical compound C1(CC1)C1=CC(=NN1)NC(C(C)C=1C=C(C=CC=1)NC(=O)C1CN(CCC1)C(\C=C\CN(C)C)=O)=O LSJOQACXADDVKU-UXBLZVDNSA-N 0.000 description 1
- LOGAIHATOJTCNF-UXBLZVDNSA-N N-[3-[1-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-1-oxopropan-2-yl]phenyl]-1-[(E)-4-(dimethylamino)but-2-enoyl]pyrrolidine-2-carboxamide Chemical compound C1(CC1)C1=CC(=NN1)NC(C(C)C=1C=C(C=CC=1)NC(=O)C1N(CCC1)C(\C=C\CN(C)C)=O)=O LOGAIHATOJTCNF-UXBLZVDNSA-N 0.000 description 1
- WAQQDYGEPRLGKN-VMPITWQZSA-N N-[3-[1-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-1-oxopropan-2-yl]phenyl]-4-[(E)-4-(dimethylamino)but-2-enoyl]morpholine-2-carboxamide Chemical compound C1(CC1)C1=CC(=NN1)NC(C(C)C=1C=C(C=CC=1)NC(=O)C1CN(CCO1)C(\C=C\CN(C)C)=O)=O WAQQDYGEPRLGKN-VMPITWQZSA-N 0.000 description 1
- FBENEJHURNUWKV-VMPITWQZSA-N N-[3-[1-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-1-oxopropan-2-yl]phenyl]-4-[(E)-4-(dimethylamino)but-2-enoyl]piperazine-1-carboxamide Chemical compound C1(CC1)C1=CC(=NN1)NC(C(C)C=1C=C(C=CC=1)NC(=O)N1CCN(CC1)C(\C=C\CN(C)C)=O)=O FBENEJHURNUWKV-VMPITWQZSA-N 0.000 description 1
- AVYVHIKSFXVDBG-UHFFFAOYSA-N N-benzyl-N-hydroxy-2,2-dimethylbutanamide Chemical compound C(C1=CC=CC=C1)N(C(C(CC)(C)C)=O)O AVYVHIKSFXVDBG-UHFFFAOYSA-N 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 102000002508 Peptide Elongation Factors Human genes 0.000 description 1
- 108010068204 Peptide Elongation Factors Proteins 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 108010012271 Positive Transcriptional Elongation Factor B Proteins 0.000 description 1
- 102000019014 Positive Transcriptional Elongation Factor B Human genes 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 102000009516 Protein Serine-Threonine Kinases Human genes 0.000 description 1
- 108010009341 Protein Serine-Threonine Kinases Proteins 0.000 description 1
- 102000009572 RNA Polymerase II Human genes 0.000 description 1
- 108010009460 RNA Polymerase II Proteins 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 101100273253 Rhizopus niveus RNAP gene Proteins 0.000 description 1
- 229910020008 S(O) Inorganic materials 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- MCRWZBYTLVCCJJ-DKALBXGISA-N [(1s,3r)-3-[[(3s,4s)-3-methoxyoxan-4-yl]amino]-1-propan-2-ylcyclopentyl]-[(1s,4s)-5-[6-(trifluoromethyl)pyrimidin-4-yl]-2,5-diazabicyclo[2.2.1]heptan-2-yl]methanone Chemical compound C([C@]1(N(C[C@]2([H])C1)C(=O)[C@@]1(C[C@@H](CC1)N[C@@H]1[C@@H](COCC1)OC)C(C)C)[H])N2C1=CC(C(F)(F)F)=NC=N1 MCRWZBYTLVCCJJ-DKALBXGISA-N 0.000 description 1
- FMXZICOMOYQPBS-RMKNXTFCSA-N [2-[1-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-1-oxopropan-2-yl]phenyl] 4-[(E)-4-(dimethylamino)but-2-enoyl]piperazine-1-carboxylate Chemical compound CN(C/C=C/C(=O)N1CCN(CC1)C(=O)OC1=C(C=CC=C1)C(C(=O)NC1=NNC(=C1)C1CC1)C)C FMXZICOMOYQPBS-RMKNXTFCSA-N 0.000 description 1
- WCJPVRLRUJHNOJ-VMPITWQZSA-N [3-[1-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-1-oxopropan-2-yl]phenyl] 4-[(E)-4-(dimethylamino)but-2-enoyl]piperazine-1-carboxylate Chemical compound CN(C/C=C/C(=O)N1CCN(CC1)C(=O)OC1=CC(=CC=C1)C(C(=O)NC1=NNC(=C1)C1CC1)C)C WCJPVRLRUJHNOJ-VMPITWQZSA-N 0.000 description 1
- NSPRQIBCWAPWFY-SNAWJCMRSA-N [4-[1-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-1-oxopropan-2-yl]phenyl] 4-[(E)-4-(dimethylamino)but-2-enoyl]piperazine-1-carboxylate Chemical compound CN(C/C=C/C(=O)N1CCN(CC1)C(=O)OC1=CC=C(C=C1)C(C(=O)NC1=NNC(=C1)C1CC1)C)C NSPRQIBCWAPWFY-SNAWJCMRSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical group 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000005078 alkoxycarbonylalkyl group Chemical group 0.000 description 1
- 125000000278 alkyl amino alkyl group Chemical group 0.000 description 1
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 125000004688 alkyl sulfonyl alkyl group Chemical group 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 125000006350 alkyl thio alkyl group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 125000005122 aminoalkylamino group Chemical group 0.000 description 1
- 125000005097 aminocarbonylalkyl group Chemical group 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 125000005128 aryl amino alkyl group Chemical group 0.000 description 1
- 125000005100 aryl amino carbonyl group Chemical group 0.000 description 1
- 125000001769 aryl amino group Chemical group 0.000 description 1
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 description 1
- 125000005110 aryl thio group Chemical group 0.000 description 1
- 125000005164 aryl thioalkyl group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- XDFFYJGKULMBKM-UHFFFAOYSA-N azanium;acetonitrile;acetate;hydrate Chemical compound [NH4+].O.CC#N.CC([O-])=O XDFFYJGKULMBKM-UHFFFAOYSA-N 0.000 description 1
- 125000003725 azepanyl group Chemical group 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 1
- 238000010256 biochemical assay Methods 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 125000002529 biphenylenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C12)* 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 125000004181 carboxyalkyl group Chemical group 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003221 ear drop Substances 0.000 description 1
- 229940047652 ear drops Drugs 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 238000003209 gene knockout Methods 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- QWXYZCJEXYQNEI-OSZHWHEXSA-N intermediate I Chemical compound COC(=O)[C@@]1(C=O)[C@H]2CC=[N+](C\C2=C\C)CCc2c1[nH]c1ccccc21 QWXYZCJEXYQNEI-OSZHWHEXSA-N 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007915 intraurethral administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- 125000006578 monocyclic heterocycloalkyl group Chemical group 0.000 description 1
- HDZGCSFEDULWCS-UHFFFAOYSA-N monomethylhydrazine Chemical compound CNN HDZGCSFEDULWCS-UHFFFAOYSA-N 0.000 description 1
- YHVNFKZUGWYSHC-UHFFFAOYSA-N n-(5-bromopyridin-2-yl)prop-2-enamide Chemical compound BrC1=CC=C(NC(=O)C=C)N=C1 YHVNFKZUGWYSHC-UHFFFAOYSA-N 0.000 description 1
- VOVZXURTCKPRDQ-CQSZACIVSA-N n-[4-[chloro(difluoro)methoxy]phenyl]-6-[(3r)-3-hydroxypyrrolidin-1-yl]-5-(1h-pyrazol-5-yl)pyridine-3-carboxamide Chemical compound C1[C@H](O)CCN1C1=NC=C(C(=O)NC=2C=CC(OC(F)(F)Cl)=CC=2)C=C1C1=CC=NN1 VOVZXURTCKPRDQ-CQSZACIVSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000012746 preparative thin layer chromatography Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 125000001325 propanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 235000004400 serine Nutrition 0.000 description 1
- 150000003355 serines Chemical class 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- MIMXIGUMAJBVCE-UHFFFAOYSA-N tert-butyl 3-amino-5-ethylpyrazole-1-carboxylate Chemical compound NC1=NN(C(=C1)CC)C(=O)OC(C)(C)C MIMXIGUMAJBVCE-UHFFFAOYSA-N 0.000 description 1
- VVDCRJGWILREQH-UHFFFAOYSA-N tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydro-2h-pyridine-1-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCC(B2OC(C)(C)C(C)(C)O2)=C1 VVDCRJGWILREQH-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 235000008521 threonine Nutrition 0.000 description 1
- 150000003588 threonines Chemical class 0.000 description 1
- 238000002877 time resolved fluorescence resonance energy transfer Methods 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 239000006208 topical dosage form Substances 0.000 description 1
- 231100000440 toxicity profile Toxicity 0.000 description 1
- 230000005029 transcription elongation Effects 0.000 description 1
- 230000037426 transcriptional repression Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- KMIOJWCYOHBUJS-HAKPAVFJSA-N vorolanib Chemical compound C1N(C(=O)N(C)C)CC[C@@H]1NC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C KMIOJWCYOHBUJS-HAKPAVFJSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
- C07D231/40—Acylated on said nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Definitions
- This invention pertains to compounds which inhibit the activity of selective transcriptional cyclin dependent kinases (CDKs) including CDK7, CDK9, CDK12, CDK13 and CDK18, more particularly transcriptional cyclin dependent kinase-7 (CDK7).
- CDKs selective transcriptional cyclin dependent kinases
- the invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compositions in the treatment of diseases or disorder associated with selective transcriptional CDKs.
- Kinases are important cellular enzymes that perform essential cellular functions such as regulating cell division and proliferation, and also appear to play a decisive role in many disease states that are characterized by uncontrolled proliferation and differentiation of cells. These disease states encompass a variety of cell types and maladies such as cancer, atherosclerosis, restenosis and other proliferative disorders (Kris M G et al., JAMA 290 (16): 2149-58, 2003).
- Cyclin-dependent kinases are relatively small proteins, with molecular weights ranging from 34 to 40 kDa, and contain little more than the kinase domain. CDK binds a regulatory protein called a cyclin. Without cyclin, CDK has little kinase activity; only the cyclin-CDK complex is an active kinase. CDKs phosphorylate their substrates on serines and threonines, so they are serine-threonine kinases (Morgan, D. O., Cell Division, 2:27, 2007).
- CDK7 cyclin-dependent kinase family
- CDK7-13 and 18 have been linked to transcription, only CDK1, 2, 4 and 6 show demonstrable association with the cell cycle.
- CDK7 has consolidated kinase activities, regulating both the cell cycle and transcription.
- CDK7 exists as a heterotrimeric complex and is believed to function as a CDK1/2-activating kinase (CAK), whereby phosphorylation of conserved residues in CDK1/2 by CDK7 is required for full catalytic CDK activity and cell cycle progression (Desai et al., Mol. Cell Biol. 15, 345-350, 1995).
- CAK CDK1/2-activating kinase
- CDK7 which complexes with cyclin H and MAT1, phosphorylates the cell cycle CDKs in the activation of T-loop, to promote their activities (Fisher et al., Cell ., August 26; 78(4): 713-24, 1994).
- CDK7 would provide a potent means of inhibiting cell cycle progression, which may be especially relevant given that there is compelling evidence from gene knockout studies in mice for lack of an absolute requirement for CDK2, CDK4 and CDK6 for the cell cycle, at least in most cell types (Malumbres et al., Nature Cell Biology, 11, 1275-1276, 2009), whilst different tumors appear to require some, but be independent of other interphase CDKs (CDK2, CDK4, CDK6). Recent genetic and biochemical studies have confirmed the importance of CDK7 for cell cycle progression (Larochelle et al., Mol Cell ., March 23; 25(6):839-50. 2007; Ganuza et al., EMBO J ., May 30; 31(11): 2498-510, 2012).
- Cyclin-dependent kinase 7 activates cell cycle CDKs and is a member of the general Transcription factor II Human (TFIIH). CDK7 also plays a role in transcription and possibly in DNA repair.
- the trimeric Cak complex CDK7/CyclinH/MAT1 is also a component of TFIIH, the general transcription/DNA repair factor IIH (Morgan, D. O., Annu. Rev. Cell Dev. Biol. 13, 261-91, 1997).
- TFIIH subunit CDK7 phosphorylates the CTD (Carboxy-Terminal-Domain) of the largest subunit of RNA polymerase II (pol II).
- the CTD of mammalian pol II consists of 52 heptad repeats with the consensus sequence 1 YSPTSPS 7 and the phosphorylation status of the Ser residues at positions 2 and 5 has been shown to be important in the activation of RNAP-II indicating that it is likely to have a crucial role in the function of the CTD.
- CDK7 which primarily phosphorylates Ser-5 (PS5) of RNAP-II at the promoter as part of transcriptional initiation (Gomes et al., Genes Dev. 2006 Mar. 1; 20(5):601-12, 2006), in contrast with CDK9, which phosphorylates both Ser-2 and Ser-5 of the CTD heptad (Pinhero et al., Eur. J. Biochem., 271, pp. 1004-1014, 2004).
- CDK7 In addition to CDK7, other CDKs have been reported to phosphorylate and regulate RNA pol (II) CTD.
- the other CDKs include, Cdk9/Cyclin T1 or T2 that constitute the active form of the positive transcription elongation factor (P-TEFb) (Peterlin and Price, Mol Cell ., August 4; 23(3): 297-305,2006) and Cdk12/Cyclin K and Cdk13/Cyclin K as the latest members of RNAPII CTD kinases (Bartkowiak et al., Genes Dev ., October 15; 24(20):2303-16, 2010; Blazek et al., Genes Dev . October 15; 25(20):2158-72, 2011).
- P-TEFb positive transcription elongation factor
- RNAP II CTD phosphorylation has been shown to preferentially effect proteins with short half-lives, including those of the anti-apoptotic BCL-2 family.
- the transcriptional non-selective cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and down-regulation of Mcl-1; (Gojo et al., Clin. Cancer Res. 8, 3527-3538, 2002).
- CDK7 enzyme complexes are involved in multiple functions in the cell: cell cycle control, transcription regulation and DNA repair. It is surprising to find one kinase involved in such diverse cellular processes, some of which are even mutually exclusive. It also is puzzling that multiple attempts to find cell cycle dependent changes in CDK7 kinase activity remained unsuccessful. This is unexpected since activity and phosphorylation state of its substrate, CDC2, fluctuate during the cell cycle. In fact, it is shown that cdk7 activity is required for the activation of bothCdc2/Cyclin A and Cdc2/Cyclin B complexes, and for cell division. (Larochelle, S. et al. Genes Dev 12,370-81, 1998).
- flavopiridol a non-selective pan-CDK inhibitor that targets CTD kinases, has demonstrated efficacy for the treatment of chronic lymphocytic leukemia (CLL), but suffers from a poor toxicity profile (Lin et al., J. Clin. Oncol. 27, 6012-6018, 2009; Christian et al., Clin. Lymphoma Myeloma, 9, Suppl. 3, S179-S185, 2009).
- CDK7 may form different complexes with different substrate specificity and presumably different in-vivo functions (Frit, P. et al., Biochimie 81, 27-38, 1999; Schutz, P. et al. Cell 102, 599-607, 2000).
- substituted heterocyclyl derivatives and pharmaceutical compositions thereof which are capable of suppressing and/or inhibiting cyclin dependent kinase-7 signalling pathway.
- ring A is cycloalkyl, aryl, heteroaryl or heterocyclyl
- ring B is aryl, cycloalkyl, heterocyclyl or absent;
- R 1 is hydrogen or alkyl
- R 2 is hydrogen, alkyl or cycloalkyl
- R 3 is hydrogen, alkyl or heteroaryl
- R 2 together with R 1 or R 3 along with the ring atoms to which they are attached forms a 5-7 membered ring;
- R 4 at each occurrence is halo, alkyl, hydroxy, alkoxy, amino, nitro, cyano or haloalkyl;
- R 5 ′ is hydrogen, halo, alkyl, alkoxy, alkoxyalkyl or —(CH 2 ) 1-3 —NR a R b ;
- R 5 ′′ is H or alkyl;
- R a and R b are each independently hydrogen, alkyl, alkoxy or alkoxyalkyl; alternatively, R a and R b together with the nitrogen atom to which they are attached form an optionally substituted ring containing 0-2 additional heteroatoms independently selected from N, O or S; wherein the optional substituent is one or more halo, alkyl, acyl, hydroxy, cyano, cyanoalkyl, haloalkyl, alkoxy, alkoxyalkyl, —COOH or —COO-alkyl;
- R 6 at each occurrence is halo, alkyl, hydroxy, alkoxy, amino, nitro, cyano or haloalkyl;
- L 1 is *—CR c R d —C(O)—, *—NR e C(O)— or absent; wherein * is point of attachment with ring A;
- R e and R d independently are hydrogen, alkyl or haloalkyl; alternatively, R c and R d together with the carbon to which they are attached form a cycloalkyl ring;
- R c is hydrogen or alkyl
- L 2 is —C(O)NH—, —C(O)O— or absent;
- n 0, 1 or 2;
- p is 0 or 1
- q 0 to 3.
- the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient (such as a pharmaceutically acceptable carrier or diluent).
- the present invention relates to the preparation of compounds of formula (I).
- substituted heterocyclyl derivatives of formula (I) which are capable of inhibiting CDK7 and therapeutic use thereof.
- alkyl alone or in combination with other term(s) means saturated aliphatic hydrocarbon chains, including C 1 -C 10 straight or C 3 -C 10 branched alkyl groups.
- alkyl include but are not limited to methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, isopentyl or neopentyl and the like.
- halo or halogen alone or in combination with other term(s) means fluorine, chlorine, bromine or iodine.
- haloalkyl means alkyl substituted with one or more halogen atoms, wherein the alkyl groups are as defined above.
- halo is used herein interchangeably with the term “halogen” means F, Cl, Br or I.
- haloalkyl include but are not limited to fluoromethyl, difluoromethyl, chloromethyl, trifluoromethyl, 2,2,2-trifluoroethyl and the like.
- hydroxy or “hydroxyl” alone or in combination with other term(s) means —OH.
- alkoxy refers to the group alkyl-O— or —O-alkyl, where alkyl groups are as defined above.
- alkoxy- groups include but are not limited to methoxy, ethoxy, n-propoxy, n-butoxy, t-butoxy and the like.
- An alkoxy group can be unsubstituted or substituted with one or more suitable groups.
- alkoxyalkyl refers to the group alkyl-O-alkyl-, wherein alkyl and alkoxy groups are as defined above.
- alkoxyalkyl- groups include but are not limited to methoxymethyl, ethoxymethyl, methoxyethyl, isopropoxymethyl and the like.
- cyano refers to —CN; and the term “cyanoalkyl” refers to alkyl substituted with —CN; wherein the alkyl groups are as defined above.
- amino refers to —NH 2 ;
- nitro refers to —NO 2 ;
- acyl refers to the group —C(O)-alkyl, wherein alkyl groups are as defined above.
- alkoxy- groups include but are not limited to acetyl, propanoyl and acrylyl.
- An alkoxy group can be unsubstituted or substituted with one or more suitable groups.
- cycloalkyl alone or in combination with other term(s) means —C 3 -C 10 saturated cyclic hydrocarbon ring.
- a cycloalkyl may be a single ring, which typically contains from 3 to 7 carbon ring atoms. Examples of single-ring cycloalkyls include but are not limited to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and the like.
- a cycloalkyl may alternatively be polycyclic or contain more than one ring. Examples of polycyclic cycloalkyls include bridged, fused and spirocyclyls and the like.
- aryl is optionally substituted monocyclic, bicyclic or polycyclic aromatic hydrocarbon ring system of about 6 to 14 carbon atoms.
- Examples of a C 6 -C 14 aryl group include, but are not limited to phenyl, naphthyl, anthryl, tetrahydronaphthyl, fluorenyl, indanyl, biphenylenyl and acenaphthyl.
- Aryl group which can be unsubstituted or substituted with one or more suitable groups.
- heterocycloalkyl refers to a non-aromatic, saturated or partially saturated monocyclic or polycyclic ring system of 3 to 15 members having at least one heteroatom or heterogroup selected from O, N, S, S(O), S(O) 2 , NH or C(O) with the remaining ring atoms being independently selected from the group consisting of carbon, oxygen, nitrogen and sulfur.
- a monocyclic heterocycloalkyl may typically contain 4 to 7 ring atoms.
- Heterocycloalkyl include, but are not limited to azetidinyl, oxetanyl, imidazolidinyl, pyrrolidinyl, oxazolidinyl, thiazolidinyl, pyrazolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl, tetrahydropyranyl, morpholinyl, oxapiperazinyl, oxapiperidinyl, tetrahydrofuryl, tetrahydropyranyl, tetrahydrothiophenyl, dihydropyranyl, indolinyl, indolinylmethyl, azepanyl and N-oxides thereof. Attachment of a heterocycloalkyl substituent can occur via either a carbon atom or a heteroatom.
- a heterocycloalkyl group can be optionally substituted with one or more suitable groups by one or more afore
- heteroaryl alone or in combination with other term(s) means a completely unsaturated ring system containing a total of 5 to 14 ring atoms. At least one of the ring atoms is a heteroatom (i.e., oxygen, nitrogen, or sulfur), with the remaining ring atoms/groups being independently selected from the group consisting of carbon, oxygen, nitrogen or sulfur.
- a heteroaryl may be a single-ring (monocyclic) or polycyclic ring system. Examples of “heteroaryl” include but are not limited to pyridyl, indolyl, benzimidazolyl, benzothiazolyl and the like.
- heterocyclyl alone or in combination with other term(s) includes both “heterocycloalkyl” and “heteroaryl” groups which are as defined above.
- heteroatom designates a sulfur, nitrogen or oxygen atom.
- the term “optionally substituted” or “substituted” or “optionally substituted with suitable groups” refers to replacement of one or more hydrogen radicals in a given structure with a radical of a specified substituent including, but not limited to: halo, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, thiol, alkylthio, arylthio, alkylthioalkyl, arylthioalkyl, alkylsulfonyl, alkylsulfonylalkyl, arylsulfonylalkyl, alkoxy, aryloxy, aralkoxy, aminocarbonyl, alkylaminocarbonyl, arylaminocarbonyl, alkoxycarbonyl, aryloxycarbonyl, haloalkyl, amino, trifluoromethyl, cyano, nitro, alkylamino, arylamino, alky
- the term ‘compound(s)’ comprises the compounds disclosed in the present invention.
- composition is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts.
- pharmaceutically acceptable it is meant the carrier, diluent or excipient must be compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
- treat refers to a method of alleviating or abrogating a disease and/or its attendant symptoms.
- prevent refers to a method of preventing the onset of a disease and/or its attendant symptoms or barring a subject from acquiring a disease.
- prevent also include delaying the onset of a disease and/or its attendant symptoms and reducing a subject's risk of acquiring a disease.
- terapéuticaally effective amount refers to that amount of the compound being administered sufficient to prevent development of or alleviate to some extent one or more of the symptoms of the condition or disorder being treated.
- “Pharmaceutically acceptable” means that, which is useful in preparing a pharmaceutical composition that is generally safe, non-toxic and neither biologically nor otherwise undesirable and includes that which is acceptable for veterinary as well as human pharmaceutical use.
- stereoisomers refers to any enantiomers, diastereoisomers, or geometrical isomers of the compounds of Formula (I), (IA), (IB), (IC), (ID), (IE), (IF) and (IG), wherever they are chiral or when they bear one or more double bonds.
- compounds of the formula (I), (IA), (IB), (IC), (ID), (IE), (IF) and (IG) are chiral, they can exist in racemic or in optically active form. It should be understood that the invention encompasses all stereochemical isomeric forms, including diastereomeric, enantiomeric and epimeric forms, as well as d-isomers and l-isomers and mixtures thereof.
- Individual stereoisomers of compounds can be prepared synthetically from commercially available starting materials which contain chiral centers or by preparation of mixtures of enantiomeric products followed by separation such as conversion to a mixture of diastereomers followed by separation or recrystallization, chromatographic techniques, direct separation of enantiomers on chiral chromatographic columns, or any other appropriate method known in the art.
- Starting compounds of particular stereochemistry are either commercially available or can be made and resolved by techniques known in the art.
- the compounds of the present invention may exist as geometric isomers.
- the present invention includes all cis, trans, syn, anti,
- E
- Z
- isomers as well as the appropriate mixtures thereof.
- the present invention provides substituted heterocyclylderivatives of formula (I), which are useful for the inhibition of CDK7.
- the present invention further provides pharmaceutical compositions comprising the said substituted heterocyclyl compounds of formula (I) and their derivatives as therapeutic agents.
- the present invention provides compounds of formula (I),
- ring A is cycloalkyl, aryl, heteroaryl or heterocyclyl
- ring B is aryl, cycloalkyl, heterocyclyl or absent;
- R 1 is hydrogen or alkyl
- R 2 is hydrogen, alkyl or cycloalkyl
- R 3 is hydrogen, alkyl or heteroaryl
- R 2 together with R 1 or R 3 along with the ring atoms to which they are attached forms a 5-7 membered ring;
- R 4 at each occurrence is halo, alkyl, hydroxy, alkoxy, amino, nitro, cyano or haloalkyl;
- R 5 ′ is hydrogen, halo, alkyl, alkoxy, alkoxyalkyl or —(CH 2 ) 1-3 —NR a R b ;
- R 5 ′′ is H or alkyl
- R a and R b are each independently hydrogen, alkyl, alkoxy or alkoxyalkyl; alternatively, R a and R b together with the nitrogen atom to which they are attached form an optionally substituted ring containing 0-2 additional heteroatoms independently selected from N, O or S; wherein the optional substituent is one or more halo, alkyl, acyl, hydroxy, cyano, cyanoalkyl, haloalkyl, alkoxy, alkoxyalkyl, —COOH or —COO-alkyl;
- R 6 at each occurrence is halo, alkyl, hydroxy, alkoxy, amino, nitro, cyano or haloalkyl;
- L 1 is *—CR c R d —C(O)—, *—NR e C(O)— or absent; wherein * is point of attachment with ring A;
- R c and R d independently are hydrogen, alkyl or haloalkyl; alternatively, R c and R d together with the carbon to which they are attached form a cycloalkyl ring;
- R e is hydrogen or alkyl
- L 2 is —C(O)NH—, —C(O)O— or absent;
- n 0, 1 or 2;
- p is 0 or 1
- q 0 to 3.
- ring A is cycloalkyl, aryl, heteroaryl or heterocyclyl
- ring B is aryl, cycloalkyl, heterocyclyl or absent;
- R 1 is hydrogen or alkyl
- R 2 is hydrogen, alkyl or cycloalkyl
- R 3 is hydrogen, alkyl or heteroaryl
- R 2 together with R 1 or R 3 along with the ring atoms to which they are attached forms a 5-7 membered ring;
- R 4 at each occurrence is halo, alkyl, hydroxy or alkoxy
- R 5 ′ is hydrogen, halo, alkyl, alkoxy, alkoxyalkyl or —(CH 2 ) 1-3 —NR a R b ;
- R 5 ′′ is H or alkyl;
- R a and R b are each independently hydrogen or alkyl; alternatively, R a and R b together with the nitrogen atom to which they are attached form an optionally substituted ring containing 0-2 additional heteroatoms independently selected from N, O or S; wherein the optional substituent is one or more halo, alkyl, hydroxy, haloalkyl or alkoxy;
- L 1 is *—CR c R d —C(O)—, *—NR e C(O)— or absent; wherein * is point of attachment with ring A;
- R c and R d independently are hydrogen, alkyl or haloalkyl; alternatively, R c and R d together with the carbon to which they are attached form a cycloalkyl ring;
- R e is hydrogen or alkyl
- L 2 is —C(O)NH—, —C(O)O— or absent;
- n 0, 1 or 2;
- p 0 or 1.
- ring B is aryl, cycloalkyl, heterocyclyl or absent;
- R 1 is hydrogen or alkyl
- R 2 is hydrogen, alkyl or cycloalkyl
- R 3 is hydrogen, alkyl or heteroaryl
- R 2 together with R 1 or R 3 along with the ring atoms to which they are attached forms a 5-7 membered ring;
- R 4 at each occurrence is halo, alkyl, hydroxy or alkoxy
- R 5 is —(NH) p —S(O) 2 —CH ⁇ CH 2 , —NH—CH 2 —CH ⁇ CH—C(O)—NR a R b ,
- R 5 ′ is hydrogen, halo, alkyl, alkoxyalkyl or —CH 2 —NR a R b ;
- R 5 ′′ is H or alkyl;
- R a and R b are each independently hydrogen or alkyl; alternatively, R a and R b together with the Nitrogen to which they are attached form an optionally substituted ring containing 0-2 additional heteroatoms independently selected from N, O or S; wherein the optional substituent is one or more halo, alkyl, hydroxy, haloalkyl or alkoxy;
- L 1 is *—CR c R d —C(O)—, *—NR e C(O)— or absent; wherein * is point of attachment with ring A;
- R c and R d independently are hydrogen, alkyl or haloalkyl; alternatively, R c and R d together with the carbon to which they are attached form a cycloalkyl ring;
- R e is hydrogen or alkyl
- L 2 is —C(O)NH—, —C(O)O— or absent;
- n 0, 1 or 2;
- p 0 or 1.
- L 1 is *—CR c R d —C(O)— or *—NR e C(O)—; wherein * is point of attachment with phenyl; R 3 , R 4 , R 5 and m are same as defined in compounds of formula (I).
- L 1 is *—CR c R d —C(O)— or *—NR e C(O)—; wherein * is point of attachment with phenyl; R 3 , R 4 , R 5 and m are same as defined in compounds of formula (I).
- ring A is aryl; preferably the said aryl is phenyl.
- ring B is aryl; preferably the said aryl is phenyl.
- ring B is heterocyclyl; preferably the said heterocylcyl is piperidinyl, pyridinyl, piperazinyl, pyrazolyl, morpholinyl, indoninyl or pyrrolidinyl.
- R c and R d are independently hydrogen or alkyl, wherein the said alkyl is methyl, ethyl or isopropyl.
- R 2 is alkyl or cycloalkyl; preferably the said alkyl is ethyl and the said cycloalkyl is cyclopropyl, cyclobutyl or cyclopentyl.
- R 5 ′ is hydrogen or —CH 2 —NR a R b .
- R 5 ′ is hydrogen or —CH 2 —NR a R b .
- R a and R b are each independently hydrogen or alkyl; preferably the said alkyl is methyl.
- R a and R b together with the nitrogen to which they are attached form an optionally substituted ring containing 0-2 additional heteroatoms independently selected from N, O or S; wherein the optional substituent is one or more halo, hydroxy, haloalkyl or alkoxy.
- ring A is aryl or heteroaryl; in another embodiment, the said aryl is phenyl.
- ring A is meta-substituted with respect to L 1 and L 2 .
- ring B is monocyclic or bicyclic cycloalkyl, aryl, heterocycloalkyl or heteroaryl.
- ring B is heterocyclyl; in another embodiment the said heterocylcyl is piperidinyl, pyridinyl,1,2,3,6-tetrahydropyridinyl, piperazinyl, pyrazinyl, pyrazolyl, morpholinyl, indolinyl or pyrrolidinyl.
- ring B is absent.
- R 2 is cycloalkyl; in another embodiment, the said cycloalkyl is cyclopropyl, cyclobutyl or cyclopentyl.
- R 2 and R 1 together with the atoms to which they are attached form a 5 or 6 membered ring.
- R 2 and R 3 together with the atoms to which they are attached form a 5 or 6 membered ring.
- R 2 and R 3 together with the atoms to which they are attached form a 6 membered aromatic ring.
- R 5 is,
- R 5 ′ and R 5 ′′ are as defined in formula (I).
- R 5 is,
- R 5 ′ and R 5 ′′ are as defined in formula (I).
- R 5 is
- R 5 ′ and R 5 ′′ are as defined in formula (I).
- R 5 is
- R 5 ′ is hydrogen, halo, alkyl, alkoxy or alkoxyalkyl; and R 5 ′′ is H or alkyl.
- R 5 is
- R 5 ′ is —CH 2 —NR a R b ;
- R 5 ′′ is H or alkyl;
- R a and R b are each independently hydrogen, alkyl, alkoxy or alkoxyalkyl.
- R 5 is
- R 5 ′ is —CH 2 —NR a R b ;
- R 5 ′′ is H or alkyl;
- R a and R b together with the nitrogen atom to which they are attached form an optionally substituted 4-7 membered heterocyclyl ring containing 0-2 additional heteroatoms independently selected from N, O or S;
- the optional substituent is one or more halo, alkyl, acyl, hydroxy, cyano, cyanoalkyl, haloalkyl, alkoxy, alkoxyalkyl, —COOH or —COO-alkyl.
- R 5 is
- R 5 is,
- R 5 ′ is —(CH 2 ) 1-3 —NR a R b ; wherein R a and R b are as defined in formula (I).
- L 1 is *—CR c R d —C(O)—; wherein * is the point of attachment with ring A; and R c and R d are as defined in claim 1 .
- L 2 is —C(O)NH— or —C(O)O—.
- L 2 is *—C(O)NH— or *—C(O)O—; wherein * is the point of attachment with ring B.
- L 2 when L 1 is —CR c R d —C(O)— or —NR e C(O)—, L 2 is absent.
- the present invention provides a compound selected from the group consisting of:
- the present invention provides a compound selected from the group consisting of:
- R 1 is hydrogen
- the compounds of the present invention are known to rapidly equilibrate, in solution, as admixtures of both tautomers:
- the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof or a stereoisomer thereof as described herein and at least one pharmaceutically acceptable excipient (such as a pharmaceutically acceptable carrier or diluent).
- the pharmaceutical composition comprises a therapeutically effective amount of at least one compound described herein.
- the compounds described in the present invention may be associated with a pharmaceutically acceptable excipient (such as a carrier or a diluent) or be diluted by a carrier or enclosed within a carrier which can be in the form of a capsule, sachet, paper or other container.
- the compounds of the present invention are kinase inhibitors.
- the compounds of the present invention are selective CDK inhibitors (e.g., being more active in inhibiting a CDK than a non-CDK kinase).
- the compounds of the present invention are selective CDK7 inhibitors (e.g., being more active in inhibiting CDK7 than a non-CDK7 kinase).
- the present invention provides pharmaceutical composition for use in treating and/or preventing a disease and/or disorder associated with aberrant activity of selective transcritptional CDKs.
- the present invention provides pharmaceutical composition for use in treating a subject suffering from diseases and/or disorder associated with aberrant activity of selective transcriptional CDKs.
- the present invention provides a method of inhibiting selective transcriptional CDKs in a subject, comprising administering to the subject in need thereof a therapeutically effective amount of a compound of the present invention.
- the present invention provides a method of treating diseases and/or disorder mediated by selective transcriptional CDKs in a subject comprising administering to the subject in need thereof a therapeutically effective amount of a compound of the present invention.
- the present invention provides pharmaceutical composition comprising the compound of formula (I), for use in treating a subject suffering from a disease or condition associated with aberrant activity of selective transcriptional CDKs.
- the present invention provides pharmaceutical composition comprising the compound of formula (I), for use in treating a subject suffering from diseases and/or disorder associated with aberrant activity of transcriptional CDK9, CDK12, CDK13 or CDK18.
- the present invention provides pharmaceutical composition comprising the compound of formula (I), for use in treating a subject suffering from diseases and/or disorder associated with aberrant activity of transcriptional CDK7.
- the present invention provides a method of treating disorders and/or diseases or condition mediated by selective transcriptional CDKs (CDK9, CDK12, CDK13 or CDK18) in a subject comprising administering a therapeutically effective amount of a compound of the present invention.
- the present invention provides a method of treating disorders and/or diseases or condition mediated by transcriptional CDK7 in a subject comprising administering a therapeutically effective amount of a compound of the present invention.
- the present invention provides a method of inhibiting selective transcriptional CDKs.
- the present invention provides a method of inhibiting particularly transcriptional CDK7, CDK9, CDK12, CDK13 or CDK18; more particularly CDK7, in a subject in need thereof by administering to the subject one or more compounds described herein in the amount effective to cause inhibition of such receptor/kinase.
- the present invention relates to methods of inhibiting the activity of a kinase in a biological sample or subject.
- the kinase is a selective transcriptional CDK.
- the selective transcriptional CDK is CDK9, CDK12, CDK13 or CDK18.
- the selective transcriptional CDK is particularly CDK7.
- the inhibition of the activity of the kinase is irreversible. In other embodiments, the inhibition of the activity of the kinase is reversible.
- the present invention provides compounds of formula (I) as covalent inhibitors of selective transcriptional CDKs. In yet another embodiment, the present invention provides compounds of formula (I) as covalent inhibitors of transcriptional CDK9, CDK12, CDK13 or CDK18. In yet another embodiment, the present invention provides compounds of formula (I) as covalent inhibitors of transcriptional CDK7.
- the compounds of the invention are typically administered in the form of a pharmaceutical composition.
- Such compositions can be prepared using procedures well known in the pharmaceutical art and comprise at least one compound of the present invention.
- the pharmaceutical composition of the present invention comprises one or more compounds described herein and one or more pharmaceutically acceptable excipients.
- the pharmaceutically acceptable excipients are approved by regulatory authorities or are generally regarded as safe for human or animal use.
- the pharmaceutically acceptable excipients include, but are not limited to, carriers, diluents, glidants and lubricants, preservatives, buffering agents, chelating agents, polymers, gelling agents, viscosifying agents, solvents and the like.
- the pharmaceutical composition can be administered by oral, parenteral or inhalation routes.
- parenteral administration include administration by injection, percutaneous, transmucosal, transnasal and transpulmonary administrations.
- suitable carriers include, but are not limited to, water, salt solutions, alcohols, polyethylene glycols, peanut oil, olive oil, gelatin, lactose, terra alba, sucrose, dextrin, magnesium carbonate, sugar, amylose, magnesium stearate, talc, gelatin, agar, pectin, acacia, stearic acid, lower alkyl ethers of cellulose, silicic acid, fatty acids, fatty acid amines, fatty acid monoglycerides and diglycerides, fatty acid esters and polyoxyethylene.
- the pharmaceutical composition may also include one or more pharmaceutically acceptable auxiliary agents, wetting agents, suspending agents, preserving agents, buffers, sweetening agents, flavouring agents, colorants or any combination of the foregoing.
- compositions may be in conventional forms, for example, tablets, capsules, solutions, suspensions, injectables or products for topical application. Further, the pharmaceutical composition of the present invention may be formulated so as to provide desired release profile.
- Administration of the compounds of the invention, in pure form or in an appropriate pharmaceutical composition can be carried out using any of the accepted routes of administration of pharmaceutical compositions.
- the route of administration may be any route which effectively transports the active compound of the present invention to the appropriate or desired site of action.
- Suitable routes of administration include, but are not limited to, oral, nasal, buccal, dermal, intradermal, transdermal, parenteral, rectal, subcutaneous, intravenous, intraurethral, intramuscular or topical.
- Solid oral formulations include, but are not limited to, tablets, capsules (soft or hard gelatin), dragees (containing the active ingredient in powder or pellet form), troches and lozenges.
- Liquid formulations include, but are not limited to, syrups, emulsions and sterile injectable liquids, such as suspensions or solutions.
- Topical dosage forms of the compounds include ointments, pastes, creams, lotions, powders, solutions, eye or ear drops, impregnated dressings and may contain appropriate conventional additives such as preservatives, solvents to assist drug penetration.
- compositions of the present invention may be prepared by conventional techniques known in literature.
- Suitable doses of the compounds for use in treating the diseases or disorders described herein can be determined by those skilled in the relevant art.
- Therapeutic doses are generally identified through a dose ranging study in humans based on preliminary evidence derived from the animal studies. Doses must be sufficient to result in a desired therapeutic benefit without causing unwanted side effects. Mode of administration, dosage forms and suitable pharmaceutical excipients can also be well used and adjusted by those skilled in the art. All changes and modifications are envisioned within the scope of the present invention.
- the compounds as disclosed in the present invention are formulated for pharmaceutical administration.
- Yet another embodiment of the present invention provides use of the compounds as disclosed in the present invention in the treatment and prevention of diseases and/or disorder associated with the aberrant activity of selective transcriptional CDKs, particularly the selective transcriptional CDK is CDK7, CDK9, CDK12, CDK13 or CDK18; more particularly CDK7.
- Yet another embodiment of the present invention provides use of the compound or a pharmaceutically acceptable salt thereof, in treating and/or preventing a disease for which the symptoms thereof are treated, improved, diminished and/or prevented by inhibition of selective transcriptional CDKs, particularly the selective transcriptional CDK is CDK7, CDK9, CDK12, CDK13 or CDK18; more particularly CDK7.
- the selective transcriptional CDK mediated disorder and/or disease or condition is proliferative disease or disorder or condition.
- the diseases and/or disorder mediated by selective transcriptional CDKs is selected from, but not limited to the group consisting of a cancer, an inflammatory disorder, an auto-inflammatory disorder or an infectious disease.
- the proliferative disease to be treated or prevented using the compounds of formula (I) will typically be associated with aberrant activity of CDKs, more particularly with CDK7, CDK9, CDK12, CDK13 or 18.
- Aberrant activity of CDK7, CDK9, CDK12, CDK13 or CDK18 may be an elevated and/or an inappropriate (e.g., abnormal) activity of CDK7, CDK9, CDK12, CDK13 or CDK18.
- CDK7, CDK9, CDK12, CDK13 or CDK18 are not overexpressed, and the activity of CDK7, CDK9, CDK12, CDK13 or CDK18 are elevated and/or inappropriate.
- CDK7, CDK9, CDK12, CDK13 or CDK18 are overexpressed, and the activity of CDK7, CDK9, CDK12, CDK13 or CDK18 are elevated and/or inappropriate.
- the compounds of the present invention are expected to be useful in the therapy of proliferative diseases such as viral diseases, fungal diseases, neurological/neurodegenerative disorders, autoimmune, inflammation, arthritis, anti-proliferative (e.g., ocular retinopathy), neuronal, alopecia and cardiovascular diseases.
- proliferative diseases such as viral diseases, fungal diseases, neurological/neurodegenerative disorders, autoimmune, inflammation, arthritis, anti-proliferative (e.g., ocular retinopathy), neuronal, alopecia and cardiovascular diseases.
- the compounds of the present invention are useful in the treatment of a variety of cancers, including but not limited to carcinoma, including that of the breast, liver, lung, colon, kidney, bladder, including small cell lung cancer, non-small cell lung cancer, head and neck, thyroid, esophagus, stomach, pancreas, ovary, gall bladder, cervix, prostate and skin, including squamous cell carcinoma; hematopoietic tumors of lymphoid lineage, including leukemia, acute lymphoblastic leukemia, acute lymphocytic leukemia, Hodgkins lymphoma, non-Hodgkins lymphoma, B-cell lymphoma, T-cell lymphoma, hairy cell lymphoma, myeloma, mantle cell lymphoma and Burkett's lymphoma; hematopoietic tumors of myeloid lineage, including acute and chronic myelogenous leukemias, myelodysplastic syndrome and prom
- the subject is a mammal including human.
- the present invention provides compounds or pharmaceutically acceptable salts or stereoisomers thereof, for use as a medicament.
- the invention provides the use of the compounds of the present invention in the manufacture of a medicament.
- the present invention provides compounds or pharmaceutically acceptable salts or stereoisomers thereof, for use in the treatment of cancer.
- the invention provides the use of the compounds of the present invention in the manufacture of a medicament for the treatment of diseases and/or disorder associated with the aberrant activity of selective transcriptional CDKs.
- the invention provides the use of the compounds of the present invention in the manufacture of a medicament for the treatment of cancer.
- the present invention provides compounds for use as a medicament for treating a subject suffering from diseases and/or disorder associated with aberrant activity of selective transcriptional CDKs.
- the present invention comprises administering to the subject in need thereof a therapeutically effective amount of a compound of the present invention along with one or more additional chemotherapeutic agents independently selected from anti-proliferative agents, anti-cancer agents, immunosuppressant agents and pain-relieving agents.
- additional chemotherapeutic agents independently selected from anti-proliferative agents, anti-cancer agents, immunosuppressant agents and pain-relieving agents.
- the method(s) of treatment of the present invention comprises administering a safe and effective amount of a compound according to formula (I) or a pharmaceutically acceptable salt thereof to a patient (particularly a human) in need thereof.
- the compounds of the present invention may be used as single drug or as a pharmaceutical composition in which the compound is mixed with various pharmacologically acceptable materials.
- the compounds of the present invention can also contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute such compounds.
- the present invention also embraces isotopically-labeled variants of the present invention which are identical to those recited herein, but for the fact that one or more atoms of the compound are replaced by an atom having the atomic mass or mass number different from the predominant atomic mass or mass number usually found in nature for the atom. All isotopes of any particular atom or element as specified are contemplated within the scope of the compounds of the invention and their uses.
- Exemplary isotopes that can be incorporated in to compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, sulfur, fluorine, chlorine and iodine, such as 2 H (“D”), 3 H, 11 C, 13 C, 14 C, 13 N, 15 N, 15 O, 17 O, 18 O, 32 P, 33 P, 35 S, 18 F, 36 Cl, 123 I and 125 I.
- Isotopically labeled compounds of the present invention can generally be prepared by following procedures analogous to those disclosed in the schemes and/or in the examples herein below, by substituting an isotopically labeled reagent for a non-isotopically labeled reagent.
- LDA Lithium diisopropylamide
- K 2 CO 3 Pitassium carbonate
- KOAc Potassium acetate
- EtOH EtOH
- NH 3 solution Ammonia solution
- Prep TLC Preparative Thin layer Chromatography
- rt Retention time
- RT Room temperature
- DMF Dimethylformamide
- h hour
- NaOH Na hydroxide
- HATU 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid-hexafluorophosphate
- LC-MS Liquid chromatography mass spectroscopy
- HCl Hydrochloric acid
- THE tetrahydrofuran
- DCM Dichloromethane
- TFA Trifluoroacetic acid
- TLC Thin layer chromatography
- DIPEA DIPEA
- work-up includes distribution of the reaction mixture between the organic and aqueous phases, separation of layers and drying the organic layer over anhydrous sodium sulphate, filtration and evaporation of the solvent.
- Purification includes purification by silica gel chromatographic techniques, generally using ethyl acetate/petroleum ether mixture of a suitable polarity as the mobile phase.
- Step-i (E)-4-bromobut-2-enoic acid (4.5 g, 27.7 mmol) was taken in DCM (30 mL) with catalytic amount of DMF followed by the addition of oxalyl chloride (5 mL). The reaction mass was allowed to stir for 1.5 h at RT, evaporated the solvent under vacuum. The residue was dissolved in DCM and was added to the pre cooled solution of 5-bromopyridin-2-amine (3.0 g, 17.34 mmol) in acetonitrile (50 mL) and DIPEA (11.0 mL, 69.36 mmol) at 0° C. The resulting reaction mixture was stirred for 2 h, added water and extracted with DCM.
- Some compounds of the present invention may be generally synthesized utilizing the process outlined in Scheme-8.
- the commercially available or synthesized intermediate-b was converted to corresponding acid chloride in presence of suitable reagents and solvents (DCM, catalytic DMF, oxalyl chloride, RT, 1.5 h) which upon reacting with intermediate-a in presence of suitable reagents and solvents (pyridine, 0° C.-RT, 12 h; or DCM, TEA, 0° C.-RT, 12 h) afforded intermediate-c.
- suitable reagents and solvents pyridine, 0° C.-RT, 12 h
- DCM, TEA 0° C.-RT, 12 h
- intermediate-c Treatment of intermediate-c with intermediate-d (boronic acid or boronate ester) by Suzuki coupling conditions in presence of suitable catalyst such as Pd(dppf)Cl 2 .DCM or PdCl 2 (PPh 3 ) 2 , suitable base such as potassium carbonate or cesiumcarbonate and in the presence of suitable solvent(s) such as 1,4-dioxane and/or water gave intermediate-e.
- suitable catalyst such as Pd(dppf)Cl 2 .DCM or PdCl 2 (PPh 3 ) 2
- suitable base such as potassium carbonate or cesiumcarbonate
- suitable solvent(s) such as 1,4-dioxane and/or water
- the present invention is further exemplified, but not limited, by the following examples that illustrate the preparation of compounds according to the invention.
- Example-1 Synthesis of (E)-N-(3′-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)-[1,1′-biphenyl]-4-yl)-4-(dimethylamino)but-2-enamide (Compound-1)
- Step-i Synthesis of tert-butyl 3-(2-(3-bromophenyl)propanamido)-5-cyclopropyl-1H-pyrazole-1-carboxylate
- Step-ii Synthesis of 2-(4′-amino-[1,1′-biphenyl]-3-yl)-N-(5-cyclopropyl-1H-pyrazol-3-yl)propanamide
- the reaction mass was heated for 12 h at 110° C. in a sealed tube.
- the reaction mass was cooled to room temperature and diluted with water and ethyl acetate.
- the separated organic layer was dried over anhydrous sodium sulphate and concentrated under reduced pressure.
- Step-iii Synthesis of (E)-N-(3′-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)-[1,1′-biphenyl]-4-yl)-4-(dimethylamino)but-2-enamide
- Some compounds of the present invention can be generally synthesized utilizing the process outlined in this scheme.
- the commercially available or synthesized intermediate-b was converted to corresponding acid chloride in presence of suitable reagents and solvents (DCM, catalytic DMF, oxalyl chloride, RT, ⁇ 1.5 h) which upon reacting with intermediate-a in presence of suitable reagents and solvents (pyridine, 0° C.-RT, 12 h; or DCM, TEA, 0° C.-RT, 12 h) afforded intermediate-c.
- suitable reagents and solvents pyridine, 0° C.-RT, 12 h; or DCM, TEA, 0° C.-RT, 12 h
- intermediate-c Treatment of intermediate-c with intermediate-g (4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane)) under suitable reagents and conditions (1,4-Dioxane, potassium acetate, Pd(dppf)Cl 2 .DCM or PdCl 2 (PPh 3 ) 2 , 12 h, 100° C.) gave intermediate-h.
- Example-2 Synthesis of (E)-N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)phenyl)pyridin-2-yl)-4-morpholinobut-2-enamide (Compound-10)
- Step-i Synthesis of tert-butyl 5-cyclopropyl-3-(2-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)propanamido)-1H-pyrazole-1-carboxylate
- reaction mass was allowed to stir for 10 minutes with degassing at RT and added PdCl 2 (dppf).DCM complex (0.046 g, 0.057 mmol).
- the reaction mass was heated for 12 h at 100° C. in a sealed tube, cooled the reaction mass and diluted with water and ethyl acetate. The aqueous layer was separated and re-extracted with ethyl acetate (2 ⁇ 25 mL). The combined organic layer was dried over anhydrous sodium sulfate and concentrated under vacuum.
- Step-ii Synthesis of (E)-N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)phenyl)pyridin-2-yl)-4-morpholinobut-2-enamide
- reaction mass was allowed to stir for 10 minutes with degassing and added PdCl 2 (dppf).DCM complex (0.06 g, 0.07 mmol), heated the reaction mass for 12 h at 100° C. in a d sealed tube.
- the reaction mass was cooled and diluted with water and ethyl acetate.
- the aqueous layer was separated and re-extracted with ethyl acetate (2 ⁇ 25 mL).
- the combined organic layer was dried over anhydrous sodium sulfate and concentrated under vacuum.
- the crude material was purified by silica gel column chromatography by eluting with 10% methanol in DCM, further purified by preparative HPLC (Method: Column: Gemini NX C18 (21.2 mm ⁇ 150 mm, 5 micron), Mobile phase: 0.01% NH 4 OH in Water, Acetonitrile:Methanol (1:1)) to afford the title compound (0.2 g, 40%).
- Example-3 Synthesis of 4-acrylamido-N-(3-((5-ethyl-1H-pyrazol-3-yl)amino)phenyl)-benzamide. (Compound-83)
- Step-i Synthesis of tert-butyl 5-ethyl-3-((3-nitrophenyl)amino)-1H-pyrazole-1-carboxylate
- the reaction mass was heated for 4 h at 100° C. in a sealed tube.
- the reaction mass was cooled and diluted with water and ethyl acetate.
- the organic layer was separated and the aqueous layer was extracted again with ethyl acetate (2 ⁇ 20 mL).
- the combined organic layer was dried over anhydrous sodium sulphate and concentrated under vacuum.
- the crude compound was purified by silica gel column chromatography by eluting with 15% ethyl acetate-hexane to afford the title compound (0.2 g, 35%).
- LCMS: m/z 333.10 (M+H) + .
- Step-ii Synthesis of tert-butyl 3-((3-aminophenyl)amino)-5-ethyl-1H-pyrazole-1-carboxylate
- Step-iii Synthesis of tert-butyl 3-((3-(4-acrylamidobenzamido)phenyl)amino)-5-ethyl-1H-pyrazole-1-carboxylate
- the crude compound was purified by silica gel column chromatography by eluting with 10% methanol-DCM, further purified by Preparative HPLC (Method: Column: X-BRIDGE PREP C18 5 MICRON OBD (19 mm ⁇ 150 mm), Mobile phase: 0.01% NH 4 OH:Acetonitrile) to afford the title compound (0.030 g, 25%).
- Example-4 Synthesis of (E)-N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3-(1-(4-(dimethylamino)-but-2-enoyl)-1,2,3,6-tetrahydropyridin-4-yl)phenyl)propanamide (Compound-84)
- Step-i Synthesis of tert-butyl 4-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)phenyl)-3,6-dihydropyridine-1(2H)-carboxylate
- the reaction mass was stirred for 10 minutes and degassed further for 10 min and added PdCl 2 (dppf).DCM (0.044 g, 0.05 mmol).
- the reaction mass was heated for 5 h at 100° C. in a sealed tube.
- the reaction mass was cooled to room temperature and diluted with water and ethyl acetate.
- Step-ii Synthesis of N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3-(1,2,3,6-tetrahydropyridin-4-yl)phenyl)propanamide
- Step-iii Synthesis of (E)-N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3-(1-(4-(dimethylamino)but-2-enoyl)-1,2,3,6-tetrahydropyridin-4-yl)phenyl)propanamide
- Step-i Synthesis of tert-butyl 4-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)phenyl)piperidine-1-carboxylate
- Step-ii Synthesis of N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3-(piperidin-4-yl)phenyl)-propanamide
- Step-iii Synthesis of (E)-N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3-(1-(4-(dimethylamino)but-2-enoyl)piperidin-4-yl)phenyl)propanamide
- Step i Synthesis of tert-butyl 3-amino-5-methyl-1H-pyrazole-1-carboxylate
- Step-ii Synthesis of tert-butyl 3-(2-(3-bromophenyl)acetamido)-5-methyl-1H-pyrazole-1-carboxylate
- Step-iii Synthesis of N-(3′-(2-((5-Methyl-1H-pyrazol-3-yl)amino)-2-oxoethyl)-[1,1′-biphenyl]-4-yl)acrylamide
- reaction mass was stirred for 10 minutes and degassed further for 10 min and added Bis(triphenylphosphine) palladium(II) dichloride (0.017 g, 0.025 mmol).
- the reaction mass was heated for 5 h at 100° C. in a sealed tube.
- the reaction mass was cooled and diluted with water and ethyl acetate.
- the separated organic layer was dried over anhydrous sodium sulphate and concentrated under reduced pressure and purified by preparative HPLC (Condition: Kinetex Evo, A: 0.1% formic acid in H 2 O, B: Acetonitrile-methanol) to afford the title compound (0.018 g, 20%).
- Step-ii Synthesis of 3-bromo-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole
- 3,4-dihydro-2H-Pyrane (0.42 g, 5 mmol) was added to a solution of 3-bromo-1H-indazole (0.5 g, 2.5 mmol) in ethyl acetate (10 mL) with catalytic amount of PTSA (0.05 g). The resulting reaction mass was stirred and heated to reflux for 5 h. The reaction mass was neutralized with aq. ammonia and diluted with ethyl acetate.
- Step-iii Synthesis of N 1 -(1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-3-yl)benzene-1,3-diamine
- Benzene-1,3-diamine (0.02 g, 0.21 mmol) and 3-bromo-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole (0.05 g, 0.17 mmol) were taken in toluene (15 mL) in a seal tube at room temperature and argon gas was purged for 5-10 min. Then sodium tert-butoxide (0.032 g, 0.34 mmol) and BINAP (0.01 g, 0.017 mmol) were added and the resulting reaction mixture was purged with argon gas for 5 min. followed by the addition of Pd 2 (dba) 3 (0.003 g, 0.003 mmol).
- Step-iv Synthesis of 4-amino-N-(3-((1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-3-yl)amino)phenyl)benzamide
- Step-v Synthesis of (E)-4-(4-(dimethylamino)but-2-enamido)-N-(3-((1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-3-yl)amino)phenyl)benzamide
- Step-ii Synthesis of 2-(3-bromophenyl)-N-(1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazol-3-yl)propanamide
- Step-iii Synthesis of 2-(4′-amino-[1,1′-biphenyl]-3-yl)-N-(1-((2-(trimethylsilyl)ethoxy)-methyl)-1H-indazol-3-yl)propanamide
- reaction mass was stirred for 10 minutes and degassed further for 10 minutes and added PdCl 2 (dppf) 2 .DCM (0.11 g, 0.13 mmol).
- the reaction mass was heated for 12 h at 110° C. in a sealed tube.
- the reaction mass was cooled and diluted with water and ethyl acetate.
- Step-iv Synthesis of N-(3′-(1-oxo-1-((1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazol-3-yl)amino)propan-2-yl)-[1,1′-biphenyl]-4-yl)acrylamide
- Step-v Synthesis of N-(3′-(1-((1H-indazol-3-yl)amino)-1-oxopropan-2-yl)-[1,1′-biphenyl]-4-yl)acrylamide
- Step-i Synthesis of (E)-4-(dimethylamino)-N-(3′-(1-oxo-1-((1-((2-(trimethylsilyl)ethoxy)-methyl)-1H-indazol-3-yl)amino)propan-2-yl)-[1,1′-biphenyl]-4-yl)but-2-enamide
- Step-ii Synthesis of (E)-N-(3′-(1-((1H-indazol-3-yl)amino)-1-oxopropan-2-yl)-[1,1′-biphenyl]-4-yl)-4-(dimethylamino)but-2-enamide
- reaction mass was stirred for 10 minutes and degassed further for 10 min and added PdCl 2 (dppf).DCM (0.17 g, 0.218 mmol).
- the reaction mass was heated for 12 h at 100° C. in a sealed tube.
- the reaction mass was cooled to room temperature and diluted with water and ethyl acetate.
- the separated organic layer was dried over anhydrous sodium sulphate and concentrated under reduced pressure.
- Step-ii Synthesis of (E)-N-(6-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)phenyl)pyrazin-2-yl)-4-(pyrrolidin-1-yl)but-2-enamide
- Step-i Synthesis of tert-butyl (S)-3-(2-(3-bromophenyl)propanamido)-5-cyclopropyl-1H-pyrazole-1-carboxylate
- reaction mass was concentrated under vacuum, and the residue was dissolved in 2 mL of dry DCM and added to a cooled solution of tert-butyl 3-amino-5-cyclopropyl-1H-pyrazole-1-carboxylate (0.078 g, 0.34 mmol) in 2 mL of DCM and TEA (0.086 g, 0.1 mL) at 0° C.
- tert-butyl 3-amino-5-cyclopropyl-1H-pyrazole-1-carboxylate 0.078 g, 0.34 mmol
- TEA 0.086 g, 0.1 mL
- Step-ii Synthesis of tert-butyl (S)-5-cyclopropyl-3-(2-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)propanamido)-1H-pyrazole-1-carboxylate
- reaction mass was allowed to stir for 10 minutes with degassing at RT and added PdCl 2 (dppf).DCM complex (0.010 g, 0.011 mmol).
- the reaction mass was heated for 12 h at 100° C. in a sealed tube, cooled the reaction mass and diluted with water and ethyl acetate. The aqueous layer was separated and re-extracted with ethyl acetate (2 ⁇ 5 mL). The combined organic layer was dried over anhydrous sodium sulfate and concentrated under vacuum.
- Step-iii Synthesis of (S, E)-N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)phenyl)pyridin-2-yl)-4-morpholinobut-2-enamide
- reaction mass was allowed to stir for 10 minutes with degassing and added PdCl 2 (dppf).DCM complex (0.005 g, 0.007 mmol), heated the reaction mass for 12 h at 100° C. in a sealed tube.
- the reaction mass was cooled and diluted with water and ethyl acetate.
- the aqueous layer was separated and re-extracted with ethyl acetate (2 ⁇ 5 mL).
- the combined organic layer was dried over anhydrous sodium sulfate and concentrated under vacuum.
- Step-i Synthesis of tert-butyl 3-(1-(3-bromophenyl)cyclopropane-1-carboxamido)-5-cyclopropyl-1H-pyrazole-1-carboxylate
- Step-ii Synthesis of tert-butyl 5-cyclopropyl-3-(1-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)cyclopropane-1-carboxamido)-1H-pyrazole-1-carboxylate
- reaction mass was stirred for 10 minutes and degassed further for 10 minutes with argon and added PdCl 2 (dppf).DCM (0.036 g, 0.045 mmol).
- Step-iii Synthesis of (E)-N-(5-cyclopropyl-1H-pyrazol-3-yl)-1-(3-(6-(4-(pyrrolidin-1-yl)but-2-enamido)pyridin-3-yl)phenyl)cyclopropane-1-carboxamide
- reaction mass was stirred for 10 minutes and degassed further for 10 min with argon and added PdCl 2 (dppf).DCM (0.033 g, 0.04 mmol). Then the reaction mass was heated for 15 h at 110° C. in a sealed tube. The reaction mass was cooled to room temperature and diluted with water and ethyl acetate.
- Example-13 Synthesis of (E)-N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-2-methyl-1-oxopropan-2-yl)phenyl)pyridin-2-yl)-4-(pyrrolidin-1-yl)but-2-enamide (Compound-95)
- Step-i Synthesis of tert-butyl 3-(2-(3-bromophenyl)-2-methylpropanamido)-5-cyclopropyl-1H-pyrazole-1-carboxylate
- Step-ii Synthesis of tert-butyl 5-cyclopropyl-3-(2-methyl-2-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)propanamido)-1H-pyrazole-1-carboxylate
- reaction mass was stirred for 10 minutes and degassed further for 10 minutes with argon and added PdCl 2 (dppf).DCM (0.027 g, 0.033 mmol).
- Step-iii Synthesis of (E)-N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-2-methyl-1-oxopropan-2-yl)phenyl)pyridin-2-yl)-4-(pyrrolidin-1-yl)but-2-enamide
- reaction mass was stirred for 10 minutes and degassed further for 10 min with argon and added PdCl 2 (dppf).DCM (0.023 g, 0.028 mmol), then heated for 15 h at 110° C. in a sealed tube.
- the reaction mass was cooled to room temperature and diluted with water and ethyl acetate.
- the compounds were screened by the above mentioned assay procedure.
- the % inhibition at 10 ⁇ M concentration and the IC 50 values of the compounds are summarized in the table-5 below wherein “+++” refers to an IC 50 value less than 0.025 ⁇ M, “++” refers to IC 50 value in range of 0.025 ⁇ M to 0.1 ⁇ M and “+” refers to an IC 50 value greater than 0.1 ⁇ M.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Description
- This application claims the benefit of Indian provisional application numbers 2803/CHE/2015, filed on Jun. 4, 2015 and 6214/CHE/2015, filed on Nov. 18, 2015; the specifications of which are hereby incorporated by reference in their entirety.
- This invention pertains to compounds which inhibit the activity of selective transcriptional cyclin dependent kinases (CDKs) including CDK7, CDK9, CDK12, CDK13 and CDK18, more particularly transcriptional cyclin dependent kinase-7 (CDK7). The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compositions in the treatment of diseases or disorder associated with selective transcriptional CDKs.
- One of the most important and fundamental processes in biology is the division of cells mediated by the cell cycle. This process ensures the controlled production of subsequent generations of cells with defined biological function. It is a highly regulated phenomenon and responds to a complex set of cellular signals both within the cell and from external sources. A complex network of tumor promoting and suppressing gene products are key components of this cellular signalling process. Over-expression of tumor-promoting components or the subsequent loss of the tumor-suppressing products will lead to unregulated cellular proliferation and the generation of tumors (Pardee, Science 246:603-608, 1989).
- Kinases are important cellular enzymes that perform essential cellular functions such as regulating cell division and proliferation, and also appear to play a decisive role in many disease states that are characterized by uncontrolled proliferation and differentiation of cells. These disease states encompass a variety of cell types and maladies such as cancer, atherosclerosis, restenosis and other proliferative disorders (Kris M G et al., JAMA 290 (16): 2149-58, 2003).
- Cyclin-dependent kinases (CDKs) are relatively small proteins, with molecular weights ranging from 34 to 40 kDa, and contain little more than the kinase domain. CDK binds a regulatory protein called a cyclin. Without cyclin, CDK has little kinase activity; only the cyclin-CDK complex is an active kinase. CDKs phosphorylate their substrates on serines and threonines, so they are serine-threonine kinases (Morgan, D. O., Cell Division, 2:27, 2007).
- The members of the cyclin-dependent kinase (CDK) family play critical regulatory roles in cell proliferation. There are currently 20 known mammalian CDKs. While CDK7-13 and 18 have been linked to transcription, only CDK1, 2, 4 and 6 show demonstrable association with the cell cycle. Unique among the mammalian CDKs, CDK7 has consolidated kinase activities, regulating both the cell cycle and transcription. In the cytosol, CDK7 exists as a heterotrimeric complex and is believed to function as a CDK1/2-activating kinase (CAK), whereby phosphorylation of conserved residues in CDK1/2 by CDK7 is required for full catalytic CDK activity and cell cycle progression (Desai et al., Mol. Cell Biol. 15, 345-350, 1995).
- CDK7, which complexes with cyclin H and MAT1, phosphorylates the cell cycle CDKs in the activation of T-loop, to promote their activities (Fisher et al., Cell., August 26; 78(4): 713-24, 1994). As such, it has been proposed that inhibiting CDK7 would provide a potent means of inhibiting cell cycle progression, which may be especially relevant given that there is compelling evidence from gene knockout studies in mice for lack of an absolute requirement for CDK2, CDK4 and CDK6 for the cell cycle, at least in most cell types (Malumbres et al., Nature Cell Biology, 11, 1275-1276, 2009), whilst different tumors appear to require some, but be independent of other interphase CDKs (CDK2, CDK4, CDK6). Recent genetic and biochemical studies have confirmed the importance of CDK7 for cell cycle progression (Larochelle et al., Mol Cell., March 23; 25(6):839-50. 2007; Ganuza et al., EMBO J., May 30; 31(11): 2498-510, 2012).
- Cyclin-dependent kinase 7 (CDK7) activates cell cycle CDKs and is a member of the general Transcription factor II Human (TFIIH). CDK7 also plays a role in transcription and possibly in DNA repair. The trimeric Cak complex CDK7/CyclinH/MAT1 is also a component of TFIIH, the general transcription/DNA repair factor IIH (Morgan, D. O., Annu. Rev. Cell Dev. Biol. 13, 261-91, 1997). As a TFIIH subunit, CDK7 phosphorylates the CTD (Carboxy-Terminal-Domain) of the largest subunit of RNA polymerase II (pol II). The CTD of mammalian pol II consists of 52 heptad repeats with the consensus sequence 1YSPTSPS7 and the phosphorylation status of the Ser residues at positions 2 and 5 has been shown to be important in the activation of RNAP-II indicating that it is likely to have a crucial role in the function of the CTD. CDK7, which primarily phosphorylates Ser-5 (PS5) of RNAP-II at the promoter as part of transcriptional initiation (Gomes et al., Genes Dev. 2006 Mar. 1; 20(5):601-12, 2006), in contrast with CDK9, which phosphorylates both Ser-2 and Ser-5 of the CTD heptad (Pinhero et al., Eur. J. Biochem., 271, pp. 1004-1014, 2004).
- In addition to CDK7, other CDKs have been reported to phosphorylate and regulate RNA pol (II) CTD. The other CDKs include, Cdk9/Cyclin T1 or T2 that constitute the active form of the positive transcription elongation factor (P-TEFb) (Peterlin and Price, Mol Cell., August 4; 23(3): 297-305,2006) and Cdk12/Cyclin K and Cdk13/Cyclin K as the latest members of RNAPII CTD kinases (Bartkowiak et al., Genes Dev., October 15; 24(20):2303-16, 2010; Blazek et al., Genes Dev. October 15; 25(20):2158-72, 2011).
- Disruption of RNAP II CTD phosphorylation has been shown to preferentially effect proteins with short half-lives, including those of the anti-apoptotic BCL-2 family. (Konig et al., Blood, 1, 4307-4312, 1997; The transcriptional non-selective cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and down-regulation of Mcl-1; (Gojo et al., Clin. Cancer Res. 8, 3527-3538, 2002).
- This suggests that the CDK7 enzyme complexes are involved in multiple functions in the cell: cell cycle control, transcription regulation and DNA repair. It is surprising to find one kinase involved in such diverse cellular processes, some of which are even mutually exclusive. It also is puzzling that multiple attempts to find cell cycle dependent changes in CDK7 kinase activity remained unsuccessful. This is unexpected since activity and phosphorylation state of its substrate, CDC2, fluctuate during the cell cycle. In fact, it is shown that cdk7 activity is required for the activation of bothCdc2/Cyclin A and Cdc2/Cyclin B complexes, and for cell division. (Larochelle, S. et al. Genes Dev 12,370-81, 1998). Indeed, flavopiridol, a non-selective pan-CDK inhibitor that targets CTD kinases, has demonstrated efficacy for the treatment of chronic lymphocytic leukemia (CLL), but suffers from a poor toxicity profile (Lin et al., J. Clin. Oncol. 27, 6012-6018, 2009; Christian et al., Clin. Lymphoma Myeloma, 9, Suppl. 3, S179-S185, 2009).
- In-vitro studies revealed substrate preferences for the different CDK7 complexes, indicating that CDK7 may form different complexes with different substrate specificity and presumably different in-vivo functions (Frit, P. et al., Biochimie 81, 27-38, 1999; Schutz, P. et al. Cell 102, 599-607, 2000).
- Thus in view of the role transcriptional CDKs play in the regulation of cell cycle, there is a need of compounds to treat diseases and/or disorder associated with selective transcriptional CDKs including CDK7, CDK9, CDK12, CDK13 and CDK18; more particularly CDK7. It is, therefore, an object of this invention to provide compounds useful in the treatment and/or prevention or amelioration of such diseases and/or disorder.
- Provided herein are substituted heterocyclyl derivatives and pharmaceutical compositions thereof, which are capable of suppressing and/or inhibiting cyclin dependent kinase-7 signalling pathway.
- In one aspect of the present invention, it comprises compounds of formula (I):
- or a pharmaceutically acceptable salt or a stereoisomer thereof;
- wherein,
- ring A is cycloalkyl, aryl, heteroaryl or heterocyclyl;
- ring B is aryl, cycloalkyl, heterocyclyl or absent;
- R1 is hydrogen or alkyl;
- R2 is hydrogen, alkyl or cycloalkyl;
- R3 is hydrogen, alkyl or heteroaryl;
- alternatively, R2 together with R1 or R3 along with the ring atoms to which they are attached forms a 5-7 membered ring;
- R4 at each occurrence is halo, alkyl, hydroxy, alkoxy, amino, nitro, cyano or haloalkyl;
- R5 is
- wherein R5′ is hydrogen, halo, alkyl, alkoxy, alkoxyalkyl or —(CH2)1-3—NRaRb; R5″ is H or alkyl;
- Ra and Rb are each independently hydrogen, alkyl, alkoxy or alkoxyalkyl; alternatively, Ra and Rb together with the nitrogen atom to which they are attached form an optionally substituted ring containing 0-2 additional heteroatoms independently selected from N, O or S; wherein the optional substituent is one or more halo, alkyl, acyl, hydroxy, cyano, cyanoalkyl, haloalkyl, alkoxy, alkoxyalkyl, —COOH or —COO-alkyl;
- R6 at each occurrence is halo, alkyl, hydroxy, alkoxy, amino, nitro, cyano or haloalkyl;
- L1 is *—CRcRd—C(O)—, *—NReC(O)— or absent; wherein * is point of attachment with ring A;
- Re and Rd independently are hydrogen, alkyl or haloalkyl; alternatively, Rc and Rd together with the carbon to which they are attached form a cycloalkyl ring;
- Rc is hydrogen or alkyl;
- L2 is —C(O)NH—, —C(O)O— or absent;
- m is 0, 1 or 2;
- p is 0 or 1; and
- q is 0 to 3.
- In yet another aspect, the present invention provides a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient (such as a pharmaceutically acceptable carrier or diluent).
- In yet another aspect, the present invention relates to the preparation of compounds of formula (I).
- In yet another aspect of the present invention, provided herein are substituted heterocyclyl derivatives of formula (I), which are capable of inhibiting CDK7 and therapeutic use thereof.
- Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of skill in art to which the subject matter herein belongs. As used in the specification and the appended claims, unless specified to the contrary, the following terms have the meaning indicated in order to facilitate the understanding of the present invention.
- As used herein, unless otherwise defined the term “alkyl” alone or in combination with other term(s) means saturated aliphatic hydrocarbon chains, including C1-C10 straight or C3-C10 branched alkyl groups. Examples of “alkyl” include but are not limited to methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, isopentyl or neopentyl and the like.
- As used herein, the term “halo” or “halogen” alone or in combination with other term(s) means fluorine, chlorine, bromine or iodine.
- As used herein, the term “haloalkyl” means alkyl substituted with one or more halogen atoms, wherein the alkyl groups are as defined above. The term “halo” is used herein interchangeably with the term “halogen” means F, Cl, Br or I. Examples of “haloalkyl” include but are not limited to fluoromethyl, difluoromethyl, chloromethyl, trifluoromethyl, 2,2,2-trifluoroethyl and the like.
- As used herein, the term “hydroxy” or “hydroxyl” alone or in combination with other term(s) means —OH.
- As used herein, the term “alkoxy” refers to the group alkyl-O— or —O-alkyl, where alkyl groups are as defined above. Exemplary alkoxy- groups include but are not limited to methoxy, ethoxy, n-propoxy, n-butoxy, t-butoxy and the like. An alkoxy group can be unsubstituted or substituted with one or more suitable groups.
- As used herein, the term “alkoxyalkyl” refers to the group alkyl-O-alkyl-, wherein alkyl and alkoxy groups are as defined above. Exemplary alkoxyalkyl- groups include but are not limited to methoxymethyl, ethoxymethyl, methoxyethyl, isopropoxymethyl and the like.
- As used herein, the term “cyano” refers to —CN; and the term “cyanoalkyl” refers to alkyl substituted with —CN; wherein the alkyl groups are as defined above.
- As used herein, the term “amino” refers to —NH2;
- As used herein, the term “nitro” refers to —NO2;
- As used herein, the term “acyl” refers to the group —C(O)-alkyl, wherein alkyl groups are as defined above. Exemplary alkoxy- groups include but are not limited to acetyl, propanoyl and acrylyl. An alkoxy group can be unsubstituted or substituted with one or more suitable groups.
- As used herein the term “cycloalkyl” alone or in combination with other term(s) means —C3-C10 saturated cyclic hydrocarbon ring. A cycloalkyl may be a single ring, which typically contains from 3 to 7 carbon ring atoms. Examples of single-ring cycloalkyls include but are not limited to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and the like. A cycloalkyl may alternatively be polycyclic or contain more than one ring. Examples of polycyclic cycloalkyls include bridged, fused and spirocyclyls and the like.
- As used herein, the term “aryl” is optionally substituted monocyclic, bicyclic or polycyclic aromatic hydrocarbon ring system of about 6 to 14 carbon atoms. Examples of a C6-C14 aryl group include, but are not limited to phenyl, naphthyl, anthryl, tetrahydronaphthyl, fluorenyl, indanyl, biphenylenyl and acenaphthyl. Aryl group which can be unsubstituted or substituted with one or more suitable groups.
- The term “heterocycloalkyl” refers to a non-aromatic, saturated or partially saturated monocyclic or polycyclic ring system of 3 to 15 members having at least one heteroatom or heterogroup selected from O, N, S, S(O), S(O)2, NH or C(O) with the remaining ring atoms being independently selected from the group consisting of carbon, oxygen, nitrogen and sulfur. A monocyclic heterocycloalkyl may typically contain 4 to 7 ring atoms. Examples of “Heterocycloalkyl” include, but are not limited to azetidinyl, oxetanyl, imidazolidinyl, pyrrolidinyl, oxazolidinyl, thiazolidinyl, pyrazolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl, tetrahydropyranyl, morpholinyl, oxapiperazinyl, oxapiperidinyl, tetrahydrofuryl, tetrahydropyranyl, tetrahydrothiophenyl, dihydropyranyl, indolinyl, indolinylmethyl, azepanyl and N-oxides thereof. Attachment of a heterocycloalkyl substituent can occur via either a carbon atom or a heteroatom. A heterocycloalkyl group can be optionally substituted with one or more suitable groups by one or more aforesaid groups.
- As used herein, the term “heteroaryl” alone or in combination with other term(s) means a completely unsaturated ring system containing a total of 5 to 14 ring atoms. At least one of the ring atoms is a heteroatom (i.e., oxygen, nitrogen, or sulfur), with the remaining ring atoms/groups being independently selected from the group consisting of carbon, oxygen, nitrogen or sulfur. A heteroaryl may be a single-ring (monocyclic) or polycyclic ring system. Examples of “heteroaryl” include but are not limited to pyridyl, indolyl, benzimidazolyl, benzothiazolyl and the like.
- As used herein, the term “heterocyclyl” alone or in combination with other term(s) includes both “heterocycloalkyl” and “heteroaryl” groups which are as defined above.
- The term “heteroatom” as used herein designates a sulfur, nitrogen or oxygen atom.
- As used in the above definitions, the term “optionally substituted” or “substituted” or “optionally substituted with suitable groups” refers to replacement of one or more hydrogen radicals in a given structure with a radical of a specified substituent including, but not limited to: halo, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, thiol, alkylthio, arylthio, alkylthioalkyl, arylthioalkyl, alkylsulfonyl, alkylsulfonylalkyl, arylsulfonylalkyl, alkoxy, aryloxy, aralkoxy, aminocarbonyl, alkylaminocarbonyl, arylaminocarbonyl, alkoxycarbonyl, aryloxycarbonyl, haloalkyl, amino, trifluoromethyl, cyano, nitro, alkylamino, arylamino, alkylaminoalkyl, arylaminoalkyl, aminoalkylamino, hydroxy, alkoxyalkyl, carboxyalkyl, alkoxycarbonylalkyl, aminocarbonylalkyl, acyl, aralkoxycarbonyl, carboxylic acid, sulfonic acid, sulfonyl, phosphonic acid, aryl and heteroaryl. It is understood that the substituent may be further substituted.
- As used herein, the term ‘compound(s)’ comprises the compounds disclosed in the present invention.
- As used herein, the term “comprise” or “comprising” is generally used in the sense of include, that is to say permitting the presence of one or more features or components.
- As used herein, the term “or” means “and/or” unless stated otherwise.
- As used herein, the term “including” as well as other forms, such as “include”, “includes” and “included” is not limiting.
- As used herein, the term “composition” is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts. By “pharmaceutically acceptable” it is meant the carrier, diluent or excipient must be compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
- As used herein, the term “treat”, “treating” and “treatment” refer to a method of alleviating or abrogating a disease and/or its attendant symptoms.
- As used herein, the term “prevent”, “preventing” and “prevention” refer to a method of preventing the onset of a disease and/or its attendant symptoms or barring a subject from acquiring a disease. As used herein, “prevent”, “preventing” and “prevention” also include delaying the onset of a disease and/or its attendant symptoms and reducing a subject's risk of acquiring a disease.
- As used herein, the term “therapeutically effective amount” refers to that amount of the compound being administered sufficient to prevent development of or alleviate to some extent one or more of the symptoms of the condition or disorder being treated.
- “Pharmaceutically acceptable” means that, which is useful in preparing a pharmaceutical composition that is generally safe, non-toxic and neither biologically nor otherwise undesirable and includes that which is acceptable for veterinary as well as human pharmaceutical use.
- The term “stereoisomers” refers to any enantiomers, diastereoisomers, or geometrical isomers of the compounds of Formula (I), (IA), (IB), (IC), (ID), (IE), (IF) and (IG), wherever they are chiral or when they bear one or more double bonds. When the compounds of the formula (I), (IA), (IB), (IC), (ID), (IE), (IF) and (IG) are chiral, they can exist in racemic or in optically active form. It should be understood that the invention encompasses all stereochemical isomeric forms, including diastereomeric, enantiomeric and epimeric forms, as well as d-isomers and l-isomers and mixtures thereof. Individual stereoisomers of compounds can be prepared synthetically from commercially available starting materials which contain chiral centers or by preparation of mixtures of enantiomeric products followed by separation such as conversion to a mixture of diastereomers followed by separation or recrystallization, chromatographic techniques, direct separation of enantiomers on chiral chromatographic columns, or any other appropriate method known in the art. Starting compounds of particular stereochemistry are either commercially available or can be made and resolved by techniques known in the art.
- Additionally, the compounds of the present invention may exist as geometric isomers. The present invention includes all cis, trans, syn, anti, entgegen (E) and zusammen (Z) isomers as well as the appropriate mixtures thereof.
- The present invention provides substituted heterocyclylderivatives of formula (I), which are useful for the inhibition of CDK7.
- The present invention further provides pharmaceutical compositions comprising the said substituted heterocyclyl compounds of formula (I) and their derivatives as therapeutic agents.
- In first embodiment, the present invention provides compounds of formula (I),
- or a pharmaceutically acceptable salt or a stereoisomer thereof;
- wherein,
- ring A is cycloalkyl, aryl, heteroaryl or heterocyclyl;
- ring B is aryl, cycloalkyl, heterocyclyl or absent;
- R1 is hydrogen or alkyl;
- R2 is hydrogen, alkyl or cycloalkyl;
- R3 is hydrogen, alkyl or heteroaryl;
- alternatively, R2 together with R1 or R3 along with the ring atoms to which they are attached forms a 5-7 membered ring;
- R4 at each occurrence is halo, alkyl, hydroxy, alkoxy, amino, nitro, cyano or haloalkyl;
- R5 is
- wherein R5′ is hydrogen, halo, alkyl, alkoxy, alkoxyalkyl or —(CH2)1-3—NRaRb;
- R5″ is H or alkyl;
- Ra and Rb are each independently hydrogen, alkyl, alkoxy or alkoxyalkyl; alternatively, Ra and Rb together with the nitrogen atom to which they are attached form an optionally substituted ring containing 0-2 additional heteroatoms independently selected from N, O or S; wherein the optional substituent is one or more halo, alkyl, acyl, hydroxy, cyano, cyanoalkyl, haloalkyl, alkoxy, alkoxyalkyl, —COOH or —COO-alkyl;
- R6 at each occurrence is halo, alkyl, hydroxy, alkoxy, amino, nitro, cyano or haloalkyl;
- L1 is *—CRcRd—C(O)—, *—NReC(O)— or absent; wherein * is point of attachment with ring A;
- Rc and Rd independently are hydrogen, alkyl or haloalkyl; alternatively, Rc and Rd together with the carbon to which they are attached form a cycloalkyl ring;
- Re is hydrogen or alkyl;
- L2 is —C(O)NH—, —C(O)O— or absent;
- m is 0, 1 or 2;
- p is 0 or 1; and
- q is 0 to 3.
- In another embodiment of the present invention, it provides compounds of formula (IA),
- or a pharmaceutically acceptable salt thereof or a stereoisomer thereof; wherein,
- ring A is cycloalkyl, aryl, heteroaryl or heterocyclyl;
- ring B is aryl, cycloalkyl, heterocyclyl or absent;
- R1 is hydrogen or alkyl;
- R2 is hydrogen, alkyl or cycloalkyl;
- R3 is hydrogen, alkyl or heteroaryl;
- alternatively, R2 together with R1 or R3 along with the ring atoms to which they are attached forms a 5-7 membered ring;
- R4 at each occurrence is halo, alkyl, hydroxy or alkoxy;
- R5 is
- wherein R5′ is hydrogen, halo, alkyl, alkoxy, alkoxyalkyl or —(CH2)1-3—NRaRb; R5″ is H or alkyl;
- Ra and Rb are each independently hydrogen or alkyl; alternatively, Ra and Rb together with the nitrogen atom to which they are attached form an optionally substituted ring containing 0-2 additional heteroatoms independently selected from N, O or S; wherein the optional substituent is one or more halo, alkyl, hydroxy, haloalkyl or alkoxy;
- L1 is *—CRcRd—C(O)—, *—NReC(O)— or absent; wherein * is point of attachment with ring A;
- Rc and Rd independently are hydrogen, alkyl or haloalkyl; alternatively, Rc and Rd together with the carbon to which they are attached form a cycloalkyl ring;
- Re is hydrogen or alkyl;
- L2 is —C(O)NH—, —C(O)O— or absent;
- m is 0, 1 or 2; and
- p is 0 or 1.
- In another embodiment of the present invention, it provides compounds of formula (IA), or a pharmaceutically acceptable salt thereof or a stereoisomer thereof, wherein, ring A is cycloalkyl, aryl, heteroaryl or heterocyclyl;
- ring B is aryl, cycloalkyl, heterocyclyl or absent;
- R1 is hydrogen or alkyl;
- R2 is hydrogen, alkyl or cycloalkyl;
- R3 is hydrogen, alkyl or heteroaryl;
- alternatively, R2 together with R1 or R3 along with the ring atoms to which they are attached forms a 5-7 membered ring;
- R4 at each occurrence is halo, alkyl, hydroxy or alkoxy;
- R5 is —(NH)p—S(O)2—CH═CH2, —NH—CH2—CH═CH—C(O)—NRaRb,
- wherein R5′ is hydrogen, halo, alkyl, alkoxyalkyl or —CH2—NRaRb; R5″ is H or alkyl;
- Ra and Rb are each independently hydrogen or alkyl; alternatively, Ra and Rb together with the Nitrogen to which they are attached form an optionally substituted ring containing 0-2 additional heteroatoms independently selected from N, O or S; wherein the optional substituent is one or more halo, alkyl, hydroxy, haloalkyl or alkoxy;
- L1 is *—CRcRd—C(O)—, *—NReC(O)— or absent; wherein * is point of attachment with ring A;
- Rc and Rd independently are hydrogen, alkyl or haloalkyl; alternatively, Rc and Rd together with the carbon to which they are attached form a cycloalkyl ring;
- Re is hydrogen or alkyl;
- L2 is —C(O)NH—, —C(O)O— or absent;
- m is 0, 1 or 2; and
- p is 0 or 1.
- In another embodiment of the present invention, it provides compounds of formula (IB),
- or a pharmaceutically acceptable salt thereof or a stereoisomer thereof;
- wherein, ring B, L1, L2, R2, R3, R4, R5, R6, m and q are same as defined in compounds of formula (I).
- In yet another embodiment of the present invention, it provides compounds of formula (IC),
- or a pharmaceutically acceptable salt thereof or a stereoisomer thereof;
- wherein, ring A, ring B, L1, R2, R3, R4, R5, R6, m and q are same as defined in compounds of formula (I).
- In yet another embodiment of the present invention, it provides compounds of formula
- or a pharmaceutically acceptable salt thereof or a stereoisomer thereof;
- wherein, ring B, L1, R2, R3, R4, R5, R6, m and q are same as defined in compounds of formula (I).
- In yet another embodiment of the present invention, it provides compounds of formula
- or a pharmaceutically acceptable salt thereof or a stereoisomer thereof; wherein, L1 is *—CRcRd—C(O)— or *—NReC(O)—; wherein * is point of attachment with phenyl; R3, R4, R5 and m are same as defined in compounds of formula (I).
- In yet another embodiment of the present invention, it provides compounds of formula (IF),
- or a pharmaceutically acceptable salt thereof or a stereoisomer thereof; wherein, L1 is *—CRcRd—C(O)— or *—NReC(O)—; wherein * is point of attachment with phenyl; R3, R4, R5 and m are same as defined in compounds of formula (I).
- In yet another embodiment of the present invention, it provides compounds of formula (IG),
- or a pharmaceutically acceptable salt thereof or a stereoisomer thereof; wherein, ring A, L1, R2, R3, R4, R5 and m are same as defined in compounds of formula (I).
- The embodiments below are illustrative of the present invention and are not intended to limit the claims to the specific embodiments exemplified.
- According to one embodiment, specifically provided are compounds of formula (I), wherein ring A is aryl; preferably the said aryl is phenyl.
- According to another embodiment, specifically provided are compounds of formula (I), wherein ring B is aryl; preferably the said aryl is phenyl.
- According to yet another embodiment, specifically provided are compounds of formula (I), wherein ring B is heterocyclyl; preferably the said heterocylcyl is piperidinyl, pyridinyl, piperazinyl, pyrazolyl, morpholinyl, indoninyl or pyrrolidinyl.
- According to yet another embodiment, specifically provided are compounds of formula (I), wherein ring B is absent.
- According to yet another embodiment, specifically provided are compounds of formula (I), wherein ring B and L2 are absent so that R5 is directly linked to ring A.
- According to yet another embodiment, specifically provided are compounds of formula (I), wherein L1 is *—CRcRd—C(O)— wherein * is the point of attachment with ring A.
- According to the preceding embodiment, specifically provided are compounds of formula (I), wherein Rc and Rd are independently hydrogen or alkyl, wherein the said alkyl is methyl, ethyl or isopropyl.
- According to yet another embodiment, specifically provided are compounds of formula (I), wherein L2 is *—C(O)NH—, *—C(O)O—, or absent; wherein * is point of attachment with ring B.
- According to yet another embodiment, specifically provided are compounds of formula (I), wherein when L1 is present, L2 is absent.
- According to yet another embodiment, specifically provided are compounds of formula (I), wherein R2 is alkyl or cycloalkyl; preferably the said alkyl is ethyl and the said cycloalkyl is cyclopropyl, cyclobutyl or cyclopentyl.
- According to yet another embodiment, specifically provided are compounds of formula (I), wherein R3 is hydrogen and alkyl; wherein the said alkyl is methyl.
- According to yet another embodiment, specifically provided are compounds of formula (I), wherein R4 is halo; preferably the said halo is fluoro.
- According to yet another embodiment, specifically provided are compounds of formula (I), wherein m is 0 or 1.
- According to yet another embodiment, specifically provided are compounds of formula (I), wherein R5 is
- wherein R5′ is hydrogen or —CH2—NRaRb.
- According to yet another embodiment, specifically provided are compounds of formula (I), wherein R5 is
- when R5 is attached to hetero atom of ring B; R5′ is hydrogen or —CH2—NRaRb.
- According to the preceding two embodiments, specifically provided are compounds of formula (I), wherein the said Ra and Rb are each independently hydrogen or alkyl; preferably the said alkyl is methyl.
- According to the preceding embodiment, specifically provided are compounds of formula (I), wherein the said Ra and Rb together with the nitrogen to which they are attached form an optionally substituted ring containing 0-2 additional heteroatoms independently selected from N, O or S; wherein the optional substituent is one or more halo, hydroxy, haloalkyl or alkoxy.
- According to yet another embodiment, specifically provided are compounds of formula (I), wherein n is 1 or 2.
- In certain embodiments of formula (I), ring A is aryl or heteroaryl; in another embodiment, the said aryl is phenyl.
- In certain embodiments of formula (I), ring A is meta-substituted with respect to L1 and L2.
- In certain embodiments of formula (I), ring B is monocyclic or bicyclic cycloalkyl, aryl, heterocycloalkyl or heteroaryl.
- In certain embodiments of formula (I), ring B is heterocyclyl; in another embodiment the said heterocylcyl is piperidinyl, pyridinyl,1,2,3,6-tetrahydropyridinyl, piperazinyl, pyrazinyl, pyrazolyl, morpholinyl, indolinyl or pyrrolidinyl.
- In certain embodiments of formula (I), ring B is absent.
- In certain embodiments of formula (I), wherein ring B and L2 are absent so that R5 is directly linked to ring A.
- In certain embodiments of formula (I), R2 is cycloalkyl; in another embodiment, the said cycloalkyl is cyclopropyl, cyclobutyl or cyclopentyl.
- In certain embodiments of formula (I), R2 and R1 together with the atoms to which they are attached form a 5 or 6 membered ring.
- In certain embodiments of formula (I), R2 and R3 together with the atoms to which they are attached form a 5 or 6 membered ring.
- In certain embodiments of formula (I), R2 and R3 together with the atoms to which they are attached form a 6 membered aromatic ring.
- In certain embodiments of formula (I), R5 is,
- wherein R5′ and R5″ are as defined in formula (I).
- In certain embodiments of formula (I), R5 is,
- wherein R5′ and R5″ are as defined in formula (I).
- In certain embodiments of formula (I), R5 is
- wherein R5′ and R5″ are as defined in formula (I).
- In certain embodiments of formula (I), R5 is
- wherein R5′ is hydrogen, halo, alkyl, alkoxy or alkoxyalkyl; and R5″ is H or alkyl.
- In certain embodiments of formula (I), R5 is
- wherein R5′ is —CH2—NRaRb; R5″ is H or alkyl; Ra and Rb are each independently hydrogen, alkyl, alkoxy or alkoxyalkyl.
- In certain embodiments of formula (I), R5 is
- wherein R5′ is —CH2—NRaRb; R5″ is H or alkyl; Ra and Rb together with the nitrogen atom to which they are attached form an optionally substituted 4-7 membered heterocyclyl ring containing 0-2 additional heteroatoms independently selected from N, O or S; wherein the optional substituent is one or more halo, alkyl, acyl, hydroxy, cyano, cyanoalkyl, haloalkyl, alkoxy, alkoxyalkyl, —COOH or —COO-alkyl.
- In certain embodiments of formula (I), R5 is
- wherein p, Ra and Rb are as defined in formula (I).
- In certain embodiments of formula (I), R5 is,
- In certain embodiments of formula (I), R5′ is —(CH2)1-3—NRaRb; wherein Ra and Rb are as defined in formula (I).
- In certain embodiments of formula (I), Ra and Rb together with the nitrogen atom to which they are attached form an optionally substituted heterocyclic ring having 0-2 additional heteroatoms selected from O, S or N; wherein the optional substituent is one or more halo, alkyl, acyl, hydroxy, cyano, cyanoalkyl, haloalkyl, alkoxy, alkoxyalkyl, —COOH or —COO-alkyl.
- In certain embodiments of formula (I), L1 is *—CRcRd—C(O)—; wherein * is the point of attachment with ring A; and Rc and Rd are as defined in claim 1.
- In certain embodiments of formula (I), L2 is —C(O)NH— or —C(O)O—.
- In certain embodiments of formula (I), L2 is *—C(O)NH— or *—C(O)O—; wherein * is the point of attachment with ring B.
- In certain embodiments of formula (I), when L1 is —CRcRd—C(O)— or —NReC(O)—, L2 is absent.
- In certain embodiments, the present invention provides a compound selected from the group consisting of:
-
Compound No. IUPAC name 1. (E)-N-(3′-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)-[1,1′- biphenyl]-4-yl)-4-(dimethylamino)but-2-enamide; 2. (E)-N-(3′-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)-[1,1′- biphenyl]-4-yl)-4-(dimethylamino)but-2-enamide (Isomer-1 of compound-1); 3. (E)-N-(3′-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)-[1,1′- biphenyl]-4-yl)-4-(dimethylamino)but-2-enamide (Isomer-2 of compound-1); 4. (E)-N-(5′-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)-2′-fluoro- [1,1′-biphenyl]-4-yl)-4-(dimethylamino)but-2-enamide; 5. (E)-N-(3′-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)-4′-fluoro- [1,1′-biphenyl]-4-yl)-4-(dimethylamino)but-2-enamide; 6. (E)-N-(3′-(1-((5-cyclopropyl-1-methyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)- [1,1′-biphenyl]-4-yl)-4-(dimethylamino)but-2-enamide; 7. (E)-N-(3′-(2-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-2-oxoethyl)-[1,1′-biphenyl]-4- yl)-4-(dimethylamino)but-2-enamide; 8. (E)-4-(dimethylamino)-N-(3′-(1-((5-ethyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2- yl)-[1,1′-biphenyl]-4-yl)but-2-enamide; 9. (E)-N-(3′-(1-((5-(tert-butyl)-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)-[1,1′- biphenyl]-4-yl)-4-(dimethylamino)but-2-enamide; 10. (E)-N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2- yl)phenyl)pyridin-2-yl)-4-morpholinobut-2-enamide; 11. (E)-N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2- yl)phenyl)pyridin-2-yl)-4-morpholinobut-2-enamide (Isomer-1 of compound-10); 12. (E)-N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2- yl)phenyl)pyridin-2-yl)-4-morpholinobut-2-enamide (Isomer-2 of compound-10); 13. (E)-N-(3′-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxobutan-2-yl)-[1,1′- biphenyl]-4-yl)-4-(dimethylamino)but-2-enamide; 14. (E)-N-(3′-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)-3-fluoro- [1,1′-biphenyl]-4-yl)-4-(dimethylamino)but-2-enamide; 15. (E)-N-(3′-(1-((5-cyclobutyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)-[1,1′- biphenyl]-4-yl)-4-(dimethylamino)but-2-enamide; 16. (E)-N-(6-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2- yl)phenyl)pyridin-3-yl)-4-(dimethylamino)but-2-enamide; 17. (E)-N-(3′-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)-2-fluoro- [1,1′-biphenyl]-4-yl)-4-(dimethylamino)but-2-enamide; 18. N-(3′-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)-[1,1′- biphenyl]-4-yl)acrylamide; 19. N-(3′-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)-3-fluoro-[1,1′- biphenyl]-4-yl)acrylamide; 20. N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2- yl)phenyl)pyridin-2-yl)acrylamide; 21. N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2- yl)phenyl)pyridin-2-yl)acrylamide (Isomer-1 of compound-20); 22. N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2- yl)phenyl)pyridin-2-yl)acrylamide (Isomer-2 of compound-20); 23. N-(5′-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)-2′,3-difluoro- [1,1′-biphenyl]-4-yl)acrylamide; 24. N-(6-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2- yl)phenyl)pyridin-3-yl)acrylamide; 25. 2-(4′-acrylamido-3′-fluoro-[1,1′-biphenyl]-3-yl)-N-(5-cyclopropyl-1H-pyrazol-3-yl)- 3-methylbutanamide; 26. 2-(3-(5-acrylamidopyridin-2-yl)phenyl)-N-(5-cyclopropyl-1H-pyrazol-3- yl)butanamide; 27. 2-(4′-acrylamido-3′-fluoro-[1,1′-biphenyl]-3-yl)-N-(5-cyclopropyl-1H-pyrazol-3- yl)butanamide; 28. (E)-N-(3′-(1-((5-cyclopentyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)-3-fluoro- [1,1′-biphenyl]-4-yl)-4-(dimethylamino)but-2-enamide; 29. (E)-N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3-(1-(4-(dimethylamino)but-2- enoyl)indolin-5-yl)phenyl)propanamide; 30. N-(3′-(1-((5-cyclopropyl-4-methyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)-[1,1′- biphenyl]-4-yl)acrylamide; 31. (E)-N-(3′-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxobutan-2-yl)-3-fluoro- [1,1′-biphenyl]-4-yl)-4-(dimethylamino)but-2-enamide; 32. (E)-N-(3′-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)-3-fluoro- [1,1′-biphenyl]-4-yl)-4-(diethylamino)but-2-enamide; 33. (E)-N-(3′-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)-3-fluoro- [1,1′-biphenyl]-4-yl)-4-(pyrrolidin-1-yl)but-2-enamide; 34. (E)-N-(3′-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)-3-fluoro- [1,1′-biphenyl]-4-yl)-4-morpholinobut-2-enamide; 35. (E)-N-(6-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2- yl)phenyl)pyridin-3-yl)-4-morpholinobut-2-enamide; 36. (E)-N-(6-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-3-methyl-1-oxobutan-2- yl)phenyl)pyridin-3-yl)-4-(dimethylamino)but-2-enamide; 37. (E)-4-((6-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2- yl)phenyl)pyridin-3-yl)amino)-N,N-dimethylbut-2-enamide; 38. (E)-N-(6-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)phenyl)- 2-fluoropyridin-3-yl)-4-(dimethylamino)but-2-enamide; 39. (E)-N-(6-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2- yl)phenyl)pyridin-3-yl)-4-(piperidin-1-yl)but-2-enamide; 40. (E)-N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2- yl)phenyl)pyridin-2-yl)-4-(piperidin-1-yl)but-2-enamide; 41. (E)-N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2- yl)phenyl)pyridin-2-yl)-4-methoxybut-2-enamide; 42. (E)-N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2- yl)phenyl)pyridin-2-yl)-4-(dimethylamino)but-2-enamide; 43. (E)-N-(3′-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-3-methyl-1-oxobutan-2-yl)-3- fluoro-[1,1′-biphenyl]-4-yl)-4-(dimethylamino)but-2-enamide; 44. (E)-N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-3-methyl-1-oxobutan-2- yl)phenyl)pyridin-2-yl)-4-morpholinobut-2-enamide; 45. (E)-N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2- yl)phenyl)pyridin-2-yl)-4-(3-fluoropyrrolidin-1-yl)but-2-enamide; 46. (E)-N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2- yl)phenyl)pyridin-2-yl)-4-((S)-3-fluoropyrrolidin-1-yl)but-2-enamide; 47. (E)-N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2- yl)phenyl)pyridin-2-yl)-4-((S)-3-fluoropyrrolidin-1-yl)but-2-enamide (Isomer-1 of compound-46); 48. E)-N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2- yl)phenyl)pyridin-2-yl)-4-((S)-3-fluoropyrrolidin-1-yl)but-2-enamide (Isomer-2 of compound-46); 49. (E)-N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2- yl)phenyl)pyridin-2-yl)-4-((R)-3-fluoropyrrolidin-1-yl)but-2-enamide 50. (E)-N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2- yl)phenyl)pyridin-2-yl)-4-((R)-3-fluoropyrrolidin-1-yl)but-2-enamide (Isomer-1 of compound-49); 51. (E)-N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2- yl)phenyl)pyridin-2-yl)-4-((R)-3-fluoropyrrolidin-1-yl)but-2-enamide (Isomer-2 of compound-49); 52. (E)-N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2- yl)phenyl)pyridin-2-yl)-4-(pyrrolidin-1-yl)but-2-enamide; 53. (E)-N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)- phenyl)pyridin-2-yl)-4-(pyrrolidin-1-yl)but-2-enamide (Isomer-1 of compound-52); 54. (E)-N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)- phenyl)pyridin-2-yl)-4-(pyrrolidin-1-yl)but-2-enamide (Isomer-2 of compound-52); 55. (E)-N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2- yl)phenyl)pyridin-2-yl)-4-(diethylamino)but-2-enamide; 56. (E)-N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-3-methyl-1-oxobutan-2- yl)phenyl)pyridin-2-yl)-4-(dimethylamino)but-2-enamide; 57. (E)-N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2- yl)phenyl)pyridin-2-yl)-4-(3-fluoropiperidin-1-yl)but-2-enamide; 58. (E)-N-(6-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)phenyl)- 2-fluoropyridin-3-yl)-4-morpholinobut-2-enamide; 59. (E)-N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)phenyl)- 6-fluoropyridin-2-yl)-4-morpholinobut-2-enamide; 60. (E)-N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2- yl)phenyl)pyridin-3-yl)-4-morpholinobut-2-enamide; 61. (E)-N-(3′-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)-[1,1′- biphenyl]-3-yl)-4-morpholinobut-2-enamide; 62. (E)-N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2- yl)phenyl)pyridin-2-yl)-4-(methoxy(methyl)amino)but-2-enamide; 63. (E)-N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)phenyl)- 3-fluoropyridin-2-yl)-4-morpholinobut-2-enamide; 64. (E)-N-(6-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)phenyl)- 2-fluoropyridin-3-yl)-4-(3-fluoropyrrolidin-1-yl)but-2-enamide; 65. N-(3′-(1-((5-cyclopropyl-1H-pyrazol-3 -yl)amino)-1-oxopropan-2-yl)-3-methoxy- [1,1′-biphenyl]-4-yl)acrylamide; 66. N-(3′-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)-3-methyl-[1,1′- biphenyl]-4-yl)acrylamide; 67. N-(3′-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)-3,5-dimethyl- [1,1′-biphenyl]-4-yl)acrylamide; 68. (E)-N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2- yl)phenyl)pyridin-2-yl)-4-((2-methoxyethyl)(methyl)amino)but-2-enamide; 69. (E)-N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2- yl)phenyl)pyridin-2-yl)-4-(1H-imidazol-1-yl)but-2-enamide; 70. (E)-N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2- yl)phenyl)pyridin-2-yl)-4-((S)-2-(methoxymethyl)pyrrolidin-1-yl)but-2-enamide ; 71. (E)-N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2- yl)phenyl)pyridin-2-yl)-4-((S)-2-(methoxymethyl)pyrrolidin-1-yl)but-2-enamide (Isomer-1 of compound-70); 72. (E)-N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2- yl)phenyl)pyridin-2-yl)-4-((S)-2-(methoxymethyl)pyrrolidin-1-yl)but-2-enamide (Isomer-2 of compound-70); 73. N-(3′-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)-2-methoxy- [1,1′-biphenyl]-4-yl)acrylamide; 74. N-((5-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2- yl)phenyl)pyridin-2-yl)methyl)acrylamide; 75. N-(3′-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)-2-methyl-[1,1′- biphenyl]-4-yl)acrylamide; 76. 2-(3-(1-acryloylindolin-5-yl)phenyl)-N-(5-cyclopropyl-1H-pyrazol-3- yl)propanamide; 77. (E)-N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2- yl)phenyl)pyridin-2-yl)-4-((2S,4S)-4-fluoro-2-(methoxymethyl)pyrrolidin-1-yl)but- 2-enamide; 78. (E)-4-(3-cyanopyrrolidin-1-yl)-N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)- 1-oxopropan-2-yl)phenyl)pyridin-2-yl)but-2-enamide; 79. N-(6-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2- yl)phenyl)pyrazin-2-yl)acrylamide; 80. (E)-N-(3′-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)-3-fluoro- [1,1′-biphenyl]-4-yl)-4-((S)-3-fluoropyrrolidin-1-yl)but-2-enamide; 81. methyl ((E)-4-((5-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2- yl)phenyl)pyridin-2-yl)amino)-4-oxobut-2-en-1-yl)-L-prolinate; 82. (E)-4-((S)-2-(cyanomethyl)pyrrolidin-1-yl)-N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol- 3-yl)amino)-1-oxopropan-2-yl)phenyl)pyridin-2-yl)but-2-enamide; 83. 4-acrylamido-N-(3-((5-ethyl-1H-pyrazol-3-yl)amino)phenyl)benzamide; 84. (E)-N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3-(1-(4-(dimethylamino)but-2-enoyl)- 1,2,3,6-tetrahydropyridin-4-yl)phenyl)propanamide; 85. (E)-N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3-(1-(4-(dimethylamino)but-2- enoyl)piperidin-4-yl)phenyl)propanamide; 86. N-(3′-(2-((5-methyl-1H-pyrazol-3-yl)amino)-2-oxoethyl)-[1,1′-biphenyl]-4- yl)acrylamide; 87. N-(3′-(1-((5-ethyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)-[1,1′-biphenyl]-4- yl)acrylamide; 88. N-(3′-(1-((5-(tert-butyl)-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)-[1,1′-biphenyl]- 4-yl)acrylamide; 89. (E)-N-(3-((1H-indazol-3-yl)amino)phenyl)-4-(4-(dimethylamino)but-2- enamido)benzamide; 90. N-(3′-(1-((1H-indazol-3-yl)amino)-1-oxopropan-2-yl)-[1,1′-biphenyl]-4- yl)acrylamide; 91. (E)-N-(3′-(1-((1H-indazol-3-yl)amino)-1-oxopropan-2-yl)-[1,1′-biphenyl]-4-yl)-4- (dimethylamino)but-2-enamide; 92. (E)-N-(6-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2- yl)phenyl)pyrazin-2-yl)-4-(pyrrolidin-1-yl)but-2-enamide; 93. (S,E)-N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2- yl)phenyl)pyridin-2-yl)-4-morpholinobut-2-enamide; 94. (E)-N-(5-cyclopropyl-1H-pyrazol-3-yl)-1-(3-(6-(4-(pyrrolidin-1-yl)but-2- enamido)pyridin-3-yl)phenyl)cyclopropane-1-carboxamide; and 95. (E)-N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-2-methyl-1-oxopropan-2- yl)phenyl)pyridin-2-yl)-4-(pyrrolidin-1-yl)but-2-enamide; - or a pharmaceutically acceptable salt or a stereoisomer thereof.
- In certain embodiments, the present invention provides a compound selected from the group consisting of:
-
Compound No. IUPAC name 96. (E)-N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-3-methyl-1-oxobutan-2- yl)phenyl)pyridin-2-yl)-4-(pyrrolidin-1-yl)but-2-enamide; 97. (E)-N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-3-methyl-1-oxobutan-2- yl)phenyl)pyridin-2-yl)-4-(3-fluoropyrrolidin-1-yl)but-2-enamide; 98. (E)-N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-3-methyl-1-oxobutan-2- yl)phenyl)pyridin-2-yl)-4-(3-hydroxypyrrolidin-1-yl)but-2-enamide; 99. (E)-N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-3-methyl-1-oxobutan-2- yl)phenyl)pyridin-2-yl)-4-(piperidin-1-yl)but-2-enamide; 100. (E)-N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-3-methyl-1-oxobutan-2- yl)phenyl)pyridin-2-yl)-4-(3-fluoropiperidin-1-yl)but-2-enamide; 101. (E)-N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-3-methyl-1-oxobutan-2- yl)phenyl)pyridin-2-yl)-4-(3-hydroxypiperidin-1-yl)but-2-enamide; 102. (E)-N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-3-methyl-1-oxobutan-2- yl)phenyl)pyridin-2-yl)-4-(4-fluoropiperidin-1-yl)but-2-enamide; 103. (E)-N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-3-methyl-1-oxobutan-2- yl)phenyl)pyridin-2-yl)-4-(4-hydroxy-4-methylpiperidin-1-yl)but-2-enamide; 104. (E)-N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-3-methyl-1-oxobutan-2- yl)phenyl)pyridin-2-yl)-4-(4,4-difluoropiperidin-1-yl)but-2-enamide; 105. (E)-N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-3-methyl-1-oxobutan-2- yl)phenyl)pyridin-2-yl)-4-(diethylamino)but-2-enamide; 106. (E)-N-(1-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2- yl)phenyl)piperidin-4-yl)-4-(dimethylamino)but-2-enamide; 107. (E)-N-(3-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)phenyl)- 1-methyl-1H-pyrazol-5-yl)-4-(dimethylamino)but-2-enamide; 108. (E)-N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3-(4-(4-(dimethylamino)but-2- enoyl)piperazin-1-yl)phenyl)propanamide; 109. 3-(1((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)phenyl (E)-4-(4- (dimethylamino)but-2-enoyl)piperazine-1-carboxylate; 110. (E)-4-((S)-2-cyanopyrrolidin-1-yl)-N-(5-(3-((S)-1-((5-cyclopropyl-1H-pyrazol-3 - yl)amino)-1-oxopropan-2-yl)phenyl)pyridin-2-yl)but-2-enamide; 111. (E)-4-((2S,4S)-2-(cyanomethyl)-4-fluoropyrrolidin-1-yl)-N-(5-(3-((S)-1-((5- cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)phenyl)pyridin-2-yl)but-2- enamide; 112. (E)-N-(3′-((S)-1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)-3 - fluoro-[1,1′-biphenyl]-4-yl)-4-((S)-2-(methoxymethyl)pyrrolidin-1-yl)but-2- enamide; 113. (E)-N-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)phenyl)-4- (4-(dimethylamino)but-2-enoyl)morpholine-2-carboxamide; 114. (E)-N-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)phenyl)-4- (4-(dimethylamino)but-2-enamido)tetrahydro-2H-pyran-3-carboxamide ; 115. (E)-N-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)phenyl)-1- (4-(dimethylamino)but-2-enoyl)pyrrolidine-2-carboxamide; 116. (E)-N-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)phenyl)-1- (4-(dimethylamino)but-2-enoyl)piperidine-2-carboxamide; 117. (E)-N-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)phenyl)-1- (4-(dimethylamino)but-2-enoyl)piperidine-3-carboxamide; 118. (E)-N-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)phenyl)-4- (dimethylamino)but-2-enamide; 119. (E)-N-(4-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)phenyl)-4- (dimethylamino)but-2-enamide; 120. (E)-N-(2-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)phenyl)-4- (dimethylamino)but-2-enamide; 121. 2-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)phenyl (E)-4-(4- (dimethylamino)but-2-enoyl)piperazine-1-carboxylate; 122. 4-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)phenyl (E)-4-(4- (dimethylamino)but-2-enoyl)piperazine-1-carboxylate; 123. (E)-N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)phenyl)- 6-fluoropyridin-2-yl)-4-(dimethylamino)but-2-enamide; 124. (E)-N-(3-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2- yl)phenyl)pyridin-4-yl)-4-morpholinobut-2-enamide; 125. (E)-N-(3′-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)-[1,1′- biphenyl]-2-yl)-4-morpholinobut-2-enamide; 126. (E)-N-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)phenyl)-4- (4-(dimethylamino)but-2-enoyl)piperazine-1-carboxamide; 127. (E)-N-(6-(3-((S)-1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2- yl)phenyl)pyridin-2-yl)-4-((S)-3-fluoropyrrolidin-1-yl)but-2-enamide; 128. (E)-N-(6-(3-((S)-1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2- yl)phenyl)pyrazin-2-yl)-4-((S)-3-fluoropyrrolidin-1-yl)but-2-enamide; 129. (E)-N-(5-(3-((S)-1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2- yl)phenyl)pyridin-2-yl)-4-((S)-3-(trifluoromethyl)pyrrolidin-1-yl)but-2-enamide; 130. (E)-4-((2S,4S)-2-cyano-4-fluoropyrrolidin-1-yl)-N-(5-(3-((S)-1-((5-cyclopropyl-1H- pyrazol-3-yl)amino)-1-oxopropan-2-yl)phenyl)pyridin-2-yl)but-2-enamide; 131. (E)-4-((S)-2-cyanopyrrolidin-1-yl)-N-(5-(3-((S)-1-((5-cyclopropyl-1H-pyrazol-3- yl)amino)-1-oxopropan-2-yl)phenyl)pyridin-2-yl)but-2-enamide; 132. (S,E)-N-(3′-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)-3-fluoro- [1,1′-biphenyl]-4-yl)-4-(diethylamino)but-2-enamide; 133. (E)-N-(4-(3-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-4-methylisoquinolin-6- yl)phenyl)-4-(dimethylamino)but-2-enamide; 134. (E)-N-(4-(4-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)pyridin- 2-yl)phenyl)-4-(dimethylamino)but-2-enamide; 135. (E)-N-(4-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2- yl)phenyl)cyclohexyl)-4-(dimethylamino)but-2-enamide; 136. (E)-N-(3-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2- yl)phenyl)cyclohexyl)-4-(dimethylamino)but-2-enamide; 137. (E)-4-(dimethylamino)-N-(3′-(1-oxo-1-(pyrazolo[1,5-a]pyridin-2-ylamino)propan-2- yl)-[1,1′-biphenyl]-4-yl)but-2-enamide; 138. (E)-N-(3′-(3-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1,1,1-trifluoro-3-oxopropan- 2-yl)-[1,1′-biphenyl]-4-yl)-4-(dimethylamino)but-2-enamide; 139. (E)-N-(3′-(1-((5-cyclopentyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)-[1,1′- biphenyl]-4-yl)-4-(dimethylamino)but-2-enamide; 140. (E)-N-(3′-(1-((5-cyclohexyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)-[1,1′- biphenyl]-4-yl)-4-(dimethylamino)but-2-enamide; 141. (E)-N-(3′-(1-((5-cyclopropyl-4-methyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)- [1,1′-biphenyl]-4-yl)-4-(dimethylamino)but-2-enamide; 142. (E)-N-(3′-(1-((5-cyclopropyl-4-(pyridin-2-yl)-1H-pyrazol-3-yl)amino)-1-oxopropan- 2-yl)-[1,1′-biphenyl]-4-yl)-4-(dimethylamino)but-2-enamide; and 143. (E)-N-(3′-(3-(5-cyclopropyl-1H-pyrazol-3-yl)-1-methylureido)-[1,1′-biphenyl]-4- yl)-4-(dimethylamino)but-2-enamide; - or a pharmaceutically acceptable salt or a stereoisomer thereof.
- In certain embodiments, when R1 is hydrogen, the compounds of the present invention are known to rapidly equilibrate, in solution, as admixtures of both tautomers:
- Accordingly, in the present invention, where only one tautomer is indicated for the compounds of formula (I), is also within the scope of the present invention, unless specifically noted otherwise.
- In certain embodiments, the present invention provides a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof or a stereoisomer thereof as described herein and at least one pharmaceutically acceptable excipient (such as a pharmaceutically acceptable carrier or diluent). Preferably, the pharmaceutical composition comprises a therapeutically effective amount of at least one compound described herein. The compounds described in the present invention may be associated with a pharmaceutically acceptable excipient (such as a carrier or a diluent) or be diluted by a carrier or enclosed within a carrier which can be in the form of a capsule, sachet, paper or other container.
- In yet another embodiment, the compounds of the present invention are kinase inhibitors. In certain embodiments, the compounds of the present invention are selective CDK inhibitors (e.g., being more active in inhibiting a CDK than a non-CDK kinase). In certain embodiments, the compounds of the present invention are selective CDK7 inhibitors (e.g., being more active in inhibiting CDK7 than a non-CDK7 kinase).
- In another embodiment, the present invention provides pharmaceutical composition for use in treating and/or preventing a disease and/or disorder associated with aberrant activity of selective transcritptional CDKs.
- In another embodiment, the present invention provides pharmaceutical composition for use in treating a subject suffering from diseases and/or disorder associated with aberrant activity of selective transcriptional CDKs.
- In another embodiment, the present invention provides a method of inhibiting selective transcriptional CDKs in a subject, comprising administering to the subject in need thereof a therapeutically effective amount of a compound of the present invention.
- In another embodiment, the present invention provides a method of treating diseases and/or disorder mediated by selective transcriptional CDKs in a subject comprising administering to the subject in need thereof a therapeutically effective amount of a compound of the present invention.
- In an embodiment, the present invention provides pharmaceutical composition comprising the compound of formula (I), for use in treating a subject suffering from a disease or condition associated with aberrant activity of selective transcriptional CDKs. In another embodiment, the present invention provides pharmaceutical composition comprising the compound of formula (I), for use in treating a subject suffering from diseases and/or disorder associated with aberrant activity of transcriptional CDK9, CDK12, CDK13 or CDK18.
- In another embodiment, the present invention provides pharmaceutical composition comprising the compound of formula (I), for use in treating a subject suffering from diseases and/or disorder associated with aberrant activity of transcriptional CDK7.
- In yet another embodiment, the present invention provides a method of treating disorders and/or diseases or condition mediated by selective transcriptional CDKs (CDK9, CDK12, CDK13 or CDK18) in a subject comprising administering a therapeutically effective amount of a compound of the present invention.
- In yet another embodiment, the present invention provides a method of treating disorders and/or diseases or condition mediated by transcriptional CDK7 in a subject comprising administering a therapeutically effective amount of a compound of the present invention.
- In yet another embodiment, the present invention provides a method of inhibiting selective transcriptional CDKs. In another embodiment, the present invention provides a method of inhibiting particularly transcriptional CDK7, CDK9, CDK12, CDK13 or CDK18; more particularly CDK7, in a subject in need thereof by administering to the subject one or more compounds described herein in the amount effective to cause inhibition of such receptor/kinase.
- In another aspect, the present invention relates to methods of inhibiting the activity of a kinase in a biological sample or subject. In certain embodiments, the kinase is a selective transcriptional CDK. In another embodiment, the selective transcriptional CDK is CDK9, CDK12, CDK13 or CDK18. In yet another embodiment, the selective transcriptional CDK is particularly CDK7.
- In certain embodiments, the inhibition of the activity of the kinase is irreversible. In other embodiments, the inhibition of the activity of the kinase is reversible.
- In certain embodiments, the present invention provides compounds of formula (I) as covalent inhibitors of selective transcriptional CDKs. In yet another embodiment, the present invention provides compounds of formula (I) as covalent inhibitors of transcriptional CDK9, CDK12, CDK13 or CDK18. In yet another embodiment, the present invention provides compounds of formula (I) as covalent inhibitors of transcriptional CDK7.
- The compounds of the invention are typically administered in the form of a pharmaceutical composition. Such compositions can be prepared using procedures well known in the pharmaceutical art and comprise at least one compound of the present invention. The pharmaceutical composition of the present invention comprises one or more compounds described herein and one or more pharmaceutically acceptable excipients. Typically, the pharmaceutically acceptable excipients are approved by regulatory authorities or are generally regarded as safe for human or animal use. The pharmaceutically acceptable excipients include, but are not limited to, carriers, diluents, glidants and lubricants, preservatives, buffering agents, chelating agents, polymers, gelling agents, viscosifying agents, solvents and the like.
- The pharmaceutical composition can be administered by oral, parenteral or inhalation routes. Examples of the parenteral administration include administration by injection, percutaneous, transmucosal, transnasal and transpulmonary administrations.
- Examples of suitable carriers include, but are not limited to, water, salt solutions, alcohols, polyethylene glycols, peanut oil, olive oil, gelatin, lactose, terra alba, sucrose, dextrin, magnesium carbonate, sugar, amylose, magnesium stearate, talc, gelatin, agar, pectin, acacia, stearic acid, lower alkyl ethers of cellulose, silicic acid, fatty acids, fatty acid amines, fatty acid monoglycerides and diglycerides, fatty acid esters and polyoxyethylene.
- The pharmaceutical composition may also include one or more pharmaceutically acceptable auxiliary agents, wetting agents, suspending agents, preserving agents, buffers, sweetening agents, flavouring agents, colorants or any combination of the foregoing.
- The pharmaceutical compositions may be in conventional forms, for example, tablets, capsules, solutions, suspensions, injectables or products for topical application. Further, the pharmaceutical composition of the present invention may be formulated so as to provide desired release profile.
- Administration of the compounds of the invention, in pure form or in an appropriate pharmaceutical composition, can be carried out using any of the accepted routes of administration of pharmaceutical compositions. The route of administration may be any route which effectively transports the active compound of the present invention to the appropriate or desired site of action. Suitable routes of administration include, but are not limited to, oral, nasal, buccal, dermal, intradermal, transdermal, parenteral, rectal, subcutaneous, intravenous, intraurethral, intramuscular or topical.
- Solid oral formulations include, but are not limited to, tablets, capsules (soft or hard gelatin), dragees (containing the active ingredient in powder or pellet form), troches and lozenges.
- Liquid formulations include, but are not limited to, syrups, emulsions and sterile injectable liquids, such as suspensions or solutions.
- Topical dosage forms of the compounds include ointments, pastes, creams, lotions, powders, solutions, eye or ear drops, impregnated dressings and may contain appropriate conventional additives such as preservatives, solvents to assist drug penetration.
- The pharmaceutical compositions of the present invention may be prepared by conventional techniques known in literature.
- Suitable doses of the compounds for use in treating the diseases or disorders described herein can be determined by those skilled in the relevant art. Therapeutic doses are generally identified through a dose ranging study in humans based on preliminary evidence derived from the animal studies. Doses must be sufficient to result in a desired therapeutic benefit without causing unwanted side effects. Mode of administration, dosage forms and suitable pharmaceutical excipients can also be well used and adjusted by those skilled in the art. All changes and modifications are envisioned within the scope of the present invention.
- In one embodiment, the compounds as disclosed in the present invention are formulated for pharmaceutical administration.
- Yet another embodiment of the present invention provides use of the compounds as disclosed in the present invention in the treatment and prevention of diseases and/or disorder associated with the aberrant activity of selective transcriptional CDKs, particularly the selective transcriptional CDK is CDK7, CDK9, CDK12, CDK13 or CDK18; more particularly CDK7.
- Yet another embodiment of the present invention provides use of the compound or a pharmaceutically acceptable salt thereof, in treating and/or preventing a disease for which the symptoms thereof are treated, improved, diminished and/or prevented by inhibition of selective transcriptional CDKs, particularly the selective transcriptional CDK is CDK7, CDK9, CDK12, CDK13 or CDK18; more particularly CDK7.
- According to yet another embodiment, the selective transcriptional CDK mediated disorder and/or disease or condition is proliferative disease or disorder or condition.
- In yet another embodiment, the diseases and/or disorder mediated by selective transcriptional CDKs is selected from, but not limited to the group consisting of a cancer, an inflammatory disorder, an auto-inflammatory disorder or an infectious disease.
- In other embodiments, the proliferative disease to be treated or prevented using the compounds of formula (I) will typically be associated with aberrant activity of CDKs, more particularly with CDK7, CDK9, CDK12, CDK13 or 18. Aberrant activity of CDK7, CDK9, CDK12, CDK13 or CDK18 may be an elevated and/or an inappropriate (e.g., abnormal) activity of CDK7, CDK9, CDK12, CDK13 or CDK18. In certain embodiments, CDK7, CDK9, CDK12, CDK13 or CDK18 are not overexpressed, and the activity of CDK7, CDK9, CDK12, CDK13 or CDK18 are elevated and/or inappropriate. In certain other embodiments, CDK7, CDK9, CDK12, CDK13 or CDK18 are overexpressed, and the activity of CDK7, CDK9, CDK12, CDK13 or CDK18 are elevated and/or inappropriate. The compounds of formula (I), and pharmaceutically acceptable salts or stereoisomers, and compositions thereof, inhibit the activity of CDK7, CDK9, CDK12, CDK13 or CDK18 and have been useful in treating and/or preventing proliferative diseases.
- According to yet another embodiment, the compounds of the present invention are expected to be useful in the therapy of proliferative diseases such as viral diseases, fungal diseases, neurological/neurodegenerative disorders, autoimmune, inflammation, arthritis, anti-proliferative (e.g., ocular retinopathy), neuronal, alopecia and cardiovascular diseases.
- According to yet another embodiment, the compounds of the present invention are useful in the treatment of a variety of cancers, including but not limited to carcinoma, including that of the breast, liver, lung, colon, kidney, bladder, including small cell lung cancer, non-small cell lung cancer, head and neck, thyroid, esophagus, stomach, pancreas, ovary, gall bladder, cervix, prostate and skin, including squamous cell carcinoma; hematopoietic tumors of lymphoid lineage, including leukemia, acute lymphoblastic leukemia, acute lymphocytic leukemia, Hodgkins lymphoma, non-Hodgkins lymphoma, B-cell lymphoma, T-cell lymphoma, hairy cell lymphoma, myeloma, mantle cell lymphoma and Burkett's lymphoma; hematopoietic tumors of myeloid lineage, including acute and chronic myelogenous leukemias, myelodysplastic syndrome and promyelocytic leukemia; tumors of masenchymal origin, including fibrosarcoma and rhabdomyosarcoma; tumors of the central and peripheral nervous system, including astrocytoma, neuroblastoma, glioma and schwannomas; and other tumors, including seminoma, melanoma, osteosarcoma, teratocarcinoma, keratoctanthoma, xenoderoma pigmentosum, thyroid follicular cancer and Kaposi's sarcoma.
- According to yet another embodiment, the subject is a mammal including human.
- According to yet another embodiment, the present invention provides compounds or pharmaceutically acceptable salts or stereoisomers thereof, for use as a medicament.
- According to yet another embodiment, the invention provides the use of the compounds of the present invention in the manufacture of a medicament.
- According to yet another embodiment, the present invention provides compounds or pharmaceutically acceptable salts or stereoisomers thereof, for use in the treatment of cancer.
- According to yet another embodiment, the invention provides the use of the compounds of the present invention in the manufacture of a medicament for the treatment of diseases and/or disorder associated with the aberrant activity of selective transcriptional CDKs.
- In yet another embodiment, the invention provides the use of the compounds of the present invention in the manufacture of a medicament for the treatment of cancer.
- According to yet another embodiment, the present invention provides compounds for use as a medicament for treating a subject suffering from diseases and/or disorder associated with aberrant activity of selective transcriptional CDKs.
- According to yet another embodiment, the present invention comprises administering to the subject in need thereof a therapeutically effective amount of a compound of the present invention along with one or more additional chemotherapeutic agents independently selected from anti-proliferative agents, anti-cancer agents, immunosuppressant agents and pain-relieving agents.
- The method(s) of treatment of the present invention comprises administering a safe and effective amount of a compound according to formula (I) or a pharmaceutically acceptable salt thereof to a patient (particularly a human) in need thereof.
- Compounds of the invention are indicated both in the therapeutic and/or prophylactic treatment of the above-mentioned conditions. For the above-mentioned therapeutic uses the dosage administered will, of course, vary with the compound employed, the mode of administration, the treatment desired and the disorder or disease indicated.
- The compounds of the present invention may be used as single drug or as a pharmaceutical composition in which the compound is mixed with various pharmacologically acceptable materials.
- According to one embodiment, the compounds of the present invention can also contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute such compounds. For example, the present invention also embraces isotopically-labeled variants of the present invention which are identical to those recited herein, but for the fact that one or more atoms of the compound are replaced by an atom having the atomic mass or mass number different from the predominant atomic mass or mass number usually found in nature for the atom. All isotopes of any particular atom or element as specified are contemplated within the scope of the compounds of the invention and their uses. Exemplary isotopes that can be incorporated in to compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, sulfur, fluorine, chlorine and iodine, such as 2H (“D”), 3H, 11C, 13C, 14C, 13N, 15N, 15O, 17O, 18O, 32P, 33P, 35S, 18F, 36Cl, 123I and 125I. Isotopically labeled compounds of the present invention can generally be prepared by following procedures analogous to those disclosed in the schemes and/or in the examples herein below, by substituting an isotopically labeled reagent for a non-isotopically labeled reagent.
- The following abbreviations refer respectively to the definitions herein: LDA (Lithium diisopropylamide); K2CO3 (Potassium carbonate); KOAc (Potassium acetate); EtOH (Ethanol); NH3 solution (Ammonia solution); Prep TLC (Preparative Thin layer Chromatography); rt (Retention time); RT (Room temperature); DMF (Dimethylformamide); h (hour); NaOH (Sodium hydroxide); HATU (1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid-hexafluorophosphate); LC-MS (Liquid chromatography mass spectroscopy); HCl (Hydrochloric acid); THE (tetrahydrofuran); DCM (Dichloromethane); TFA (Trifluoroacetic acid); TLC (Thin layer chromatography); DIPEA (Diisopropyl Ethyl amine); Na2SO4 (Sodium sulphate); ACN/CH3CN (Acetonitrile); PdCl2(dppf)-DCM (1,1′-Bis(diphenylphosphino)ferrocene]dichloropalladium(II).dichloromethane complex); Bpin2 (Bis(pinacolato)diboron); DMSO-d6 (Dimethyl sulfoxide-d); Boc2O (Ditert-butyl dicarbonate); HPLC (High pressure liquid chromatography); NaHCO3 (Sodium bicarbonate); Pd2(dba)3 (Tris(dibenzylideneacetone)dipalladium(0)); TEA (triethyl amine), Cs2CO3 (Cesium carbonate); MHz (mega hertz); s (singlet); m (multiplet); and d (doublet).
- Following general guidelines apply to all experimental procedures described here. Until otherwise stated, experiments are performed under positive pressure of nitrogen, temperature described are the external temperature (i.e. oil bath temperature). Reagents and solvents received from vendors are used as such without any further drying or purification. Molarities mentioned here for reagents in solutions are approximate as it was not verified by a prior titration with a standard. All reactions are stirred under magnetic stir bar. Cooling to minus temperature was done by acetone/dry ice or wet ice/salts. Magnesium sulfate and sodium sulfate were used as solvent drying agent after reaction work up and are interchangeable. Removing of solvents under reduced pressure or under vacuum means distilling of solvents in rotary evaporator.
- Compounds of this invention may be made by synthetic chemical processes, examples of which are shown herein. It is meant to be understood that the order of the steps in the processes may be varied, that reagents, solvents and reaction conditions may be substituted for those specifically mentioned and that vulnerable moieties may be protected and deprotected, as necessary.
- The specifics of the process for preparing compounds of the present invention are detailed in the experimental section.
- The present invention shall be illustrated by means of some examples, which are not construed to be viewed as limiting the scope of the invention.
- Unless otherwise stated, work-up includes distribution of the reaction mixture between the organic and aqueous phases, separation of layers and drying the organic layer over anhydrous sodium sulphate, filtration and evaporation of the solvent. Purification, unless otherwise mentioned, includes purification by silica gel chromatographic techniques, generally using ethyl acetate/petroleum ether mixture of a suitable polarity as the mobile phase.
- Analysis for the compounds of the present invention unless mentioned, was conducted in general methods well known to a person skilled in the art. Having described the invention with reference to certain preferred embodiments, other embodiments will become apparent to one skilled in the art from consideration of the specification. The invention is further defined by reference to the following examples, describing in detail the analysis of the compounds of the invention.
- It will be apparent to those skilled in the art that many modifications, both to materials and methods, may be practiced without departing from the scope of the invention. Some of the intermediates were taken to next step based on TLC results, without further characterization, unless otherwise specified.
-
- 2-(3-bromophenyl)acetic acid (3 g, 13.95 mmol) in THF (15 mL) was added to a solution of 2M LDA (22 mL, 41.8 mmol) at −78° C. over a period of 10 min. The reaction mass was stirred for 1 h at −78° C. followed by the drop wise addition of methyl iodide (6.3 g, 44.6 mmol) over a period of 10 min. The reaction mass was stirred at room temperature for overnight. The reaction mass was quenched with 2N HCl and concentrated under reduced pressure to remove excess amount of THF. The residue was diluted with ether, washed twice with 2N HCl, extracted the ether layer with 10% NaOH. The combined NaOH layer was acidified with 6N HCl, extracted the compound to ether. The ether layer was washed with water followed by brine, dried and concentrated under reduced pressure to afford the crude compound (2.5 g, 78%). LCMS: m/z=229.1 (M+H)+.
-
- Methyl hydrazine (1 mL) was added to a solution of 3-cyclopropyl-3-oxopropanenitrile (1 g, 9.17 mmol) in ethanol (15 mL). The resulting reaction mass was heated to reflux for 12 h. The reaction mass was quenched with ice cold water and extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous sodium sulphate and concentrated under reduced pressure to afford the title compound (1.1 g, 97%) LCMS: m/z=138 (M+H)+.
-
- Step-i: (E)-4-bromobut-2-enoic acid (4.5 g, 27.7 mmol) was taken in DCM (30 mL) with catalytic amount of DMF followed by the addition of oxalyl chloride (5 mL). The reaction mass was allowed to stir for 1.5 h at RT, evaporated the solvent under vacuum. The residue was dissolved in DCM and was added to the pre cooled solution of 5-bromopyridin-2-amine (3.0 g, 17.34 mmol) in acetonitrile (50 mL) and DIPEA (11.0 mL, 69.36 mmol) at 0° C. The resulting reaction mixture was stirred for 2 h, added water and extracted with DCM. The combined organic phase was washed with brine, dried over anhydrous Na2SO4, filtered and concentrated under vacuum. The crude was purified by silica gel column chromatography by eluting with 10% methanol in DCM to afford (E)-4-bromo-N-(5-bromopyridin-2-yl)but-2-enamide (1.25 g, 40%), LCMS: m/z=320.9 (M+H)+.
- Step-ii: To a stirred solution of (E)-4-bromo-N-(5-bromopyridin-2-yl)but-2-enamide (1.0 g, 3.13 mmol) in acetonitrile (20 mL) was added potassium carbonate (1.0 g, 7.83 mmol) and morpholine (0.39 g, 4.7 mmol) at room temperature. The reaction mixture was heated to 60° C. for about 2 h, concentrated the reaction mixture under vacuum. The crude was purified by neutral alumina column chromatography using 10% methanol in DCM to afford the title compound (0.8 g, 60%), LCMS: m/z=326.1 (M+H)+.
-
- A solution of 4-aminobenzoic acid (1.40 g, 10 mmol) in DMF (10 mL) and pyridine (0.5 ml) was cooled to 0° C. To this solution was added acryloyl chloride (0.94 g, 10 mmol) and the resulting mixture was stirred for 3 hours at RT. The mixture was poured into 200 ml of water and the white solid obtained was filtered, washed with water and ether, dried to afford the title compound which was used in the next step without purification (1.8 g) LCMS: m/z=192.1 (M+H)+.
-
- To a solution of 5-bromopyridin-2-amine (0.5 g, 2.92 mmol) in ACN (20 mL) was added water (2 mL), DIPEA (0.75 g, 5.84 mmol) and acryloyl chloride (0.26 g, 2.92 mmol) at 0° C. After 30 min, the reaction mixture was quenched with ice-water and diluted with EtoAc. The aqueous layer was separated and extracted with EtOAc (2×25 mL). The combined organic phase was washed with brine, dried over Na2SO4, filtered and concentrated. The crude residue was purified by silica gel column by eluting with 10%-30% ethyl acetate-hexane system to afford the title compound (0.3 g, 48%) LCMS: m/z=227.8 (M+H)+.
-
- To a solution of 5-bromoindoline (0.5 g, 2.51 mmol) in DCM (5 mL) was added TEA (0.63 mL, 5.02 mmol) and acryloyl chloride (0.23 g, 2.51 mmol) at 0° C. After 30 min, the reaction mixture was quenched with ice-water and diluted with EtOAc. The aqueous layer was separated and extracted with EtOAc (2×25 mL). The combined organic phase was washed with brine, dried over Na2SO4, filtered and concentrated. The crude residue was purified by silica gel column by eluting with 10%-30% ethyl acetate-hexane system to afford the title compound (0.4 g, 63%) LCMS: m/z=253.8 (M+H)+.
-
- To a solution of (5-bromopyridin-2-yl)methanamine (0.5 g, 2.7 mmol) in ACN (20 mL) was added water (2 mL), DIPEA (0.94 mL, 5.4 mmol) and acryloyl chloride (0.24 g, 2.7 mmol) at 0° C. After 30 min, the reaction mixture was quenched with ice-water and diluted with EtoAc. The aqueous layer was separated and extracted with EtOAc (2×25 mL). The combined organic phase was washed with brine, dried over Na2SO4, filtered and concentrated. The crude residue was purified by silica gel column chromatography by eluting with 0-5% MeOH-DCM to afford the title compound (0.3 g, 46%) LCMS: m/z=240.9 (M+H)+.
-
- wherein, ring A, ring B, R1, R2, R3, R4, L1 and m are as defined in formula (I);
- Some compounds of the present invention may be generally synthesized utilizing the process outlined in Scheme-8. The commercially available or synthesized intermediate-b was converted to corresponding acid chloride in presence of suitable reagents and solvents (DCM, catalytic DMF, oxalyl chloride, RT, 1.5 h) which upon reacting with intermediate-a in presence of suitable reagents and solvents (pyridine, 0° C.-RT, 12 h; or DCM, TEA, 0° C.-RT, 12 h) afforded intermediate-c. Treatment of intermediate-c with intermediate-d (boronic acid or boronate ester) by Suzuki coupling conditions in presence of suitable catalyst such as Pd(dppf)Cl2.DCM or PdCl2(PPh3)2, suitable base such as potassium carbonate or cesiumcarbonate and in the presence of suitable solvent(s) such as 1,4-dioxane and/or water gave intermediate-e. This intermediate-e upon reaction with corresponding acid chloride of intermediate-f for 1 hour at room temperature followed by reaction with 2M N,N-dimethylamine in THE in presence of DIPEA and suitable solvent such as ACN afforded the product of interest.
- The present invention is further exemplified, but not limited, by the following examples that illustrate the preparation of compounds according to the invention.
-
- 2-(3-bromophenyl)propanoic acid (1 g, 4.36 mmol) was taken in DCM at 0° C. with catalytic amount of DMF and added oxalyl chloride (1.1 g, 8.7 mmol). The reaction mass was stirred at room temperature for 1.5 h. The reaction mass was concentrated under reduced pressure. Re-dissolved the residue in DCM and added to the cooled solution of tert-butyl 3-amino-5-cyclopropyl-1H-pyrazole-1-carboxylate (0.876 g, 3.93 mmol) (synthesis carried out as described in reference Tetrahedron Letters, 2005, vol. 46, #6p. 933-935) in pyridine (20 mL) at 0° C. The resultant reaction mass was stirred at room temperature for 12 h. The reaction mass was concentrated under reduced pressure and the residue was dissolved in DCM, washed with saturated NaHCO3 solution and brine. The organic layer was dried over anhydrous sodium sulphate and concentrated under reduced pressure and the crude was purified by silica gel column chromatography by eluting with 15% ethyl acetate-hexane to afford the title compound (0.5 g, 26.45%) LCMS: m/z=336.1 (M-Boc+3).
- To a degassed solution of tert-butyl 3-(2-(3-bromophenyl)propanamido)-5-cyclopropyl-1H-pyrazole-1-carboxylate (0.5 g, 1.15 mmol) and 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (0.378 g, 1.72 mmol) in 1,4-dioxane (20 mL) and water (4 mL), added Cs2CO3 (1.12 g, 3.44 mmol). The reaction mass was stirred for 10 minutes and degassed further for 10 min and added PdCl2(dppf).DCM (0.046 g, 0.057 mmol). The reaction mass was heated for 12 h at 110° C. in a sealed tube. The reaction mass was cooled to room temperature and diluted with water and ethyl acetate. The separated organic layer was dried over anhydrous sodium sulphate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography by eluting with 15% ethyl acetate-hexane to afford the title compound (0.2 g, 50%) LCMS: m/z=347.2 (M+H)+.
- (E)-4-bromobut-2-enoic acid (0.14 g, 0.86 mmol) was taken in DCM (5 mL) with catalytic amount of DMF followed by the addition of oxalyl chloride (0.121 g, 0.95 mmol). Stirred the reaction mass for 1.5 h, evaporated the reaction mass under reduced pressure to residue. Re dissolved the reaction mass in DCM (2 mL) and was added at 0° C. to a mixture of 2-(4′-amino-[1,1′-biphenyl]-3-yl)-N-(5-cyclopropyl-1H-pyrazol-3-yl)propanamide (0.15 g, 0.43 mmol) in acetonitrile (10 mL) and DIPEA (0.4 mL, 2.16 mmol). The resulting reaction mixture was stirred for 10 minutes at 0° C. and after completion of the reaction, a solution of N, N-dimethylamine (2M in THF, 1 mL, 2.16 mmol) was added and then allowed to stir at room temperature for 12 h. The reaction mixture was quenched with saturated NaHCO3 solution and diluted with DCM. The aqueous layer was separated and extracted with DCM (2×25 mL). The combined organic phase was washed with brine, dried over Na2SO4, filtered and concentrated under reduced pressure and purified the residue with silica gel column chromatography by eluting with 10% methanol-DCM to afford the title compound (0.015 g, 7.57%). 1HNMR (DMSO-d6, 400 MHz): δ 12.0 (s, 1H), 10.28 (d, 2H), 7.77 (d, 2H), 7.62 (t, 3H), 7.49 (s, 1H), 7.30-7.39 (m, 2H), 6.74-6.81 (m, 1H), 6.41 (d, 1H), 6.13 (s, 1H), 3.89 (dd, 1H), 3.56-3.58 (m, 2H), 2.70 (s, 6H), 1.77-1.84 (m, 1H), 1.41 (d, 2H), 1.25-1.28 (m, 1H), 0.87 (d, 2H), 0.60 (d, 2H); LCMS: m/z=458.3 (M+H)+; HPLC: 98.15%, rt: 6.54 min.
- Racemic (E)-N-(3′-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)-[1,1′-biphenyl]-4-yl)-4-(dimethylamino)but-2-enamide (0.1 g, Compound-1) was separated by using chiral prep HPLC column. (Method: Column: Lux 5 μCellulose-4 (10.0×250 mm), Elution: isocratic (95:5), A=ACN, B=0.1% DEA in EtOH) to afford the pure Isomer-1 (0.04 g) and Isomer-2 (0.04 g).
- Isomer-1 (Compound-2): 1HNMR (DMSO-d6, 400 MHz): δ 12.0 (brs, 1H), 10.42 (s, 1H), 10.17 (s, 1H), 7.75 (d, 2H), 7.58-7.64 (m, 3H), 7.48 (d, 1H), 7.36 (t, 1H), 7.30 (d, 1H), 6.72-6.76 (m, 1H), 6.28 (d, 1H), 6.12 (s, 1H), 3.87-3.89 (m, 1H), 3.05 (d, 2H), 2.17 (s, 6H), 1.80 (brs, 1H), 1.40 (d, 3H), 0.87 (dd, 2H), 0.60 (d, 2H). LCMS: m/z=458.35 (M+H)+; HPLC: 97.98%, rt: 6.06 min.; Chiral HPLC: 97.67%, rt: 6.88 min.
- Isomer-2 (Compound-3): 1HNMR (DMSO-d6, 400 MHz): δ 12.0 (brs, 1H), 10.42 (s, 1H), 10.17 (s, 1H), 7.75 (d, 2H), 7.58-7.64 (m, 3H), 7.48 (d, 1H), 7.36 (t, 1H), 7.30 (d, 1H), 6.72-6.76 (m, 1H), 6.28 (d, 1H), 6.12 (s, 1H), 3.87-3.89 (m, 1H), 3.05 (d, 2H), 2.17 (s, 6H), 1.80 (brs, 1H), 1.40 (d, 3H), 0.87 (dd, 2H), 0.60 (d, 2H). LCMS: m/z=458.35 (M+H)+; HPLC: 96.64%, rt: 6.05 min; Chiral HPLC: 98.74%, rt: 10.16 min.
- The compounds listed in the below table-1 were prepared by procedure similar to the one described in Example-1 with appropriate variations in reactants, quantities of reagents, protections and deprotections, solvents and reaction conditions. The characterization data of the compounds are also summarized herein the table-1.
-
TABLE 1 Comp.No. Structure Characterization data 4 1HNMR (DMSO-d6, 400 MHz): δ 10.46 (d, 2H), 9.75 (s, 1H), 7.78 (d, 2H), 7.48-7.52 (m, 3H), 7.32-7.35 (m, 1H), 7.21-7.26 (m, 1H), 6.74-6.78 (m, 1H), 6.47 (d, 1H), 6.11 (s, 1H), 3.96 (t, 2H), 3.85-3.90 (m, 1H), 2.81 (d, 6H), 1.79-1.82 (m, 1H), 1.39 (d, 3H), 0.86 (dd, 2H), 0.60 (dd, 2H); LCMS: m/z = 476.1 (M + H)+; HPLC: 93.72%, rt: 6.20 min. 5 1HNMR (DMSO-d6, 400 MHz): δ 10.46 (d, 2H), 9.75 (s, 1H), 7.76 (d, 2H), 7.65 (d, 1H), 7.58 (dd, 2H), 7.52-7.60 (m, 1H), 7.22 (t, 1H), 6.71-6.78 (m, 1H), 6.46 (d, 1H), 6.12 (s, 1H), 4.14 (d, 1H), 3.34-3.39 (d, 2H), 2.81 (s, 6H), 1.46-1.83 (m, 1H), 1.45 (d, 3H), 0.85-0.88 (m, 2H), 0.59-0.63 (m, 2H); LCMS: m/z = 476.1 (M + H)+; HPLC: 94.10%, rt: 10.18 min. 6 1HNMR (DMSO-d6, 400 MHz): δ 10.14 (s, 1H), 9.92 (s, 1H), 7.72 (d, 2H), 7.56-7.60 (m, 3H), 7.49 (d, 1H), 7.37 (t, 1H), 7.28 (d, 1H), 6.68- 6.74 (m, 1H), 6.24 (d, 1H), 5.81 (s, 1H), 3.88- 3.93 (m, 1H), 3.41 (s, 3H), 3.03 (d, 2H), 2.14 (s, 6H), 1.67-1.73 (m, 1H), 1.41 (d, 3H), 0.71- 0.76 (m, 2H), 0.49-0.53 (m, 2H); LCMS: m/z = 472.2 (M + H)+; HPLC: 97.67%, rt: 6.72 min. 7 1HNMR (DMSO-d6, 400 MHz): δ 12.01 (s, 1H), 10.56 (s, 1H), 10.18 (s, 1H), 7.75 (d, 2H), 7.59 (d, 2H), 7.50 (d, 1H), 7.36 (t, 1H), 7.25 (d, 1H), 6.72-6.76 (m, 1H), 6.26-6.30 (m, 1H), 6.10 (s, 1H), 3.62 (s, 2H), 3.33-3.38 (m, 1H), 3.05 (d, 2H), 2.17 (s, 6H), 1.78-1.81 (m, 1H), 0.86 (dd, 2H), 0.61 (d, 2H); LCMS: m/z = 444.0 (M + H)+; HPLC: 95.97%, rt: 5.90 min. 8 1HNMR (DMSO-d6, 400 MHz): δ 12.0 (s, 1H), 10.42 (s, 1H), 10.21 (s, 1H), 7.74 (d, 2H), 7.64 (s, 1H), 7.59 (d, 2H), 7.49 (d, 1H), 7.37 (t, 1H), 7.31 (d, 1H), 6.71-6.77 (m, 1H), 6.24-6.49 (m, 2H), 3.84-3.89 (m, 2H), 3.76-3.78 (m, 1H), 3.07 (d, 2H), 2.18 (s, 6H), 1.41 (d, 3H), 1.12 (t, 3H). LCMS: m/z = 446.35 (M + H)+; HPLC: 93.28%, rt: 5.99 min. 9 1HNMR (DMSO-d6, 400 MHz): δ 12.01 (s, 1H), 10.46 (s, 1H), 10.18 (s, 1H), 7.77 (d, 2H), 7.66 (s, 1H), 7.60 (d, 2H), 7.51 (d, 1H), 7.40 (t, 1H), 7.31 (d, 1H), 6.77-6.72 (m, 1H), 6.29 (d, 2H), 3.90 (d, 1H), 3.08 (d, 2H), 2 49 (s, 6H), 1.42 (d, 3H), 1.21 (s, 9H); LCMS: m/z = 474.35 (M + H)+; HPLC: 94.08%, rt: 3.22 min. -
- wherein, ring A, ring B, R1, R2, R3, R4, R5, L1 and mare as defined in formula (I); Some compounds of the present invention can be generally synthesized utilizing the process outlined in this scheme. The commercially available or synthesized intermediate-b was converted to corresponding acid chloride in presence of suitable reagents and solvents (DCM, catalytic DMF, oxalyl chloride, RT, ˜1.5 h) which upon reacting with intermediate-a in presence of suitable reagents and solvents (pyridine, 0° C.-RT, 12 h; or DCM, TEA, 0° C.-RT, 12 h) afforded intermediate-c. Treatment of intermediate-c with intermediate-g (4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane)) under suitable reagents and conditions (1,4-Dioxane, potassium acetate, Pd(dppf)Cl2.DCM or PdCl2(PPh3)2, 12 h, 100° C.) gave intermediate-h. Treatment of intermediate-h with intermediate-i by Suzuki coupling conditions in presence of suitable catalyst such as Pd(dppf)Cl2.DCM or PdCl2(PPh3)2, suitable base such as potassium carbonate or cesium carbonate and in the presence of suitable solvent(s) such as 1,4-dioxane and/or water afforded the product of interest.
-
- To a degassed solution of tert-butyl 3-(2-(3-bromophenyl)propanamido)-5-cyclopropyl-1H-pyrazole-1-carboxylate (5.0 g, 11.52 mmol) and 4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane) (3.5 g, 13.8 mmol) in 1,4-dioxane (50 mL) was added potassium acetate (3.3 g, 34.5 mmol). The reaction mass was allowed to stir for 10 minutes with degassing at RT and added PdCl2(dppf).DCM complex (0.046 g, 0.057 mmol). The reaction mass was heated for 12 h at 100° C. in a sealed tube, cooled the reaction mass and diluted with water and ethyl acetate. The aqueous layer was separated and re-extracted with ethyl acetate (2×25 mL). The combined organic layer was dried over anhydrous sodium sulfate and concentrated under vacuum. The crude material was purified by silica gel column chromatography by eluting with 20% ethyl acetate in hexane to afford the title compound (4.0 g, 60%), LCMS: m/z=482.2 (M+H)+.
- To a degassed solution of tert-butyl-5-cyclopropyl-3-(2-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)propanamido)-1H-pyrazole-1-carboxylate (0.5 g, 1.04 mmol) and (E)-N-(5-bromopyridin-2-yl)-4-morpholinobut-2-enamide (0.27 g, 0.83 mmol) in 1,4-dioxane (20 mL) and water (5 mL) was added Cs2CO3 (0.84 g, 2.6 mmol). The reaction mass was allowed to stir for 10 minutes with degassing and added PdCl2(dppf).DCM complex (0.06 g, 0.07 mmol), heated the reaction mass for 12 h at 100° C. in a d sealed tube. The reaction mass was cooled and diluted with water and ethyl acetate. The aqueous layer was separated and re-extracted with ethyl acetate (2×25 mL). The combined organic layer was dried over anhydrous sodium sulfate and concentrated under vacuum. The crude material was purified by silica gel column chromatography by eluting with 10% methanol in DCM, further purified by preparative HPLC (Method: Column: Gemini NX C18 (21.2 mm×150 mm, 5 micron), Mobile phase: 0.01% NH4OH in Water, Acetonitrile:Methanol (1:1)) to afford the title compound (0.2 g, 40%). 1HNMR (DMSO-d6, 400 MHz): δ 12.02 (s, 1H), 10.76 (s, 1H), 10.41 (s, 1H), 8.61 (s, 1H), 8.26 (d, 1H), 8.05 (d, 1H), 7.69 (s, 1H), 7.55 (d, 1H), 7.42-7.34 (m, 2H), 6.82-6.75 (m, 1H), 6.47 (d, 1H), 6.12 (s, 1H), 3.91-3.86 (m, 1H), 3.60-3.58 (m, 4H), 3.13 (d, 2H), 2.37 (s, 4H), 1.83-1.76 (m, 1H), 1.41 (d, 3H), 0.87-0.85 (d, 2H), 0.60-0.59 (m, 2H); LCMS: m/z=501.10 (M+H)+; HPLC: 97.63%, rt: 4.27 min.
- Racemic (E)-N-(5-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)-phenyl)pyridin-2-yl)-4-morpholinobut-2-enamide was separated by using chiral preparative HPLC column (Method: Column: Chiral Pak IA (20 mm×250 mm, 5 micron), Elution: isocratic (50:50), A=ACN, B=MeOH, Flow: 20 mL/min) to afford the pure Isomer-1 and Isomer-2.
- Isomer-1 (Compound-11): 1HNMR (DMSO-d6, 400 MHz): δ 12.02 (s, 1H), 10.77 (s, 1H), 10.43 (s, 1H), 8.62-8.61 (m, 1H), 8.27 (d, 1H), 8.06 (d, 1H), 7.69 (s, 1H), 7.56 (d, 1H), 7.43-7.34 (m, 2H), 6.82-6.75 (m, 1H), 6.47 (d, 1H), 6.11 (s, 1H), 3.86 (m, 1H), 3.60-3.58 (m, 4H), 3.12 (d, 2H), 2.38 (s, 4H), 1.83-1.76 (m, 1H), 1.41 (d, 3H), 0.89-0.84 (m, 2H), 0.62-0.58 (m, 2H); LCMS: m/z=501.3 (M+H)+; HPLC: 99.26%, rt: 3.45 min.; Chiral HPLC: 97.58%, rt: 7.54 min.
- Isomer-2 (Compound-12): 1HNMR (DMSO-d6, 400 MHz): δ 12.02 (s, 1H), 10.75 (s, 1H), 10.41 (s, 1H), 8.61-8.60 (m, 1H), 8.27-8.20 (m, 1H), 8.05 (d, 1H), 7.68 (s, 1H), 7.55 (d, 1H), 7.42-7.33 (m, 2H), 6.81-6.74 (m, 1H), 6.47 (d, 1H), 6.10 (s, 1H), 3.89-3.87 (m, 1H), 3.59-3.57 (m, 4H), 3.10 (d, 2H), 2.31 (s, 4H), 1.81-1.77 (m, 1H), 1.40 (d, 3H), 0.87-0.85 (m, 2H), 0.61-0.57 (m, 2H); LCMS: m/z=501.2 (M+H)+; HPLC: 99.04%, rt: 3.44 min.; Chiral HPLC: 95.42%, rt: 9.07 min.
- The compounds listed in the below table-2 were prepared by a procedure similar to the one described in Example-2 with appropriate variations in reactants, quantities of reagents, protections and deprotections, solvents and reaction conditions. The characterization data of the compounds are also summarized herein the table-2.
-
TABLE 2 Comp. No. Structure Characterization Data 13 1HNMR (DMSO-d6, 400 MHz): δ 11.99 (s, 1H), 10.41 (s, 1H), 10.13 (m, 1H), 7.73-7.71 (m, 2H), 7.60 (s, 1H), 7.60-7.54 (m, 2H), 7.46-7.44 (d, 1H), 7.35-7.31 (m. 1H), 7.27-7.25 (m, 1H). 6.74-6.67 (m, 1H), 6.27-6.23 (m, 1H), 6.11 (s, 1H), 3.62-3.58 (m, 1H), 3.02 (d, 2H), 2.14 (s, 6H), 2.06-1.99 (m, 1H), 1.78-1.73 (m, 1H), 1.70-1.63 (m, 1H), 0.84-0.79 (m, 5H), 0.58-0.57 (m, 2H); LCMS: m/z = 472.5 (M + H)+; HPLC: 94.51%, rt: 6.18 min. 14 1HNMR (DMSO-d6, 400 MHz): δ 12.02 (s, 1H), 10.42 (s, 1H), 9.91 (s, 1H), 8.09-8.05 (m, 1H), 7.65 (s, 1H), 7.65-7.51 (m, 2H), 7.44 (d, 1H), 7.42-7.28 (m, 2H), 6.76-6.68 (m, 1H), 6.45 (d, 1H), 6.08 (s, 1H), 3.86-3.82 (m, 1H), 3.05 (d, 2H), 2.13 (s, 6H), 1.77-1.75 (m, 1H), 1 38 (d, 3H), 0.83 (m, 2H), 0.57 (m, 2H); LCMS: m/z = 476.1 (M + H)+; HPLC: 95.68%, rt: 6.12 min. 15 1HNMR (DMSO-d6, 400 MHz): δ 12.02 (s, 1H), 10.46 (s, 1H), 10.18 (s, 1H), 7.76 (d, 2H), 7.65 (s, 1H), 7.60 (d, 2H), 7.49 (d, 1H), 7.39-7.30 (m, 2H), 6.78-6.71 (m, 1H), 6.32-6.27 (m, 2H), 3.93-3.88 (m, 1H), 3.07-3.05 (m, 2H), 2.22-2.19 (m, 8H), 2.07-2.05 (m, 2H), 1.97-1.87 (m, 3H), 1.42 (d, 3H); LCMS: m/z = 472.2 (M + H)+; HPLC: 98.85%, rt: 3.71 min. 16 1HNMR (DMSO-d6, 400 MHz): δ 12.05 (s, 1H), 10.47 (d, 2H), 8.86 (d, 1H), 8.23-8.21 (m, 1H), 8.10 (s, 1H), 7.91 (d, 1H), 7.87-7.85 (m, 1H), 7.40-7.39 (m, 2H), 6.81-6.77 (m, 1H), 6.32 (d, 1H), 6.14 (s, 1H), 3.93-3.91 (m, 1H), 3.09-3.07 (m, 2H), 2.41 (s, 6H), 1.81-1.79 (m, 1H), 1.42 (d, 3H), 0.86 (m, 2H), 0.61 (m, 2H); LCMS: m/z = 459 (M + H)+; HPLC: 95.54%, rt: 5.79 min. 17 1HNMR (DMSO-d6, 400 MHz): δ 12.02 (s, 1H), 10.43 (s, 1H), 10.36 (s, 1H), 7.80-7.76 (d, 1H), 7.53 (s, 1H), 7 48-7.34 (m, 5H), 6.79-6.74 (m, 1H), 6.29 (d, 1H), 6.13 (s, 1H), 3.91-3.86 (m, 1H), 3.05 (d, 2H), 2.18 (s, 6H), 1.78 (m, 1H), 1.38 (d, 3H), 0.83-0.81 (m, 2H), 0.60-0.58 (m, 2H); LCMS: m/z = 476.2 (M + H)+; HPLC: 99.40%, rt: 3.44 min. 18 1HNMR (DMSO-d6, 400 MHz): δ 12.05 (s, 1H), 10.41 (s, 1H), 10.25 (m, 1H), 7.77 (d, 2H), 7.64- 7.59 (m, 3H), 7.50 (d, 1H), 7.39-7.31 (m, 2H), 6.48-6.46 (m, 1H), 6.29 (d, 1H), 6.13 (s, 1H), 5.75 (d, 1H), 3.88 (s, 1H), 1.79 (m, 1H), 1.40 (d, 3H), 0.85 (d, 2H), 0.61 (d, 2H); LCMS: m/z = 400.8 (M + H)+; HPLC: 97.91%, rt: 4.47 min 19 1HNMR (DMSO-d6, 400 MHz): δ 12.03 (s, 1H), 10.41 (s, 1H), 10.05 (s, 1H), 8.13 (t, 1H), 7.70 (s, 1H), 7.60-7.55 (m, 2H), 7.49 (d, 1H), 7.42-7.34 (m, 2H), 6.68-6.62 (m, 1H), 6.32-6.28 (m, 1H), 6.13 (s, 1H), 5.81-5.78 (m, 1H), 3.92-3.87 (m, 1H), 1.84-1.78 (m, 1H), 1.42 (d, 3H), 0.88-0.86 (m, 2H), 0.63-0.61 (m, 2H); LCMS: m/z = 419.1 (M + H)+; HPLC: 98.28%, rt: 7.07 min. 20 1HNMR (DMSO-d6, 400 MHz): δ 12.05 (s, 1H), 10.95 (s, 1H), 10.41 (s, 1H), 8.63 (s,1H), 8.29 (d, 1H), 8.09 (d, 1H), 7.70 (s, 1H), 7.57 (d, 1H), 7.44-7.35 (m, 2H), 6.67-6.54 (m, 1H), 6.35-6.30 (d, 1H), 6.13 (s, 1H), 5.78 (d, 1H), 3.91-3.89 (m, 1H), 1.80-1.78 (m, 1H), 1.45 (d, 3H), 0.88-0.86 (m, 2H), 0.60-0.62 (m, 2H); LCMS: m/z = 402.2 (M + H)+; HPLC: 99.41%, rt: 3.84 min. 21 1HNMR (DMSO-d6, 400 MHz): δ 12.05 (s, 1H), 10.95 (s, 1H), 10.41 (s, 1H), 8.63 (s, 1H), 8.29 (d, 1H), 8.09 (d, 1H), 7.70 (s, 1H), 7.57 (d, 1H), 7.44-7.35 (m, 2H), 6.67- 6.54 (m, 1H), 6.35-6.30 (d, 1H), 6.13 (s, 1H), 5.78 (d, 1H), 3.91-3.89 (m, 1H), 1.80-1 78 (m, 1H), 1.45 (d, 3H), 0.88-0.86 (m, 2H), 0.60-0.62 (m, 2H); LCMS: m/z = 402.2 (M + H)+; HPLC: 97.74%, rt: 6.12 min.; Chiral HPLC: 96.78 %, rt: 6.57 min. (Isomer-1 of compound-20) 22 1HNMR (DMSO-d6, 400 MHz): δ 12.05 (s, 1H), 10.95 (s, 1H), 10.41 (s, 1H), 8.63 (s, 1H), 8.29 (d, 1H), 8.09 (d, 1H), 7.70 (s, 1H), 7.57 (d, 1H), 7.44-7.35 (m, 2H), 6.67-6.54 (m, 1H), 6.35-6.30 (d, 1H), 6.13 (s, 1H), 5.78 (d, 1H), 3.91-3.89 (m, 1H), 1.80-1.78 (m, 1H), 1.45 (d, 3H), 0.88-0.86 (m, 2H), 0.60-0.62 (m, 2H); LCMS: m/z = 402.2 (M + H)+; HPLC: 95.96%, rt: 6.11 min; Chiral HPLC: 98.55 %, rt: 12.37 min. (Isomer-2 of compound-20) 23 1HNMR (DMSO-d6, 400 MHz): δ 12.03 (s, 1H), 10.42 (s, 1H), 10.09 (s, 1H), 8.15 (t, 1H), 7.55 (d, 1H), 7.47 (d, 1H), 7.37 (d, 2H), 7.28 (t, 1H), 6.66-6.54 (m, 1H), 6.32-6.27 (d, 1H), 6.13 (s, 1H), 5.79 (d, 1H), 3.88 (d, 1H), 1.80-1.78 (m, 1H), 1.40 (d, 3H), 0.88-0.86 (m, 2H), 0.61-0.60 (m, 2H); LCMS: m/z = 436.9 (M + H)+; HPLC: 96.49%, rt: 4.21 min. 24 1HNMR (DMSO-d6, 400 MHz): δ 12.02 (s, 1H), 10.49-10.46 (d, 2H), 8 88 (s, 1H), 8.28 (d, 1H), 8.10 (s, 1H), 7.93-7.86 (m, 2H), 7.44-7.39 (m, 2H), 6.47-6.43 (m, 1H), 6.33-6.29 (d, 1H), 6.14 (s, 1H), 5.84 (d, 1H), 3.95-3.89 (m, 1H), 1.81-1.78 (m, 1H), 1.42 (d, 3H), 0.88-0.86 (d, 2H), 0.62-0.60 (d, 2H); LCMS: m/z = 402.2 (M + H)+; HPLC: 99.66%, rt: 3.54 min. 25 1HNMR (DMSO-d6, 400 MHz): δ 12.05-11.93 (brs, 1H), 10.7 (s, 1H), 10.06 (s, 1H), 8.14 (t, 1H), 7.69 (s, 1H), 7.58-7.55 (m, 2H), 7.48 (d, 1H), 7.42-7.35 (m, 2H), 6.65 (dd. 1H), 6.35 (d, 1H), 6.18 (s, 1H), 5.80 (d, 1H), 3.45-3.35 (m, 1H), 1.81-1.78 (m, 1H), 1.24 (s, 1H), 0.98 (d, 3H), 0.86 (d, 2H), 0.67 (d, 3H), 0.61 (d, 2H); LCMS: m/z = 447.0 (M + H)+; HPLC: 98.63%, rt: 4.63 min. 26 1HNMR (DMSO-d6, 400 MHz): δ 12.02 (s, 1H), 10.42 (s, 2H), 8.92 (s, 1H), 8.36 (s, 1H), 8.22 (s, 1H),7.44 (d, 2H), 7.37 (d, 2H), 6.51 (s, 1H), 6.35-6.31 (m, 1H), 6.26 (d, 1H), 5.75 (d, 1H), 3.83-3.89 (m, 1H), 2.05-1.99 (m, 1H), 1.80-1.67 (m, 2H), 0.86-0.84 (m, 5H), 0.59-0.57 (m, 2H); LCMS: m/z = 416.30 (M + H)+; HPLC: 97.41%, rt: 7.99 min. 27 1HNMR (DMSO-d6, 400 MHz): δ 12.02 (s, 1H), 10.42 (s, 1H), 10.01 (s, 1H), 8.12 (t, 1H), 7.65 (s, 1H), 7.53 (d, 2H), 7.44 (d, 1H), 7.37 (d, 2H), 6.65-6.51 (m, 1H), 6.27 (d, 1H), 6.09 (s, 1H), 5.75 (d, 1H), 3.63-3.59 (m, 1H), 2.05-1.99 (m, 1H), 1.83-1.69 (m, 2H), 0.86-0.84 (m, 5H), 0.62-0.61 (m, 2H); LCMS: m/z = 433.3 (M + H)+; HPLC: 97.21%, rt: 4.33 min. 28 1HNMR (DMSO-d6, 400 MHz): δ 11.99 (s, 1H), 10.42 (s, 1H), 9.93 (s,1H), 8.10 (t, 1H), 7.69 (s, 1H), 7.59 (d, 2H), 7.45-7.35 (m, 1H), 7.35-7.33 (m, 2H), 6.79-6.80 (m, 1H), 6.46 (d, 1H), 6.25 (s, 1H), 3.92-3.87 (m, 1H), 3.06 (d, 2H), 2.91-2.99 (m, 1H), 2.16 (s, 6H), 1.93 (s, 2H), 1.66-1.49 (m, 6H), 1.42-1.41 (m 3H); LCMS: m/z = 504.55 (M + H)+; HPLC: 96.66%, rt: 4.66 min. 29 1HNMR (DMSO-d6, 400 MHz): δ 12.02 (s, 1H), 10.41 (s, 1H), 8.20 (d, 1H), 7.64 (s, 1H), 7.51-7.43 (m, 3H), 7.37-7.35 (m, 1H), 7.37-7.27 (m, 1H), 6.83-6.78 (m, 1H), 6.76 (d, 1H), 6.11 (s, 1H), 4.26-4.21 (m, 2H), 3 88-3.33 (m, 1H), 3.22-3.20 (m, 2H), 3.10-3.08 (m, 2H), 2.18 (s, 6H), 1.83-1.77 (m, 1H), 1.37 (d, 3H), 0.84-0.82 (m, 2H), 0.62-0.57 (m, 2H); LCMS: m/z = 484.4 (M + H)+; HPLC: 95.47%, rt: 4.25 min. 30 1HNMR (DMSO-d6, 400 MHz): δ 11.85 (s, 1H), 10.3 (s, 1H), 9.64 (s, 1H), 7.78-7.76 (m, 2H), 7.66-7.61 (m, 3H), 7.51 (d, 1H), 7.40-7.34 (m, 2H), 6.45 (dd, 1H), 6.25 (dd, 1H), 5.77 (dd, 1H), 3.87-3.86 (brs, 1H), 1.72-1.69 (m, 4H), 1.43-1.42 (m, 3H), 0.82 (d, 2H), 0.67 (d, 2H); LCMS: m/z = 415.3 (M + H)+; HPLC: 97.49, rt: 5.03 min. 31 1HNMR (DMSO-d6, 400 MHz): δ 12.02 (s, 1H), 10.43 (s, 1H), 9.93 (s, 1H), 8.11 (t, 1H), 7.67 (s, 1H), 7.53 (d, 2H), 7.44 (d, 1H), 7.37 (d, 1H), 7.17 (s, 1H), 6.79-6.75 (m, 1H), 6.49-6.45 (m, 1H), 6.18 (s, 1H), 3.66-3.63 (m, 1H), 3.07-3.06 (m, 2H), 2.18 (s, 6H), 2.08-2.08 (m, 1H), 1.82-1.80 (m, 1H), 1.69-1.68 (m, 1H), 0.87-0.84 (m, 5H), 0.62 (s, 2H); LCMS: m/z = 490.1 (M + H)+; HPLC: 98.55%, rt: 4.54 min. 32 1HNMR (DMSO-d6, 400 MHz): δ 12.01 (s, 1H), 10.40 (s, 1H), 9.91 (s, 1H), 8.09 (t, 1H), 7.68 (s, 1H), 7.56-7.47 (m, 2H), 7.46 (d, 1H), 7.38-7.32 (m, 2H), 6.83-6.76 (m, 1H), 6.52 (d, 1H), 6.13 (s, 1H), 3.89-3.87 (m, 1H), 3.20 (d, 2H), 2.49-2.44 (m, 4H), 1.82-1.78 (m, 1H), 1.41 (d, 3H), 0.99-0.96 (m, 6H), 0.86 (d, 2H), 0.62 (d, 2H); LCMS: m/z = 504.40 (M + H)+; HPLC: 98.75%, rt: 4.47 min. 33 1HNMR (DMSO-d6, 400 MHz): δ 12.01 (s, 1H), 10.40 (s, 1H), 9.92 (s, 1H), 8.12-8.08 (m, 1H), 7.68 (s, 1H), 7.56-7.53 (m, 2H), 7.46 (d, 1H), 7.40-7.32 (m, 2H), 6.83-6.77 (m, 1H), 6.46 (d, 1H), 6.11 (s, 1H), 3.91-3 85 (m, 1H), 3.22 (d, 2H), 2.49-2.47 (m, 4H), 1.82-1.76 (m, 1H), 1.70 (d, 4H), 1.41 (d, 3H), 0.85 (d, 2H), 0.62-0.58 (m, 2H); LCMS: m/z = 502.40 (M + H)+; HPLC: 95.31%, rt: 4.43 min. 34 1HNMR (DMSO-d6, 400 MHz): δ 12.01 (s, 1H), 10.41 (s, 1H), 9.94 (s, 1H), 8.10 (t, 1H), 7.68 (s, 1H), 7.56-7.53 (m, 2H), 7.46 (d, 1H), 7.40-7.32 (m, 2H), 6.78-6.72 (m, 1H), 6.48 (d, 1H), 6.11 (s, 1H), 3.91-3.85 (m, 1H), 3.60 (d, 4H), 3.10 (d, 2H), 2.38 (s, 4H), 1.83-1.74 (m, 1H), 1.41 (d, 3H), 0.88-0.85 (m, 2H), 0.61-0.58 (m, 2H); LCMS: m/z = 518.40 (M + H)+; HPLC: 98.37%, rt: 4.23 min. 35 1HNMR (DMSO-d6, 400 MHz): δ 12.01 (s, 1H), 10.41 (s, 2H), 8.85 (s, 1H), 8.21 (d, 1H), 8.08 (s, 1H),7.91-7.83 (m, 2H), 7.41-7.37 (m, 2H), 6.81-6.74 (m, 1H), 6.31 (d, 1H), 6.12 (s, 1H), 3.93-3.88 (m, 1H), 3.60 (t, 4H), 3.16-3.13 (m, 2H), 2.39 (s, 4H), 1.83-1.76 (m, 1H), 1.40 (d, 3H), 0.87-0.84 (d, 2H), 0.62-0.60 (m, 2H); LCMS: m/z = 501.40 (M + H)+; HPLC: 97.02%, rt: 4.17 min. 36 1HNMR (DMSO-d6, 400 MHz): δ 12.02 (s, 1H), 10.49 (s, 1H), 10.40 (s, 1H), 8.87-8.86 (m, 1H), 8.23-8.20 (m, 1H), 8.10 (s, 1H), 7.90-7.84 (m, 2H), 7.42-7.38 (m, 2H), 6.82-6.75 (m, 1H), 6.32-6.28 (m, 1H), 6.14 (s, 1H), 3.40-3.37 (m, 1H), 3.08 (d, 2H), 2.41-2.35 (m, 1H), 2.19 (s, 6H), 1.81-1.77 (m, 1H), 0.98 (d, 3H), 0.86 (d, 2H), 0.66 (m, 3H), 0.61 (s, 2H); LCMS: m/z = 487.4 (M + H)+; HPLC: 96.73%, rt: 6.05 min. 37 1HNMR (DMSO-d6, 400 MHz): δ 12.00 (s, 1H), 10.42 (s, 1H), 8.07 (s, 1H), 7.97 (s, 1H), 7.73 (d, 1H), 7.64 (d, 1H), 7.33-7.25 (m, 2H), 7.02-6.99 (m, 1H), 6.67-6.61 (m, 2H), 6.40 (t, 1H), 6.12 (s, 1H), 3.94-3.84 (m, 3H), 2.97 (s, 3H), 2.95 (s, 3H), 1.82-1.78 (m, 1H), 1.38 (d, 3H), 0.86 (d, 2H), 0.61-0.59 (m, 2H); LCMS: m/z = 459.30 (M + H)+; HPLC: 90.11%, rt: 4.01 min. 38 1HNMR (DMSO-d6, 400 MHz): δ 12.02 (s, 1H), 10.46 (s, 1H), 10.15 (s, 1H), 8.66-8.61 (m, 1H), 8.03 (s, 1H), 7.89-7.84 (m, 2H), 7.41-7.40 (m, 2H), 6.82-6.75 (m, 1H), 6.53-6.47 (m, 1H), 6.12 (s, 1H), 3.92-3.90 (m, 1H), 3.06-3.04 (d, 2H), 2.18 (s, 6H), 1.81 (m, 1H), 1.40 (d, 3H), 0.87-0.85 (m, 2H), 0.61-0.60 (m, 2H); LCMS: m/z = 477.5 (M + H)+; HPLC: 97.38%, rt: 5.77 min. 39 1HNMR (DMSO-d6, 400 MHz): δ 12.01 (s, 1H), 10.44 (s, 1H), 10.37 (s, 1H), 8.85-8.84 (s, 1H), 8.20 (d, 1H), 8.08 (s, 1H), 7.89 (d, 1H), 7.86-7.83 (m, 1H), 7.41-7.36 (m, 2H), 6.81-6.74 (m, 1H), 6.26 (d, 1H), 6.13 (s, 1H), 3.91-3.90 (m, 1H), 3.16-3.10 (m, 2H), 2.34 (s, 4H), 1.81-1.77 (m, 1H), 1.54-1.51 (m, 4H), 1.41-1.39 (m, 5H), 0.85 (d, 2H), 0.62-0.59 (m, 2H); LCMS: m/z = 499.60 (M + H)+; HPLC: 98.43% rt: 5.75 min. 40 1HNMR (DMSO-d6, 400 MHz): δ 12.01 (s, 1H), 10.74 (s, 1H), 10.40 (s, 1H), 8.61 (d, 1H), 8.27 (d, 1H), 8.05 (d, 1H), 7.69 (s, 1H), 7.55 (d, 1H), 7.42-7.34 (m, 2H), 6.83-6.76 (m, 1H), 6.43 (d, 1H), 6.12 (s, 1H), 3.90-3.86 (m, 1H), 3.07-3.05 (d, 2H), 2.32 (s, 4H), 1.82-1.77 (m, 1H), 1.53- 1.48 (m, 4H), 1.42-1.37 (m, 5H), 0.87-0.85 (d, 2H), 0.60-0.59 (m, 2H); LCMS: m/z = 499.70 (M + H)+; HPLC: 97.36%, rt: 5.90 min. 41 1HNMR (DMSO-d6, 400 MHz): δ 12.00 (s, 1H), 10.81 (s, 1H), 10.43 (s, 1H), 8.61 (d, 1H), 8.27 (d, 1H), 8.08-8.05 (m, 1H), 7.68 (s, 1H), 7.55 (d, 1H), 7.43-7.34 (m, 2H), 6.89-6.83 (m, 1H), 6.53- 6.48 (m, 1H), 6.10 (s, 1H), 4.10-4.09 (m, 2H), 3.96-3.90 (m, 1H), 3.31 (s, 3H), 1.80-1.78 (m, 1H), 1.41-1.39 (d, 3H), 0.86-0.83 (m, 2H), 0.60-0.58 (m, 2H); LCMS: m/z = 446.4 (M + H)+; HPLC: 95.99%, rt: 4.05 min. 42 1HNMR (DMSO-d6, 400 MHz): δ 12.05 (s, 1H), 10.75 (s, 1H), 10.41 (d, 1H), 8.61 (s, 1H), 8.28-8.26 (d, 1H), 8.07-8.05 (m, 1H), 7.69 (s, 1H), 7.55 (d, 1H), 7.42-7.34 (m, 2H), 6.83-6.76 (m, 1H), 6.44 (d, 1H), 6.11 (s, 1H), 3.89-3.87 (m, 1H), 3.06-3.04 (d, 2H), 2.15 (s, 6H), 1.78-1.76 (m, 1H), 1.42-1.40 (d, 3H), 0.87-0.84 (m, 2H), 0.61-0.59 (m, 2H); LCMS: m/z = 459.4 (M + H)+; HPLC: 96.38%, rt: 4.26 min. 43 1HNMR (DMSO-d6, 400 MHz): δ 12.02 (s, 1H), 10.43 (s, 1H), 9.94 (s, 1H), 8.13-8.09 (m, 1H), 7.67 (s, 1H), 7.55-7.52 (m, 2H), 7.46-7.44 (m, 1H), 7.40-7.33 (m, 2H), 6.79-6.72 (m, 1H), 6.49-6.45 (m, 1H), 6.13 (s, 1H), 3.34-3.31 (m, 1H), 3.09-3.07 (d, 2H), 2.40-2.36 (m, 1H), 2.17 (s, 6H), 1.81-1.76 (m, 1H), 0.97 (d, 3H), 0.85 (d, 2H), 0.66 (m, 3H), 0.61 (s, 2H); LCMS: m/z = 504.4 (M + H)+; HPLC: 98.59%, rt: 4.42 min. 44 1HNMR (DMSO-d6, 400 MHz): δ 12.02 (s, 1H), 10.77 (s, 1H), 10.44 (s, 1H), 8.60 (s, 1H), 8.27 (d, 1H), 8.05 (d, 1H), 7.67 (s, 1H), 7.56 (d, 1H), 7.41-7.35 (m, 2H), 6.81-6.77 (m, 1H), 6.47 (d, 1H), 6.13 (s, 1H), 3.60-3.58 (m, 5H), 3.11 (d, 2H), 2.67-2.66 (m, 1H), 2.38 (s, 4H), 1.81-1.79 (m, 1H), 0.97 (d, 3H), 0.86 (d, 2H), 0.67 (d, 3H), 0.60 (s, 2H); LCMS: m/z = 529.40 (M + H)+; HPLC: 95.50%, rt: 4.56 min. 45 1HNMR (DMSO-d6, 400 MHz): δ 12.02-11.98 (brs, 1H), 10.77 (s, 1H), 10.43 (s, 1H), 8.62 (s, 1H), 8.27 (d, 1H), 8.16 (s, 1H), 8.07 (d, 1H), 7.69 (s, 1H), 7.56 (d, 1H), 7.43-7.35 (m, 1H), 6.85-6.80 (m, 1H), 6.48 (d, 1H), 6.11 (s, 1H), 5.30-5.10 (m, 1H), 3.90-3.89 (m, 1H), 2.88-2.79 (m, 2H), 2.70-2.59 (m, 2H), 2.33-2.32 (m, 1H), 2.21-2.09 (m, 2H), 1.82-1.78 (m, 2H), 1.41 (d, 3H), 0.88-0.86 (m, 2H), 0.62-0.59 (m, 2H); LCMS: m/z = 503.60 (M + H)+; HPLC: 92.66%, rt: 4.11 min. 46 1HNMR (DMSO-d6, 400 MHz): δ 12.02-11.98 (brs, 1H), 10.77 (s, 1H), 10.43 (s, 1H), 8.62 (s, 1H), 8.27 (d, 1H), 8.16 (s, 1H), 8.07 (d, 1H), 7.69 (s, 1H), 7.56 (d, 1H), 7.43-7.35 (m, 1H), 6.85-6.80 (m, 1H), 6.48 (d, 1H), 6.11 (s, 1H), 5.30-5.10 (m, 1H), 3.90-3.89 (m, 1H), 2.88-2.79 (m, 2H), 2.70-2.59 (m, 2H), 2.33-2.32 (m, 1H), 2.21-2.09 (m, 2H), 1.82-1.78 (m, 2H), 1.41 (d, 3H), 0.88-0.86 (m, 2H), 0.62-0.59 (m, 2H); LCMS: m/z = 503.30 (M + H)+; HPLC: 95.38%, rt: 5.41 min. 47 1HNMR (DMSO-d6, 400 MHz): δ 12.02-11.98 (brs, 1H), 10.77 (s, 1H), 10.43 (s, 1H), 8.62 (s, 1H), 8.27 (d, 1H), 8.16 (s, 1H), 8.07 (d, 1H), 7.69 (s, 1H), 7.56 (d, 1H), 7.43-7.35 (m, 1H), 6.85-6.80 (m, 1H), 6.48 (d, 1H), 6.11 (s, 1H), 5.30-5.10 (m, 1H), 3.90-3.89 (m, 1H), 2.88-2.79 (m, 2H), 2.70-2.59 (m, 2H), 2.33-2.32 (m, 1H), 2.21- 2.09 (m, 2H), 1.82-1.78 (m, 2H), 1.41 (d, 3H), 0.88-0.86 (m, 2H), 0.62-0.59 (m, 2H); LCMS: m/z = 503.30 (M + H)+; HPLC: 97.79%, rt: 5.94 min.; Chiral HPLC: 98.06%, rt: 10.20 min. (Isomer-1 of compound-46) 48 1HNMR (DMSO-d6, 400 MHz): δ 12.02-11.98 (brs, 1H), 10.77 (s, 1H), 10.43 (s, 1H), 8.62 (s, 1H), 8.27 (d, 1H), 8.16 (s, 1H), 8.07 (d, 1H), 7.69 (s, 1H), 7.56 (d, 1H), 7.43-7.35 (m, 1H), 6.85-6.80 (m, 1H), 6.48 (d, 1H), 6.11 (s, 1H), 5.30-5.10 (m, 1H), 3.90-3.89 (m, 1H), 2.88-2.79 (m, 2H), 2.70-2.59 (m, 2H), 2.33-2.32 (m, 1H), 2.21- 2.09 (m, 2H), 1.82-1.78 (m, 2H), 1.41 (d, 3H), 0.88-0.86 (m, 2H), 0.62-0.59 (m, 2H); LCMS: m/z = 503.30 (M + H)+; HPLC: 95.92%, rt: 5.94 min.; Chiral HPLC: 97.74%, rt: 15.18 min. (Isomer-2 of compound-46) 49 1HNMR (DMSO-d6, 400 MHz): δ 12.02-11.98 (brs, 1H), 10.77 (s, 1H), 10.43 (s, 1H), 8.62 (s, 1H), 8.27 (d, 1H), 8.16 (s, 1H), 8.07 (d, 1H), 7.69 (s, 1H), 7.56 (d, 1H), 7.43-7.35 (m, 1H), 6.85-6.80 (m, 1H), 6.48 (d, 1H), 6.11 (s, 1H), 5.30-5.10 (m, 1H), 3.90-3.89 (m, 1H), 2.88-2.79 (m, 2H), 2.70-2.59 (m, 2H), 2.33-2.32 (m, 1H), 2.21- 2.09 (m, 2H), 1.82-1.78 (m, 2H), 1.41 (d, 3H), 0.88-0.86 (m, 2H), 0.62-0.59 (m, 2H); LCMS: m/z = 503.30 (M + H)+; HPLC: 97.79%, rt: 5.94 min. 50 1HNMR (DMSO-d6, 400 MHz): δ 12.02-11.98 (brs, 1H), 10.77 (s, 1H), 10.43 (s, 1H), 8.62 (s, 1H), 8.27 (d, 1H), 8.16 (s, 1H), 8 07 (d, 1H), 7.69 (s, 1H), 7.56 (d, 1H), 7.43-7.35 (m, 1H), 6.85-6.80 (m, 1H), 6.48 (d, 1H), 6.11 (s, 1H), 5.30-5.10 (m, 1H), 3.90-3.89 (m, 1H), 2.88-2.79 (m, 2H), 2.70-2.59 (m, 2H), 2.33-2.32 (m, 1H), 2.21- 2.09 (m, 2H), 1.82-1.78 (m, 2H), 1.41 (d, 3H), 0.88-0.86 (m, 2H), 0.62-0.59 (m, 2H); LCMS: m/z = 503.30 (M + H)+; HPLC: 98.31%, rt: 5.97 min; Chiral HPLC: 98.56%, rt: 10.44 min. (Isomer-1 of compound-49) 51 1HNMR (DMSO-d6, 400 MHz): δ 12.02-11.98 (brs, 1H), 10.77 (s, 1H), 10.43 (s, 1H), 8.62 (s, 1H), 8.27 (d, 1H), 8.16 (s, 1H), 8.07 (d, 1H), 7.69 (s, 1H), 7.56 (d, 1H), 7.43-7.35 (m, 1H), 6.85-6.80 (m, 1H), 6.48 (d, 1H), 6.11 (s, 1H), 5.30-5.10 (m, 1H), 3.90-3.89 (m, 1H), 2.88-2.79 (m, 2H), 2.70-2.59 (m, 2H), 2.33-2.32 (m, 1H), 2.21- 2.09 (m, 2H), 1.82-1.78 (m, 2H), 1.41 (d, 3H), 0.88-0.86 (m, 2H), 0.62-0.59 (m, 2H); LCMS: m/z = 503.60 (M + H)+; HPLC: 97.48%, rt: 5.48 min. Chiral HPLC: 97.95%, rt: 20.50 min. (Isomer-2 of compound-49) 52 1HNMR (DMSO-d6, 400 MHz): δ 12.03 (s, 1H), 10.74 (s, 1H), 10.42 (s, 1H), 8.62 (s, 1H), 8.27 (d, 1H), 8.07 (d, 1H), 7.69 (s, 1H), 7.56 (d, 1H), 7.43-7.35 (m, 2H), 6.88-6.81 (m, 1H), 6.50 (d, 1H), 6.13 (s, 1H), 3.90-3.87 (m, 1H), 3.24 (s, 2H), 2.50 (m, 4H), 1.82-1.77 (m, 1H), 1.70 (m, 4H), 1.41 (d, 3H), 0.87-0.85 (d, 2H), 0.61-0.60 (d, 2H); LCMS: m/z = 485.64 (M + H)+; HPLC: 96.15%, rt: 8.45 min. 53 1HNMR (DMSO-d6, 400 MHz): δ 12.03 (s, 1H), 10.74 (s, 1H), 10.42 (s, 1H), 8.62 (s, 1H), 8.27 (d, 1H), 8.07 (d, 1H), 7.69 (s, 1H), 7.56 (d, 1H), 7.43-7.35 (m, 2H), 6.88-6.81 (m, 1H), 6.50 (d, 1H), 6.13 (s, 1H), 3.90-3.87 (m, 1H), 3.24 (s, 2H), 2.50 (m, 4H), 1.82-1.77 (m, 1H), 1.70 (m, 4H), 1.41 (d, 3H), 0.87-0.85 (d, 2H), 0.61-0.60 (d, 2H); LCMS: m/z = 485.64 (M + H)+; HPLC: 94.40%, rt: 5.95 min.; Chiral HPLC: 97.27%, rt: 13.51 min. (Isomer-1 of compound-52) 54 1HNMR (DMSO-d6, 400 MHz): δ 12.03 (s, 1H), 10.74 (s, 1H), 10.42 (s, 1H), 8.62 (s, 1H), 8.27-8.24 (d, 1H), 8.07-8.02 (d, 1H), 7.69 (s, 1H), 7.57-7.55 (d, 1H), 7.43-7.35 (m, 2H), 6.89-6.82 (m, 1H), 6.50 (d, 1H), 6.13 (s, 1H), 3.91-3.88 (m, 1H), 3.24 (s, 2H), 2.50 (m, 4H), 1.82-1.77 (m, 1H), 1.70 (m, 4H), 1.41-1.40 (d, 3H), 0.87- 0.85 (d, 2H), 0.61-0.60 (d, 2H); LCMS: m/z = 485.64 (M + H)+; HPLC: 94.04%, rt: 5.97 min.; Chiral HPLC: 95.43%, rt: 16.67 min. (Isomer-2 of compound-52) 55 1HNMR (DMSO-d6, 400 MHz): δ 10.77 (s, 1H), 10.43 (s, 1H), 8.62 (s, 1H), 8.28 (d, 1H), 8.15 (m, 1H), 8.06 (d, 1H), 7.69 (s, 1H), 7.56 (d, 1H), 7.43-7.35 (m, 2H), 6.85-6.80 (m, 1H), 6.47 (d, 1H), 6.13 (s, 1H), 3.91-3.87 (m, 1H), 3.25 (d, 2H), 2.52-2.32 (m, 4H), 1.82-1.78 (m, 1H), 1.41 (d, 3H), 0.99-0.97 (m, 6H), 0.86 (d, 2H), 0.62-0.60 (m, 2H); LCMS: m/z = 487.6 (M + H)+; HPLC: 97.05%, rt: 4.10 min. 56 1HNMR (DMSO-d6, 400 MHz): δ 12.02 (s, 1H), 10.77 (s, 1H), 10.46 (s, 1H), 8.61 (s, 1H), 8.29-8.21 (m, 1H), 8.06 (d, 1H), 7.68 (s, 1H), 7.57 (d, 1H), 7.44-7.36 (m, 2H), 6.84-6.77 (m, 1H), 6.44 (d, 1H), 6.13 (s, 1H), 3.06 (d, 2H), 2.33 (s, 1H), 2.17 (s. 6H), 1.81-1.78 (m, 1H), 0.99-0.97 (d, 3H), 0.86 (d, 2H), 0.67 (d, 3H), 0.62-0.59 (m, 2H); LCMS: m/z = 487.6 (M + H)+; HPLC: 95.92%, rt: 4.35 min. 57 1HNMR (DMSO-d6, 400 MHz): δ 12.02(s, 1H), 10.78 (s, 1H), 10.43 (s, 1H), 8.63 (d, 1H), 8.28 (d, 1H), 8.08 (dd, 1H), 7.70 (s, 1H), 7.57 (d, 1H), 7.44-7.40 (m, 1H), 7.38-7.36 (m, 1H), 6.84-6.77 (m, 1H), 6.56-6.45 (m, 1H), 6.14 (s, 1H), 4.73-4.59 (m, 1H), 3.93-3.88 (m, 1H), 3.17-3.16 (m, 2H), 2.78-2.67 (m, 2H), 2.45-2.25 (m, 2H), 1.85- 1.78 (m, 3H), 1.74-1.46 (m, 2H), 1.42 (d, 3H), 0.87 (d, 2H), 0.61 (d, 2H); LCMS: m/z = 517.6 (M + H)+; HPLC: 99.22%, rt: 3.40 min. 58 1HNMR (DMSO-d6, 400 MHz): δ 12.02 (s, 1H), 10.48 (s, 1H), 10.17 (s, 1H), 8.65 (d, 1H), 8.05 (s, 1H), 7.91-7.85 (m, 2H), 7.43-7.42 (m, 2H), 6.81-6.76 (m, 1H), 6.55-6.52 (m, 1H), 6.14 (s, 1H), 3.94-3.92 (m, 1H), 3.62-3.60 (m, 4H), 3.16-3.13 (m, 2H), 2.40 (s, 4H), 1.82-1.79 (m, 1H), 1.43 (d, 3H), 0.87 (d, 2H), 0.62 (d, 2H); LCMS: m/z = 519.2 (M + H)+; HPLC: 98.82%, rt: 5.92 min. 59 1HNMR (DMSO-d6, 400 MHz): δ 12.02 (s, 1H), 10.43 (s, 1H), 10.36 (s, 1H), 8.21-8.18 (d, 1H), 8.12-8.07 (m, 1H), 7.59-7.58 (m, 1H), 7.44-7.38 (m, 3H), 6.85-6.78 (m, 1H), 6.46-6.42 (d, 1H), 6.11 (s, 1H), 3.90-3.87 (m, 1H), 3.61-3.58 (m, 4H), 3.16-3.11 (m, 2H), 2.38-2.32 (m, 4H), 1.88-1.77 (m, 1H), 1.41-1.39 (m, 3H), 0.89-0.84 (m, 2H), 0.62-0.58 (m, 2H); LCMS: m/z = 519 (M + H)+; HPLC: 98.28%, rt: 3.82 min. 60 1HNMR (DMSO-d6, 400 MHz): δ 12.02 (s, 1H), 10.43 (s, 1H), 10.36 (s, 1H), 8.21-8.18 (d, 1H), 8.55-8.54 (m, 1H), 8.35 (s, 1H), 7.66 (s, 1H), 7.55-7.53 (m, 1H), 7.47-7.40 (m, 2H), 6.83-6.76 (m, 1H), 6.34-6.30 (d, 1H), 6.15 (s, 1H), 3.95-3.93 (m, 1H), 3.61-3.58 (m, 4H), 3.16-3.11 (m, 2H), 2.38-2.32 (m, 4H), 1.88-1.77 (m, 1H), 1.41- 1.39 (m, 3H), 0.89-0.84 (m, 2H), 0.62-0.58 (m, 2H); LCMS: m/z = 501.1 (M + H)+; HPLC: 95.28%, rt: 5.61 min. 61 1HNMR (DMSO-d6, 400 MHz): δ 12.02 (s, 1H), 10.43 (s, 1H), 10.36 (s, 1H), 7.93 (s, 1H), 7.68-7.66 (d, 1H), 7.62 (s, 1H), 7.47-7.35 (m, 4H), 7.31-7.29 (d, 1H), 6.78-6.71 (m, 1H), 6.32-6.28 (d, 1H), 6.14 (s, 1H), 3.91-3.88 (m, 1H), 3.61- 3.58 (m, 4H), 3.17-3.11 (m, 2H), 2.39-2.32 (m, 4H), 1.82-1.75 (m, 1H), 1.41-1.36 (m, 3H), 0.88-0.86 (m, 2H), 0.61-0.60 (m, 2H); LCMS: m/z = 500.1 (M + H)+; HPLC: 95.40%, rt: 6.08 min. 62 1HNMR (DMSO-d6, 400 MHz): δ 12.02 (s, 1H), 10.82 (s, 1H), 10.42 (s, 1H), 8.64-8.63 (d, 1H), 8.31- 8.29 (d, 1H), 8.10-8.08 (m, 1H), 7.71 (s, 1H), 7.59-7.57 (d, 1H), 7.45-7.41 (m, 1H), 7.38-7.36 (d, 1H), 6.92-6.85 (m, 1H), 6.49-6.45 (d, 1H), 6.13 (s, 1H), 3.92-3.90 (m, 1H), 3.44 (s, 5H), 2.55 (s, 3H), 1.84-1.80 (m, 1H), 1.44-1.42 (m, 3H), 0.89-0.86 (m, 2H), 0.64-0.60 (m, 2H); LCMS: m/z = 475.6 (M + H)+; HPLC: 95.10%, rt: 4.01 min. 63 1HNMR (DMSO-d6, 400 MHz): δ 12.02 (s, 1H), 10.48 (s, 1H), 10.41 (s, 1H), 8.56 (s, 1H), 8.09-8.06 (m, 1H), 7.76 (s, 1H), 7.64-7.63 (d, 1H), 7.46-7.39 (m, 2H), 6.81-6.74 (m, 1H), 6.38-6.34 (d, 1H), 6.14 (s, 1H), 3.95-3.88 (m, 1H), 3.61-3.59 (m, 4H), 3.16-3.13 (m, 2H), 2.40 (s, 4H), 1.84-1.79 (m, 1H), 1.43-1.42 (d, 3H), 0.88-0.86 (m, 2H), 0.62-0.60 (m, 2H); LCMS: m/z = 519.60 (M + H)+; HPLC: 95.10%, rt: 5.79 min. 64 1HNMR (DMSO-d6, 400 MHz): δ 12.02 (s, 1H), 10.48 (s, 1H), 10.21 (s, 1H), 8.68-8.63 (m, 1H), 8.04 (s, 1H), 7.90-7.86 (m, 2H), 7.88-7.85 (m, 2H), 7.42-7.41 (d, 2H), 6.85-6.81 (m, 1H), 6.55-6.52 (d, 1H), 6.14 (s, 1H), 5.61-5.21 (m, 1H), 3.93-3.91 (m, 1H), 2.85-2.81 (m, 2H), 2.26-2.21 (m, 2H), 2.01-1.80 (m, 3H), 1.42-1.40 (d, 3H), 0.88-0.86 (m, 2H), 0.61-0.60 (m, 2H); LCMS: m/z = 520.30 (M + H)+; HPLC: 95.27%, rt: 6.29 min. 65 1HNMR (DMSO-d6, 400 MHz): δ 12.01 (s, 1H), 10.41 (s, 1H), 9.47 (s, 1H), 8.17-8.15 (d, 1H), 7.60 (s, 1H), 7.55-7.53 (d, 1H), 7.41-7.37 (m, 1H), 7.33-7.32 (m, 1H), 7.25-7.21 (d, 1H), 7.20-7.18 (d, 1H), 6.80-6.72 (m, 1H), 6.27-6.22 (d, 1H), 6.13 (s, 1H), 5.74-5.71 (d, 1H), 3.93-3.86 (m, 3H), 2.61-2.35 (m, 1H), 1.86-1.72 (m, 1H), 1.46 (d, 3H), 0.88-0.86 (m, 2H), 0.62-0.64 (m, 2H), LCMS: m/z = 431.5 (M + H)+; HPLC: 95.38%, rt: 4.20 min. 66 1HNMR (DMSO-d6, 400 MHz): δ 12.01 (s, 1H), 10.4 (s, 1H), 9.53 (s, 1H), 7.65- 7.61 (m, 2H), 7.51-7.49 (d, 2H), 7.47-7.43 (d, 1H), 7.41-7.38 (m, 1H), 7.36-7.33 (d, 1H), 6.62-6.53 (m, 1H), 6.28-6.24 (s, 1H), 6.10 (s, 1H), 5.77-5.74 (d, 1H), 3.91-3.85 (m, 1H), 2.32-2.29 (s, 3H), 1.82-1.78 (m, 1H), 1.42-1.40 (d, 3H), 0.88-0.86 (m, 2H), 0.62-0.60 (m, 2H), LCMS: m/z = 415.1 (M + H)+; HPLC: 95.38%, rt: 4.47 min. 67 1HNMR (DMSO-d6, 400 MHz): δ 12.10 (s, 1H), 10.41 (s, 1H), 9.51 (s, 1H), 7.60 (s, 1H), 7.51-7.42 (d, 1H), 7.38-7.32 (m, 4H), 6.62 (s, 1H), 6.65-653 (m, 1H), 6.14-6.13 (d, 1H), 5.76-5.73 (m, 1H), 3.32-3.22 (m, 1H) 2.62-2.51 (s, 3H), 2.53-2.24 (s, 3H), 1.81-1.70 (m, 1H), 1.47 (d, 3H), 0.88-0.86 (m, 2H), 0.62-0.64 (m, 2H), LCMS: m/z = 429.2 (M + H)+; HPLC: 99.38%, rt: 4.48 min. 68 1HNMR (DMSO-d6, 400 MHz): δ 12.10 (s, 1H), 10.82 (s, 1H), 10.41 (s, 1H), 8.62-8.61 (d, 1H), 8.29-8.27 (d, 1H), 8.08-8.05 (m, 1H), 7.70 ( s, 1H), 7.57-7.55 (d, 1H), 7.43-7.35 (m, 2H), 6.87-6.80 (m, 1H), 6.51-6.47 (d, 1H), 6.13 (s, 1H), 3.91-3.89 (m, 1H), 3.45-3.42 (d, 2H), 3.24 (s, 3H), 3.18-3.15 (d. 2H), 2.53-2.51 (d, 2H), 2.20 (s, 3H), 1.82-179 (m, 1H), 1.43-1.41 (d, 3H), 0.86-0.85 (m, 2H), 0.62-0.61 (m, 2H) LCMS: m/z = 503.30 (M + H)+; HPLC: 97.87%, rt: 7.07 min. 69 1HNMR (DMSO-d6, 400 MHz): δ 12.10 (s, 1H), 11.79 (s, 1H), 10.41 (s, 1H), 8.60-8.59 (m, 1H), 8.17-8.15 (d, 1H), 8.06-8.04 (m, 1H), 7.09 (s, 1H), 7.67 (s, 1H), 7.57-7.53 (m, 2H), 7.42-7.33 (m, 2H), 7.10-7.07 (d, 1H), 6.96 (s, 1H), 6.14-6.07 (m, 2H), 3.91-3.84 (m, 1H), 3.31-3.29 (d, 2H), 1.80-1.40 (m, 1H), 1.40-1.39 (d, 3H), 0.87-0.81 (m, 2H), 0.59-0.56 (m, 2H) LCMS: m/z = 482.23 (M + H)+; HPLC: 99.21%, rt: 5.91 min. 70 1HNMR (DMSO-d6, 400 MHz): δ 12.10 (s, 1H), 10.78 (s, 1H), 10.41 (s, 1H), 8.62-8.61 (d, 1H), 8.29- 8.27 (d, 1H), 8.08-8.05 (m, 1H), 7.69 (s, 1H), 7.57-7.55 (d, 1H), 7.43-7.39 (m, 1H), 7.40-7.35 (d, 1H), 6.87-6.83 (m, 1H), 6.47- 6.43 (d, 1H), 6.13 (s, 1H), 3.91- 3.89 (m, 1H), 3.67-3.64 (m, 1H), 3.34 (s, 3H), 3.28-3.12 (m, 2H), 3.07-2.98 (m, 1H), 2.64-2.52 (m, 2H), 2.19-2.17 (m, 1H), 1.85-180 (m, 2H), 1.67-1.64 (m, 2H), 1.50-1.48 (m, 1H), 1.43-1.41 (d, 3H), 0.86-0.85 (m, 2H), 0.62-0.61 (m, 2H) LCMS: m/z = 529.35 (M + H)+; HPLC: 98.94%, rt: 6.06 min. 71 1HNMR (DMSO-d6, 400 MHz): δ 11.01 (s, 1H), 10.53 (s, 1H), 9.93 (s, 1H), 8.65-8.64 (d, 1H), 8.29- 8.27 (d, 1H), 8.12-8.09 (m, 1H), 7.70 (s, 1H), 7.58-7.56 (d, 1H), 7.44-7.36 (m, 2H), 6.89-6.85 (m, 1H), 6.66-6.62 (d, 1H), 6.11 (s, 1H), 3.99-3.97 (m, 1H), 3.94-3.90 (m, 2H), 3.71 (s, 1H), 3.66-3.56 (m, 2H), 3.52-3.50 (m, 1H), 3.34 (s, 3H), 3.16-3.14 (m, 1H), 2.13-2.01 (m, 1H), 2.00-1.88 (m, 1H), 1.86-1.80 (m, 3H), 1.43-1.42 (d, 3H), 0.89-0.84 (m, 2H), 0.62-0.58 (m, 2H); LCMS: m/z = 529.30 (M + H)+; HPLC: 95.22%, rt: 5.36 min. (Isomer-1 of compound-70) 72 1HNMR (DMSO-d6, 400 MHz): δ 11.01 (s, 1H), 10.53 (s, 1H), 9.93 (s, 1H), 8.65-8.64 (d, 1H), 8.29- 8.27 (d, 1H), 8.12-8.09 (m, 1H), 7.70 (s, 1H), 7.58-7.56 (d, 1H), 7.44-7.36 (m, 2H), 6.89-6.85 (m, 1H), 6.66-6.62 (d, 1H), 6.11 (s, 1H), 3.99-3.97 (m, 1H), 3.94-3.90 (m, 2H), 3.71 (s, 1H), 3.66-3.56 (m, 2H), 3.52-3.50 (m, 1H), 3.34 (s, 3H), 3.16-3.14 (m, 1H), 2.13-2.01 (m, 1H), 2.00-1.88 (m, 1H), 1.86-1.80 (m, 3H), 1.43-1.42 (d, 3H), 0.89-0.84 (m, 2H), 0.62-0.58 (m, 2H); LCMS: m/z = 529.30 (M + H)+; HPLC: 95.02%, rt: 5.61 min. (Isomer-2 of compound-70) 73 1HNMR (DMSO-d6, 400 MHz): δ 12.01 (s, 1H), 10.40 (s, 1H), 10.26 (s, 1H), 7.54 (s, 1H), 7.42 (s, 1H), 7.31-7.22 (m, 5H), 6.48-6.42 (m, 1H), 6.30-6.25 (d, 1H), 6.13 (s, 1H), 5.74-5.71 (d, 1H), 3.86-3.84 (m, 1H), 3.72-3.70 (d, 3H), 2.61-2.35 (m, 1H), 1.39-1.23 (d, 3H), 0.88-0.86 (m, 2H), 0.62-0.64 (m, 2H), LCMS: m/z = 430.51 (M + H)+; HPLC: 95.75%, rt: 4.07 min. 74 1HNMR (DMSO-d6, 400 MHz): δ 12.05 (s, 1H), 10.45 (s, 1H), 8.78-8.77 (m. 2H), 8.02-8.00 (m, 1H), 7.68 (s, 1H), 7.57-7.55 (m, 1H), 7.45-7.37 (m, 3H), 6.38-6.31 (m, 1H), 6.16-6.12 (m, 2H), 5.66-5.63 (m, 1H), 4.49-4.48 (m, 2H), 3.92-3.90 (m, 1H), 1.82-1.78 (m, 1H), 1.42-1.41 (m, 3H), 0.88-0.86 (m, 2H), 0.61-0.60 (m, 2H); LCMS: m/z = 416.3 (M + H)+; HPLC: 95.62%, rt: 3.80 min. 75 1HNMR (DMSO-d6, 400 MHz): δ 12.01 (s, 1H), 10.41 (s, 1H), 9.52 (s, 1H), 7.53 (s, 2H), 7.34-7.32 (m, 3H), 7.16-7.13 (d, 2H), 6.61-6.52 (m, 1H), 6.28-6.24 (d, 1H), 6.10 (s, 1H), 5.77-5.74 (d, 1H), 3.90-3.81 (m, 1H), 2.20 (s, 3H), 1.80-1.70 (m, 1H), 1.39-138 (d, 3H), 0.88-0.86 (m, 2H), 0.62-0.64 (m, 2H), LCMS: m/z = 414.5 (M + H)+; HPLC: 97.6%, rt: 9.68 min. 76 1HNMR (DMSO-d6, 400 MHz): δ 12.01 (s, 1H), 10.41 (s, 1H), 8.22-8.20 (d, 2H), 7.64 (s, 1H), 7.53 (s, 1H), 7.50-7.46 (m, 1H), 7.38-7.35 (m, 1H), 7.31-7.29 (d, 1H), 6.80-6.74 (m, 1H), 6.34- 6.29 (d, 1H), 6.13 (s, 1H), 5.85-5.82 (d, 1H), 4.29-4.24 (m, 2H), 3.89-3.87 (m, 1H), 3.33-3.15 (m, 2H), 1.82-1.78 (m, 1H), 1.41-1.40 (d, 3H), 0.88-0.86 (m, 2H), 0.62-0.64 (m, 2H), LCMS: m/z = 427.15 (M + H)+; HPLC: 97.60%, rt: 4.53 77 1HNMR (DMSO-d6, 400 MHz): δ 12.01 (s, 1H), 11.89 (s, 1H), 10.43 (s, 1H), 8.62-8.61 (d, 1H), 8.31-8.27 (m, 1H), 8.08-8.05 (m, 1H), 7.70 (s, 1H), 7.58-7.56 (d, 1H), 7.44-7.36 (m, 2H), 6.89- 6.85 (m, 1H), 6.48-6.44 (d, 1H), 6.11 (s, 1H), 3.99-3.87 (m, 1H), 3.71-3.66 (m, 1H), 3.47-3.43 (m, 1H), 3.34 (s, 3H), 3.20-3.15 (m, 2H), 3.09-3.05 (m, 2H), 2.72-2.67 (m, 1H), 2.37-2.33 (m, 2H), 1.80-1.75 (m, 2H), 1.43-1.41 (m, 3H), 0.89-0.84 (m, 2H), 0.62-0.58 (m, 2H); LCMS: m/z = 547.30 (M + H)+; HPLC: 95.24%, rt: 6.08 min. 78 1HNMR (DMSO-d6, 400 MHz): δ 12.01 (s, 1H), 11.89 (s, 1H), 10.43 (s, 1H), 8.62-8.61 (d, 1H), 8.31-8.27 (d, 1H), 8.08-8.05 (m, 1H), 7.70 (s, 1H), 7.58-7.56 (d, 1H), 7.44-7.36 (m, 2H), 6.89- 6.79 (m, 1H), 6.48-6.44 (d, 1H), 6.11 (s, 1H), 3.99-3.87 (m, 1H), 3.43-3.40 (m, 3H), 2.76-2.66 (m, 4H), 2.32 (s, 1H), 1.97-1.92 (m, 1H), 1.83-1.78 (m, 1H), 1.43-1.41 (m, 3H), 0.89-0.84 (m, 2H), 0.62-0.58 (m, 2H); LCMS: m/z = 510.20 (M + H)+; HPLC: 95.16%, rt: 5.96 min. 79 1HNMR (DMSO-d6, 400 MHz): δ 12.01 (s, 1H), 11.04 (s, 1H), 10.32 (s, 1H), 9.40 (s, 1H), 8.92 (s, 1H), 8.10 (s, 1H), 7.97-7.98 (d, 1H), 7.46-7.46 (m, 2H), 6.89-6.79 (m, 1H), 6.48-6.44 (d, 1H), 6.11 (s, 1H), 5.88-5.85 (d, 1H), 3.99-3.87 (m, 1H), 2.08-1.78 (m, 1H), 1.43-1.41 (m, 3H), 0.89-0.84 (m, 2H), 0.62-0.58 (m, 2H); LCMS: m/z = 402.80 (M + H)+; HPLC: 95.62%, rt: 3.46 min. 80 1HNMR (DMSO-d6, 400 MHz): δ 12.01 (s, 1H), 10.41 (s, 1H), 9.96 (s, 1H), 8 14-8.10 (m, 1H), 7.69 (s, 1H), 7.57-7.54 (m, 2H), 7.48-7.47 (d, 1H), 7.46-7.33 (m, 2H), 6.89-6.79 (m, 1H), 6.48-6.44 (d, 1H), 6.11 (s, 1H), 5.28-5.14 (m, 1H), 3.99-3.87 (m, 1H), 3.28-3.26 (m, 2H), 2.90-2.80 (m, 2H), 2.70-2.66 (m, 1H), 2.35-2.32 (m, 2H), 2.20-2.08 (m, 1H), 1.83-1.78 (m, 2H), 1.43-1.41 (m, 3H), 0.89-0.84 (m, 2H), 0.62-0.58 (m, 2H); LCMS: m/z = 520.31 (M + H)+; HPLC: 91.57%, rt: 6.11 min. 81 1HNMR (DMSO-d6, 400 MHz): δ 12.01 (s, 1H), 11.89 (s, 1H), 10.43 (s, 1H), 8.62-8.61 (d, 1H), 8.29-8.27 (d, 1H), 8.08-8.05 (m, 1H), 7.70 (s, 1H), 7.58-7.56 (d, 1H), 7.44-7.36 (m, 2H), 6.89-6.85 (m, 1H), 6.48-6.44 (d, 1H), 6.11 (s, 1H), 4.44 (s, 4H), 4.15-4.01 (m, 3H), 3.96-3.93 (m, 1H), 3.92 (s, 3H), 3.60-3.43 (m, 1H), 2.09-2.05 (m, 1H), 1.82-1.43 (m, 1H), 1.43-1.41 (m, 3H), 0.89-0.84 (m, 2H), 0.62-0.58 (m, 2H); LCMS: m/z = 543.25 (M + H)+; HPLC: 95.52%, rt: 6.07 min. 82 1HNMR (DMSO-d6, 400 MHz): δ 12.01 (s, 1H), 11.89 (s, 1H), 10.43 (s, 1H), 8.62-8.61 (d, 1H), 8.31- 8.27 (d, 1H), 8.08-8.05 (m, 1H), 7.70 (s, 1H), 7.58-7.56 (d, 1H), 7.44-7.36 (m, 2H), 6.89-6.79 (m, 1H), 6.48-6.44 (d, 1H), 6.11 (s, 1H), 3.99-3.87 (m, 1H), 3.64-3.61 (m, 1H), 3.10-3.02 (m, 2H), 2.74- 2.68 (m, 1H), 2.67-2.62 (m, 2H), 2.28-2.22 (m, 1H), 2.01-1.94 (m, 1H), 1.84-1.68 (m, 3H), 1.61-1.60 (m, 1H), 1.43-1.41 (d, 3H), 0.89-0.84 (m, 2H), 0.62-0.58 (m, 2H); LCMS: m/z = 524.21 (M + H)+; HPLC: 93.58%, rt: 6.07 -
- To a degassed solution of tert-butyl 3-amino-5-ethyl-1H-pyrazole-1-carboxylate (synthesized similar to intermediate-1-A) (0.5 g, 2.36 mmol) and 1-bromo-3-nitrobenzene (0.571 g, 2.84 mmol) in 1,4-dioxane (20 mL) added Cs2CO3 (1.91 g, 5.92 mmol), stirred the reaction mass for 10 minutes at RT and degassed further for 10 min and added Xantphos (0.136 g, 0.236. mmol) and Pd2(dba)3 (0.108 g, 0.118 mmol). The reaction mass was heated for 4 h at 100° C. in a sealed tube. The reaction mass was cooled and diluted with water and ethyl acetate. The organic layer was separated and the aqueous layer was extracted again with ethyl acetate (2×20 mL). The combined organic layer was dried over anhydrous sodium sulphate and concentrated under vacuum. The crude compound was purified by silica gel column chromatography by eluting with 15% ethyl acetate-hexane to afford the title compound (0.2 g, 35%). LCMS: m/z=333.10 (M+H)+.
- tert-butyl-5-ethyl-3-((3-nitrophenyl)amino)-1H-pyrazole-1-carboxylate (0.2 g, 0.60 mmol) was taken in ethanol, 10% Pd/C (0.05 g) was added and reaction mass was stirred at RT under H2 pressure (40 Psi) for 4 h in a Parr shaker. Reaction mixture was filtered on a celite bed, washed with ethanol and the filtrate was concentrated under vacuum to get the title compound. (0.13 g, 49%) LCMS: m/z=302.8 (M+H)+.
- To a solution of 4-acrylamidobenzoic acid (0.098 g (intermediate-11), 0.52 mmol) in DMF (4 mL), was added HATU (0.245 g, 0.64 mmol) followed by DIPEA (0.2 mL, 1.05 mmol) and finally added tert-butyl 3-((3-aminophenyl)amino)-5-ethyl-1H-pyrazole-1-carboxylate (0.13 g, 0.430 mmol). The reaction mixture was stirred for 12 h at room temperature. The reaction mixture was quenched with ice-water and diluted with ethyl acetate. The aqueous layer was separated and extracted with ethyl acetate (2×25 mL). The combined organic phase was washed with brine, dried over Na2SO4, filtered and concentrated. (0.13 g, 90%). LCMS: m/z=476.2 (M+H)+.
- To a solution of tert-butyl-3-((3-(4-acrylamidobenzamido)phenyl)amino)-5-ethyl-1H-pyrazole-1-carboxylate (0.13 g, 0.33 mmol) in DCM (3 mL), TFA (1 mL) was added at 0° C. The reaction mass was stirred at room temperature for 2 h. The reaction mass was concentrated under vacuum to afford crude compound. The crude compound was purified by silica gel column chromatography by eluting with 10% methanol-DCM, further purified by Preparative HPLC (Method: Column: X-BRIDGE PREP C18 5 MICRON OBD (19 mm×150 mm), Mobile phase: 0.01% NH4OH:Acetonitrile) to afford the title compound (0.030 g, 25%). 1HNMR (DMSO-d6, 400 MHz): δ 11.5 (s, 1H), 10.38 (s, 1H), 9.93 (s, 3H), 8.23 (s, 1H), 7.91 (d, 1H), 7.76 (d, 1H), 7.64 (s, 1H), 7.05-6.98 (m, 3H), 6.46-6.40 (m, 1H), 6.29-6.24 (d, 1H), 5.78 (d, 1H), 5.62 (s, 1H), 2.52-2.50 (m, 2H), 1.16-1.12 (t, 3H); LCMS: m/z=376.10 (M+H)+; HPLC: 92.00%, rt: 3.28 min.
-
- To a degassed solution of tert-butyl 3-(2-(3-bromophenyl)propanamido)-5-cyclopropyl-1H-pyrazole-1-carboxylate (0.45 g, 1.03 mmol) and tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydropyridine-1(2H)-carboxylate (0.42 g, 1.37 mmol) in 1,4-dioxane (20 mL) and water (1 mL) K2CO3 (0.45 g, 3.26 mmol) was added. The reaction mass was stirred for 10 minutes and degassed further for 10 min and added PdCl2(dppf).DCM (0.044 g, 0.05 mmol). The reaction mass was heated for 5 h at 100° C. in a sealed tube. The reaction mass was cooled to room temperature and diluted with water and ethyl acetate. The separated organic layer was dried over anhydrous sodium sulphate and concentrated under reduced pressure, purified the compound by combi flash column by eluting with 70% ethyl acetate-hexane system to afford the title compound (0.3 g, 66%) LCMS: m/z=437.2 (M+H)+.
- TFA (1 mL) was slowly added to a stirred solution of tert-butyl 4-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)phenyl)-3,6-dihydropyridine-1(2H)-carboxylate (0.1 g, 0.22 mmol) in dry DCM (10 mL) under argon atmosphere at 0° C. The resulting reaction mixture was allowed to warm to room temperature and stirred for 1 h. After completion of the reaction, excess solvents were removed under reduced pressure to dryness to afford the title compound (0.13 g title compound as TFA salt). LCMS: m/z=337.1 (M+H)+.
- To a solution of (E)-4-(dimethylamino)but-2-enoic acid (0.063 g, 0.37 mmol) in DMF (5 mL) was added HATU (0.21 g, 0.55 mmol) at 0° C. followed by DIPEA (0.14 mL, 1.11 mmol) and finally added N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3-(1,2,3,6-tetrahydropyridin-4-yl)phenyl)propanamide (0.17 g, 0.37 mmol). The reaction mass was stirred for 1 h at room temperature. The reaction mixture was quenched with ice-water and diluted with ethyl acetate. The aqueous layer was separated and extracted with ethyl acetate (2×25 mL). The combined organic phase was washed with brine, dried over Na2SO4, filtered and concentrated under reduced pressure and further purified by preparative HPLC condition (Column: X-bridge prep C18 5u OBD (19*150 mm), Mobile phase: Ammonia-water) to afford the title compound as free base (0.02 g, 12%); 1HNMR (DMSO-d6, 400 MHz): δ 12.02 (s, 1H), 10.38 (s, 1H), 7.44 (s, 1H), 7.24-7.27 (m, 3H), 6.59-6.66 (m, 2H), 6.13 (s, 2H), 4.15-4.25 (m, 2H), 3.81-3.83 (d, 2H), 3.73-3.74 (m, 2H), 3.4 (s, 1H), 3.03 (s, 2H), 2.14 (s, 6H), 1.79-1.82 (m, 1H), 1.36 (d, 3H), 0.87 (d, 2H), 0.6 (d, 2H). LCMS: m/z=448.2 (M+H)+; HPLC: 98.28%, rt: 5.92 min.
-
- 10% Pd/C was added to a degassed solution of tert-butyl 4-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)phenyl)-3,6-dihydropyridine-1(2H)-carboxylate (0.12 g, 0.28 mmol) in methanol (10 mL). The reaction mixture was subjected to hydrogenation at 45 PSi in Parr shaker for 40 minutes. The reaction mass was filtered through celite bed and washed the celite bed with methanol. The filtrate was concentrated under reduced pressure to afford the title compound (0.11 g, 87%). LCMS: m/z=439.1 (M+H)+.
- TFA (1 mL) was slowly added to a stirred solution of tert-butyl 4-(3-(1-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-1-oxopropan-2-yl)phenyl)piperidine-1-carboxylate (0.11 g, 0.25 mmol) in dry DCM (5 mL) under argon atmosphere at 0° C. The resulting reaction mixture was allowed to warm to room temperature and stirred for 1 h. After completion of the reaction, excess solvents were removed under reduced pressure to dryness to afford the title compound (0.12 g title compound as TFA salt). LCMS: m/z=339.25 (M+H)+.
- To a solution of (E)-4-(dimethylamino)but-2-enoic acid (0.063 g, 0.37 mmol) in DMF (5 mL) was added HATU (0.21 g, 0.55 mmol) at 0° C. followed by DIPEA (0.14 g, 1.11 mmol) and finally added N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3-(piperidin-4-yl)phenyl)propanamide (0.17 g, 0.37 mmol). The reaction mass was stirred for 1 h at room temperature. The reaction mixture was quenched with ice-water and diluted with ethyl acetate. The aqueous layer was separated and extracted with ethyl acetate (2×25 mL). The combined organic phase was washed with brine, dried over Na2SO4, filtered and concentrated under reduced pressure and purified by prep HPLC (X bridge C18 (21.2*150 mm), ammonium hydroxide/water-acetonitrile) to afford the title compound (0.021 g, 9.3%). 1HNMR (DMSO-d6, 400 MHz): δ 11.98 (s, 1H), 10.33 (s, 1H), 7.13-7.21 (m, 3H), 7.05 (d, 1H), 6.51-6.62 (m, 2H), 6.09 (s, 1H), 4.53 (d, 1H), 4.11 (d, 1H), 3.75 (d, 1H), 3.09 (t, 1H), 2.98 (d, 2H), 2.63-2.75 (m, 2H), 2.11 (s, 6H), 1.75-1.77 (m, 3H), 1.44-1.47 (m, 2H), 1.30 (d, 3H), 0.84 (d, 2H), 0.57 (d, 2H); LCMS: m/z=450.0 (M+H)+; HPLC: 98.00%, rt: 6.44 min.
-
- 60% NaH (0.5 g, 20.6 mmol) was added to a stirred solution of 5-methyl-1H-pyrazol-3-amine (2 g, 20.6 mmol) in THF (50 mL) at 0° C. over a period of 10 min followed by the addition of Boc anhydride (4.5 mL, 20.6 mmol). The reaction mass was stirred at room temperature over a period of 2 h. The reaction mass was diluted with ethyl acetate and water. The separated organic layer was dried over anhydrous sodium sulphate and concentrated under reduced pressure, the residue was purified by combiflash by eluting with 30% ethyl acetate-hexane system to afford the title compound (1.8 g, 80%) LCMS: m/z=198.0 (M+H)+.
- To a solution of 2-(3-bromophenyl)acetic acid (0.5 g, 2.32 mmol) in DCM (20 mL) was added EDCI (0.88 g, 0.4.65 mmol) at 0° C. followed by DIPEA (1.12 mL, 6.97 mmol) and finally added tert-butyl 3-amino-5-methyl-1H-pyrazole-1-carboxylate (0.4 g, 2.09 mmol). The reaction mass was stirred for 12 h at room temperature. The reaction mixture was quenched with ice-water and diluted with DCM. The aqueous layer was separated and extracted with ethyl acetate (2×25 mL). The combined organic phase was washed with brine, dried over Na2SO4, filtered and concentrated under reduced pressure and purified by eluting with 20% ethyl acetate-hexane in combiflash to afford the title compound (0.3 g, 60%). LCMS: m/z=395.9 (M+H)+.
- To a degassed solution of tert-butyl 3-(2-(3-bromophenyl)acetamido)-5-methyl-1H-pyrazole-1-carboxylate (0.2 g, 0.5 mmol) and N-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acrylamide (0.166 g, 0.6 mmol) in DMF (2.5 mL) and water (0.5 mL), K2CO3 (0.12 g, 0.81 mmol) was added. The reaction mass was stirred for 10 minutes and degassed further for 10 min and added Bis(triphenylphosphine) palladium(II) dichloride (0.017 g, 0.025 mmol). The reaction mass was heated for 5 h at 100° C. in a sealed tube. The reaction mass was cooled and diluted with water and ethyl acetate. The separated organic layer was dried over anhydrous sodium sulphate and concentrated under reduced pressure and purified by preparative HPLC (Condition: Kinetex Evo, A: 0.1% formic acid in H2O, B: Acetonitrile-methanol) to afford the title compound (0.018 g, 20%). 1HNMR (DMSO-d6, 400 MHz): δ 11.78 (s, 1H), 10.14 (s, 1H), 10.04 (s, 1H), 7.811 (d, 2H), 7.789 (t, 3H), 7.55 (d, 1H), 7.438 (t, 1H), 7.33 (d, 1H), 6.53-6.47 (m, 1H), 6.34 (d, 1H), 6.29 (s, 1H), 5.80 (d, 1H), 3.71 (s, 2H), 2.22 (s, 3H); LCMS: m/z=361.1 (M+H)+; HPLC: 96.04%, rt: 3.39 min.
- The compounds listed in the below table-3 were prepared by procedure similar to the one described in Example-6 with appropriate variations in reactants, quantities of reagents, protections and deprotections, solvents and reaction conditions. The characterization data of the compounds are also summarized herein the table-3.
-
TABLE 3 Compound No. Structure Characterization data 87 1HNMR (DMSO-d6, 400 MHz): δ 11.99 (s, 1H), 10.43 (s, 1H), 10.27 (s, 1H), 7.77 (d, 2H), 7.66-7.60 (m, 3H), 7.50 (d, 1H), 7.38 (t, 1H), 7.32 (d, 1H), 6.49-6.42 (m, 1H), 6.30-6.25 (m, 2H), 5.77 (dd, 1H), 3.90 (dd, 1H), 2.5 (q, 2H), 1.42 (d, 3H), 1.13 (t, 3H); LCMS: m/z = 389.20 (M + H)+; HPLC: 95.10%, rt: 12.02 min. 88 1HNMR (DMSO-d6, 400 MHz): δ 12.06 (s, 1H), 10.45 (s, 1H), 10.26 (s, 1H), 7.78 (d, 2H), 7.76 (t, 3H), 7.51 (d, 1H), 7.40-7.31 (m, 2H), 6.46-6.42 (m, 1H), 6.30-6.25 (m, 2H), 5.77 (dd, 1H), 3.91 (d, 1H), 1.43 (d, 3H), 1.22 (s, 9H); LCMS: m/z = 417.1 (M + H)+; HPLC: 97.51%, rt: 4.38 min. -
- Bromine (1.5 g, 9.4 mmol) in 2M NaOH solution (10 mL) was added drop wise to a suspension of indazole (1.5 g, 12.7 mmol) in 2M NaOH solution (23 mL) at ambient temperature. Stirred the reaction mass for 3 h at room temperature and added sodium bisulfate (0.05 g) followed by the addition of 2N HCl. The solid precipitated was filtered out and washed with water, suction dried followed by in Rotavap under reduced pressure to afford the title compound (2 g, 80%). LCMS: m/z=197.1 (M+H)+.
- 3,4-dihydro-2H-Pyrane (0.42 g, 5 mmol) was added to a solution of 3-bromo-1H-indazole (0.5 g, 2.5 mmol) in ethyl acetate (10 mL) with catalytic amount of PTSA (0.05 g). The resulting reaction mass was stirred and heated to reflux for 5 h. The reaction mass was neutralized with aq. ammonia and diluted with ethyl acetate. The separated organic layer was dried over anhydrous sodium sulphate and concentrated under reduced pressure and purified by silica gel column chromatography by eluting with 5% ethyl acetate-hexane to afford the title compound (0.4 g, 51%) LCMS: m/z=283 (M+3).
- Benzene-1,3-diamine (0.02 g, 0.21 mmol) and 3-bromo-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole (0.05 g, 0.17 mmol) were taken in toluene (15 mL) in a seal tube at room temperature and argon gas was purged for 5-10 min. Then sodium tert-butoxide (0.032 g, 0.34 mmol) and BINAP (0.01 g, 0.017 mmol) were added and the resulting reaction mixture was purged with argon gas for 5 min. followed by the addition of Pd2(dba)3 (0.003 g, 0.003 mmol). The argon gas purging was continued for additional 15 min. before sealing the reaction vial. Then the reaction mixture was heated at 110° C. for 8 h. After completion of the reaction by TLC, reaction mass was filtered through celite and the filtrate was evaporated, the residue was purified by combiflash by eluting with 0-40% ethyl acetate-hexane to afford the desired compound (0.025 g, 56%); LCMS: m/z=309.2 (M+H)+.
- To a solution of 4-aminobenzoic acid (0.052 g, 0.78 mmol) in DMF (10 mL) was added HATU (0.15 g, 0.41 mmol) at 0° C. followed by DIPEA (0.12 mL, 0.96 mmol) and finally added N1-(1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-3-yl)benzene-1,3-diamine (0.1 g, 0.32 mmol). The reaction mass was stirred for 12 h at room temperature. The reaction mixture was quenched with ice-water and diluted with ethyl acetate. The aqueous layer was separated and extracted with ethyl acetate (2×25 mL). The combined organic phase was washed with brine, dried over Na2SO4, filtered and concentrated under reduced pressure and purified with silica gel column chromatography by eluting with 40% ethyl acetate-hexane to afford the title compound (0.07 g, 50%). LCMS: m/z=428.2 (M+H)+.
- (E)-4-bromobut-2-enoic acid (0.32 g, 1.99 mmol) was taken in DCM (20 mL) with catalytic amount of DMF followed by the addition of oxalyl chloride (0.27 g, 2.17 mmol). The reaction mass was stirred for 2 h, concentrated the reaction mass under reduced pressure to residue. Re dissolved the residue in DCM (2 mL) and was added at −5° C. to a mixture of 4-amino-N-(3-((1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-3-yl)amino)phenyl)benzamide (0.42 g, 0.99 mmol) in acetonitrile (10 mL) and DIPEA (0.7 mL, 3.96 mmol). The resulting reaction mixture was stirred for 10 minutes at −5° C. and after completion of the reaction, a solution of N, N-dimethylamine (2M in THF, 1.5 mL, 2.97 mmol) was added and then allowed to stir at room temperature for 12 h. The reaction mixture was quenched with saturated NaHCO3 solution and diluted with DCM. The aqueous layer was separated and extracted with DCM (2×25 mL). The combined organic phase was washed with brine, dried over Na2SO4, filtered and concentrated under reduced pressure and purified the residue with silica gel column chromatography by eluting with 10% methanol-DCM to afford the title compound (0.12 g, 20%). LCMS: m/z=539.3 (M+H)+.
- Methanolic HCl (0.3 mL) was added to a solution of (E)-4-(4-(dimethylamino)but-2-enamido)-N-(3-((1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-3-yl)amino)phenyl)benzamide (0.12 g, 0.20 mmol) in DCM (4 mL) at room temperature and stirred for 2 h, concentrated the reaction mass under reduced pressure. The residue was dissolved in DCM and basified with NaHCO3 solution. The separated organic phase was washed with brine, dried over Na2SO4, filtered and concentrated under reduced pressure and purified using prep. TLC by eluting with 10% methanol-DCM and triturated the resulting compound with ether to afford the title compound (0.012 g, 16%). 1HNMR (DMSO-d6, 400 MHz): δ 11.98 (s, 1H), 10.34 (s, 1H), 10.04 (s, 1H), 8.86 (s, 1H), 8.11 (s, 1H), 7.97 (t, 3H), 7.78 (d, 2H), 7.47 (d, 1H), 7.32-7.38 (m, 2H), 7.19 (t, 1H), 7.11 (d, 1H), 7.02 (t, 1H), 6.76-6.80 (m, 1H), 6.30-6.34 (m, 1H), 3.12-3.14 (m, 2H), 2.08 (s, 6H); LCMS: m/z=455.3 (M+H)+; HPLC: 95.93%, rt: 6.14 min.
-
- NaH (0.89 g, 22.3 mmol) was added lot wise to a stirred solution of 3-amino indazole (2.5 g, 18.6 mmol) in DMF at 0° C., the reaction mass was stirred for 15 min followed by the addition of SEM chloride. The reaction mass was stirred at ambient temperature for 2 h and was quenched with ethyl acetate and ice cold water. The ethyl acetate layer was separated, washed with water followed by brine, dried and concentrated under reduced pressure, purified the crude by combiflash to afford the desired title compound (2.5 g, 50%) LCMS: m/z=264.1 (M+H)+.
- To a solution of 2-(3-bromophenyl)propanoic acid (1.2 g, 5.2 mmol) in DCM (15 mL) was added oxalyl chloride (1.1 mL, 13.1 mmol) dropwise at 0° C. followed by the addition of one drop of DMF. The reaction mass was stirred for 1 h and concentrated under reduced pressure. The resulting crude residue was redissolved in DCM (5 mL) and added to a stirred solution of 1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazol-3-amine (1.38 g, 5.2 mmol) in pyridine (15 mL) and DCM (15 mL) at 0° C. The resulting reaction mass was stirred at ambient temperature for 1 h. The reaction mass was diluted with ethyl acetate and water. The separated organic layer was dried over anhydrous sodium sulphate and concentrated under reduced pressure, the residue was purified by combiflash by eluting with 20% ethyl acetate-hexane system to afford the title compound (1.3 g, 54%) LCMS: m/z=474.4 (M+H)+.
- To a degassed solution of 2-(3-bromophenyl)-N-(1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazol-3-yl)propanamide (1.3 g, 2.7 mmol) and N-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acrylamide (0.92 g, 4.1 mmol) in 1,4-dioxane (15 mL) and water (4 mL), Cs2CO3 (2.72 g, 8.3 mmol) was added. The reaction mass was stirred for 10 minutes and degassed further for 10 minutes and added PdCl2(dppf)2.DCM (0.11 g, 0.13 mmol). The reaction mass was heated for 12 h at 110° C. in a sealed tube. The reaction mass was cooled and diluted with water and ethyl acetate. The separated organic layer was dried over anhydrous sodium sulphate and concentrated under reduced pressure, purified the compound by silica gel column chromatography by eluting with 40% ethyl acetate-hexane system to afford the title compound (1 g, 78%) LCMS: m/z=487.4 (M+H)+.
- TEA (0.34 mL, 2.4 mmol) was added to a solution of 2-(4′-amino-[1,1′-biphenyl]-3-yl)-N-(1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazol-3-yl)propanamide (0.4 g, 0.8 mmol) in DCM (8 mL) at 0° C. The reaction mass was stirred for 5 minutes and added acryloyl chloride (0.088 g, 0.9 mmol) in DCM (1 mL). The resultant reaction mass was stirred for 20 minutes at 0° C., quenched the reaction mass with ice cold water and DCM. The separated organic layer was washed with water followed by brine, dried and concentrated under reduced pressure to afford the title compound (0.4 g crude) LCMS: m/z=541.2 (M+H)+.
- TFA (5 mL) was slowly added to a stirred solution of N-(3′-(1-oxo-1-((1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazol-3-yl)amino)propan-2-yl)-[1,1′-biphenyl]-4-yl)acrylamide (0.4 g, 0.7 mmol) in dry DCM (5 mL) under argon atmosphere at 0° C. The resulting reaction mixture was allowed to warm to room temperature and stirred for 12 h. After completion of the reaction, excess solvents were removed under reduced pressure. The resulting residue was stirred with aqueous NH3 solution (10 mL) for 1 h. The solid separated was filtered and washed with ether and hexane and further purified by preparative HPLC condition (Column: Zorbax C18 (21.2*150 mm), Mobile phase: Acetonitrile-water) to afford the title compound as free base (0.04 g, 13%). 1HNMR (DMSO-d6, 400 MHz): δ 12.65 (s, 1H), 10.53 (s, 1H), 10.26 (s, 1H), 7.78 (d, 2H), 7.73 (s, 1H), 7.65 (t, 3H), 7.54 (d, 1H), 7.39-7.45 (m, 3H), 7.29 (t, 1H), 7.0 (t, 1H), 6.42-6.49 (m, 1H), 6.26 (dd, 1H), 5.77 (dd, 1H), 4.03 (dd, 1H), 1.50 (d, 3H). LCMS: m/z=411.1 (M+H)+; HPLC: 98.43%, rt: 3.95 min.
-
- To a solution of (E)-4-bromobut-2-enoic acid (0.35 g, 2.1 mmol) in DCM (8 mL) was added oxalyl chloride (0.27 mL 2.3 mmol) drop wise at 0° C. followed by the addition of one drop of DMF, stirred the reaction mass for 1.5 h and concentrated under reduced pressure. The resulting crude residue redissolved in DCM (2 mL) and added to a stirred solution of 2-(4′-amino-[1,1′-biphenyl]-3-yl)-N-(1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazol-3-yl)propanamide (0.51 g, 1 mmol) in DIPEA (0.94 mL, 5.3 mmol) and acetonitrile (10 mL) at 0° C. for 20 minutes followed by the addition of 2M N,N-dimethylamine solution in THE (1.3 mL) at 0° C. The resulting reaction mass was stirred at ambient temperature for 12 h. The reaction mass was diluted with DCM and water. The separated organic layer was dried over anhydrous sodium sulphate and concentrated under reduced pressure, the residue was purified by combiflash by eluting with 8% methanol-chloroform system to afford the title compound (0.3 g, 48%). LCMS: m/z=598.1 (M+H)+.
- TFA (5 mL) was slowly added to a stirred solution of (E)-4-(dimethylamino)-N-(3′-(1-oxo-1-((1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazol-3-yl)amino)propan-2-yl)-[1,1′-biphenyl]-4-yl)but-2-enamide (0.3 g, 0.5 mmol) in dry DCM (5 mL) under argon atmosphere at 0° C. The resulting reaction mixture was allowed to warm to room temperature and stirred for 12 h.
- After completion of the reaction, excess solvents were removed under reduced pressure. The crude was purified by preparative HPLC condition (Column: Xbridge C18 (19*150 mm), Mobile phase: Ammonium acetate-Acetonitrile-water) to afford the title compound as free base (0.01 g, 4.2%). 1HNMR (DMSO-d6, 400 MHz): δ 12.64 (s, 1H), 10.52 (s, 1H), 10.17 (s, 1H), 7.75 (t, 3H), 7.62-7.67 (m, 4H), 7.53 (d, 1H), 7.39-7.45 (m, 3H), 7.30 (t, 1H), 6.71-6.76 (m, 1H), 6.28 (d, 1H), 4.03 (d, 1H), 3.06 (d, 2H), 2.18 (s, 6H), 1.51 (d, 3H). LCMS: m/z=468.1 (M+H)+; HPLC: 90.40%, rt: 6.25 min.
-
- To a degassed solution of tert-butyl 5-cyclopropyl-3-(2-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)propanamido)-1H-pyrazole-1-carboxylate (1.5 g, 3.11 mmol) and 6-chloropyrazin-2-amine (0.32 g, 2.49 mmol) in 1,4-dioxane (40 mL) and water (10 mL), Cs2CO3 (2.5 g, 7.69 mmol) was added. The reaction mass was stirred for 10 minutes and degassed further for 10 min and added PdCl2(dppf).DCM (0.17 g, 0.218 mmol). The reaction mass was heated for 12 h at 100° C. in a sealed tube. The reaction mass was cooled to room temperature and diluted with water and ethyl acetate. The separated organic layer was dried over anhydrous sodium sulphate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography by eluting with 15% ethyl acetate-hexane to afford the title compound (1 g, 50%) LCMS: m/z=349.2 (M+H)+.
- (E)-4-bromobut-2-enoic acid (Intermediate-1d, 0.227 g, 1.31 mmol) was taken in DCM (5 mL) with catalytic amount of DMF followed by the addition of oxalyl chloride (0.121 g, 0.95 mmol). The reaction mass was stirred for 1.5 h, concentrated the reaction mass under reduced pressure to residue. Re dissolved the reaction mass in DCM (2 mL) and was added at 0° C. to a mixture of 2-(3-(6-aminopyrazin-2-yl)phenyl)-N-(5-cyclopropyl-1H-pyrazol-3-yl)propanamide (0.30 g, 0.86 mmol) in acetonitrile (5 mL) and DIPEA (0.37 mL, 2.16 mmol). The resulting reaction mixture was stirred for 10 minutes at 0° C. and after completion of the reaction, a solution of pyrrolidine (0.086 g, 1.2 mmol) was added and then allowed to stir at room temperature for 12 h. The reaction mixture was quenched with saturated NaHCO3 solution and diluted with DCM. The aqueous layer was separated and extracted with DCM (2×25 mL). The combined organic phase was washed with brine, dried over Na2SO4, filtered and concentrated under reduced pressure and purified the residue with silica gel column chromatography by eluting with 10% methanol-DCM to afford the title compound (0.01 g, 10%). 1HNMR (DMSO-d6, 400 MHz): δ 12.10 (s, 1H), 11.25 (s, 1H), 10.49 (s, 1H), 9.93 (s, 1H), 9.39 (s, 1H), 8.95 (m, 1H), 8.09 (s, 1H), 7.97-7.95 (d, 1H), 7.53-7.47 (m, 1H), 6.91-6.84 (m, 1H), 6.71-6.67 (d, 1H), 6.11 (s, 1H), 4.09-4.06 (m, 2H), 3.94-3.93 (m, 1H), 3.61-3.55 (m, 2H), 2.79-2.77 (m, 2H), 2.08-1.88 (m, 2H), 1.82-1.77 (m, 3H), 1.44-1.43 (m, 3H), 0.88-0.85 (m, 2H), 0.64-0.62 (m, 2H), LCMS: m/z=485.2 (M+H)+, HPLC: 95.04%, rt: 7.07 min.
-
- (S)-2-(3-bromophenyl)propanoic acid (0.08 g, 0.34 mmol) (synthesis carried out as described in reference WO2014/201073 A1) was taken in 2 mL DCM at 0° C. with catalytic amount of DMF and added oxalyl chloride (0.42 g, 0.34 mmol), allowed to stir the reaction mass at room temperature for 1.5 h. The reaction mass was concentrated under vacuum, and the residue was dissolved in 2 mL of dry DCM and added to a cooled solution of tert-butyl 3-amino-5-cyclopropyl-1H-pyrazole-1-carboxylate (0.078 g, 0.34 mmol) in 2 mL of DCM and TEA (0.086 g, 0.1 mL) at 0° C. The resultant reaction mass was stirred at room temperature for 1 h, after 1 h, the reaction mixture was diluted with DCM then washed with saturated NaHCO3 solution followed by brine solution. The organic layer was dried over anhydrous sodium sulfate, concentrated under vacuum and purified by silica gel column chromatography by eluting with 15% ethyl acetate in hexane to afford the title compound (0.1 g, 53%). LCMS: m/z=436.1 (M+H)+.
- To a degassed solution of tert-butyl (S)-3-(2-(3-bromophenyl)propanamido)-5-cyclopropyl-1H-pyrazole-1-carboxylate (0.1 g 0.23 mmol) and 4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane) (0.087 g, 0.34 mmol) in 1,4-dioxane (5 mL) was added potassium acetate (0.045 g, 0.46 mmol). The reaction mass was allowed to stir for 10 minutes with degassing at RT and added PdCl2(dppf).DCM complex (0.010 g, 0.011 mmol). The reaction mass was heated for 12 h at 100° C. in a sealed tube, cooled the reaction mass and diluted with water and ethyl acetate. The aqueous layer was separated and re-extracted with ethyl acetate (2×5 mL). The combined organic layer was dried over anhydrous sodium sulfate and concentrated under vacuum. The crude was purified by silica gel column chromatography by eluting with 20% ethyl acetate in hexane to afford the title compound (0.065 g, 58%), LCMS: m/z=482.2 (M+H)+.
- To a degassed solution of tert-butyl (S)-5-cyclopropyl-3-(2-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)propanamido)-1H-pyrazole-1-carboxylate (0.065 g, 0.13 mmol) and (E)-N-(5-bromopyridin-2-yl)-4-morpholinobut-2-enamide (0.044 g, 0.13 mmol) in 1,4-dioxane (2 mL) and water (0.1 mL) was added Cs2CO3 (0.084 g, 0.26 mmol). The reaction mass was allowed to stir for 10 minutes with degassing and added PdCl2(dppf).DCM complex (0.005 g, 0.007 mmol), heated the reaction mass for 12 h at 100° C. in a sealed tube. The reaction mass was cooled and diluted with water and ethyl acetate. The aqueous layer was separated and re-extracted with ethyl acetate (2×5 mL). The combined organic layer was dried over anhydrous sodium sulfate and concentrated under vacuum. The crude was purified by silica gel column chromatography by eluting with 10% methanol in DCM (further purified by Preparative HPLC, Column: GEMINI NX C18:21.2 mm*150 mm, A: 0.01% Ammonia, B: ACN/MeOH) to afford the title compound (0.006 g, 8%). 1HNMR (CD3OD-d6, 400 MHz): δ 8.57-8.56 (d, 1H), 8.26-8.24 (d, 1H), 8.04-8.02 (m, 1H), 7.65 (s, 1H), 7.53-7.50 (m, 1H), 7.44-7.39 (m, 2H), 7.00-6.93 (m, 1H), 6.43-6.39 (d, 1H), 6.13 (s, 1H), 3.89-3.88 (m, 1H), 3.73-3.70 (m, 4H), 3.23-3.21 (m, 2H), 2.51-2.48 (m, 4H), 1.86-1.81 (m, 1H), 1.54-1.39 (d, 3H), 0.94-0.92 (m, 2H), 0.68-0.62 (m, 2H); LCMS: m/z=501.1 (M+H)+; HPLC: 96.27%, rt: 5.88 min., Chiral HPLC: 90.84%, rt: 8.87 min.
-
- To a solution of 1-(3-bromophenyl)cyclopropane-1-carboxylic acid (0.4 g, 1.66 mmol) (synthesis carried out as described in references EP1206446 B1; and WO2005/19161A1) in DMF (5 mL) was added HATU (0.94 g, 2.49 mmol) followed by DIPEA (0.86 mL, 4.98 mmol) at 0° C. and finally added tert-butyl 3-amino-5-cyclopropyl-1H-pyrazole-1-carboxylate (0.37 g, 1.66 mmol). The reaction mass was stirred for 15 h at room temperature. The reaction mixture was quenched with ice-water and diluted with ethyl acetate. The aqueous layer was separated and extracted with ethyl acetate (2×25 mL). The combined organic phase was washed with brine, dried over Na2SO4, filtered and concentrated the crude residue was purified by 100-200 silica gel column chromatography to afford desired title compound (0.4 g, 54%). LCMS: m/z=448.0 (M+H)+.
- To a degassed solution of tert-butyl 3-(1-(3-bromophenyl)cyclopropane-1-carboxamido)-5-cyclopropyl-1H-pyrazole-1-carboxylate (0.2 g, 0.45 mmol) and 4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane) (0.25 g, 0.54 mmol) in 1,4-dioxane (10 mL) was added KOAc (0.13 g, 1.35 mmol). The reaction mass was stirred for 10 minutes and degassed further for 10 minutes with argon and added PdCl2(dppf).DCM (0.036 g, 0.045 mmol). The reaction mass was heated for 15 h at 110° C. in a sealed tube. Then the reaction mass was cooled to room temperature and diluted with water and ethyl acetate. The separated organic layer was dried over anhydrous sodium sulphate and concentrated under vacuum and purified by silica gel column chromatography by eluting with 15% ethyl acetate-hexane to afford the title compound (0.2 g, crude) LCMS: m/z=494.2 (M+H)+.
- To a degassed solution of tert-butyl 5-cyclopropyl-3-(1-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)cyclopropane-1-carboxamido)-1H-pyrazole-1-carboxylate (0.2 g, 0.4 mmol) and (E)-N-(5-bromopyridin-2-yl)-4-(pyrrolidin-1-yl)but-2-enamide (0.1 g, 0.33 mmol) (synthesised similar to intermediate 3-B) in 1,4-dioxane (10 mL) and water (2 mL) Cs2CO3 (0.26 g, 0.81 mmol) was added. The reaction mass was stirred for 10 minutes and degassed further for 10 min with argon and added PdCl2(dppf).DCM (0.033 g, 0.04 mmol). Then the reaction mass was heated for 15 h at 110° C. in a sealed tube. The reaction mass was cooled to room temperature and diluted with water and ethyl acetate. The separated organic layer was dried over anhydrous sodium sulphate and concentrated under vacuum and purified by silica gel column chromatography by eluting with 0-5% MeOH-DCM and further purified by preparative HPLC (Method: A: 0.005% TFA in water, B: ACN-MeOH, Column: Kinetex 5μ (150 mm×19.0 mm) to afford the title compound (0.02 g, 10%). 1HNMR (DMSO-d6, 400 MHz): δ 12.01 (s, 1H), 10.90 (s, 1H), 10.85 (brs, 1H), 8.69-8.68 (d, 1H), 8.28-8.26 (m, 1H), 8.16-8.13 (m, 1H), 7.75 (s, 1H), 7.67-7.65 (m, 1H), 7.50-7.42 (m, 2H), 6.88-6.81 (m, 1H), 6.49-6.45 (m, 1H), 6.05 (s, 1H), 3.21-3.18 (m, 2H), 2.55-2.45 (m, 4H), 1.82-1.70 (m, 1H), 1.70-1.68 (m, 4H), 1.45-1.42 (m, 2H), 1.16-1.12 (m, 2H), 0.89-0.84 (m, 2H), 0.62-0.58 (m, 2H); LCMS: m/z=497.3 (M+H)+; HPLC: 93.65%, rt: 4.52 min.
-
- To the solution of 2-(3-bromophenyl)-2-methylpropanoic acid (0.4 g, 1.66 mmol)(synthesis carried out as described in reference US2008/194600A1) in DMF (5 mL) was added HATU (0.94 g, 2.49 mmol) followed by DIPEA (0.86 mL, 4.98 mmol) at 0° C. and finally added tert-butyl 3-amino-5-cyclopropyl-1H-pyrazole-1-carboxylate (0.37 g, 1.66 mmol).
- The reaction mass was stirred for 15 h at room temperature. The reaction mixture was quenched with ice-water and diluted with ethyl acetate. The aqueous layer was separated and extracted with ethyl acetate (2×25 mL). The combined organic phase was washed with brine, dried over Na2SO4, filtered and concentrated the crude residue was purified by 100-200 silica gel column chromatography to afford desired compound (0.15 g, 20%). LCMS: m/z=450.0 (M+H)+.
- To a degassed solution of tert-butyl 3-(2-(3-bromophenyl)-2-methylpropanamido)-5-cyclopropyl-1H-pyrazole-1-carboxylate (0.15 g, 0.45 mmol) and 4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane) (0.1 g, 0.4 mmol) in 1,4-dioxane (10 mL) was added KOAc (0.1 g, 1.0 mmol). The reaction mass was stirred for 10 minutes and degassed further for 10 minutes with argon and added PdCl2(dppf).DCM (0.027 g, 0.033 mmol). The reaction mass was heated for 15 h at 110° C. in a sealed tube. Cooled the reaction mass and diluted with water and ethyl acetate. The separated organic layer was dried over anhydrous sodium sulphate and concentrated under vacuum and purified by silica gel column chromatography by eluting with 15% ethyl acetate-hexane to afford the title compound (0.15 g, 92%) LCMS: m/z=496.3 (M+H)+.
- To a degassed solution of tert-butyl 5-cyclopropyl-3-(2-methyl-2-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)propanamido)-1H-pyrazole-1-carboxylate (0.14 g, 0.28 mmol) and (E)-N-(5-bromopyridin-2-yl)-4-(pyrrolidin-1-yl)but-2-enamide (0.09 g, 0.28 mmol) in 1,4-dioxane (10 mL) and water (2 mL) added Cs2CO3 (0.17 g, 0.56 mmol). The reaction mass was stirred for 10 minutes and degassed further for 10 min with argon and added PdCl2(dppf).DCM (0.023 g, 0.028 mmol), then heated for 15 h at 110° C. in a sealed tube. The reaction mass was cooled to room temperature and diluted with water and ethyl acetate. The separated organic layer was dried over anhydrous sodium sulphate and concentrated under vacuum and the residue was purified by silica gel column chromatography by eluting with 0-5% MeOH-DCM and further purified by preparative HPLC (Method: A: 0.005% TFA in water, B: ACN-MeOH, Column: Kinetex 5μ (150 mm×19.0 mm) to afford the title compound (0.004 g, 2.85%). 1HNMR (DMSO-d6, 400 MHz): δ 11.05 (s, 1H), 9.89 (brs, 1H), 9.49 (s, 1H), 8.68-8.67 (m, 1H), 8.28-8.26 (m, 1H), 8.15-8.12 (m, 1H), 7.65 (s, 1H), 7.659-7.57 (m, 1H), 7.46-7.42 (m, 1H), 7.34-7.32 (m, 1H), 6.85-6.79 (m, 1H), 6.66-6.62 (m, 1H), 6.12 (s, 1H), 3.07-3.05 (m, 2H), 2.5 (s, 4H), 2.00-1.80 (m, 5H), 1.60 (s, 6H), 0.90-0.87 (m, 2H), 0.64-0.60 (m, 2H); LCMS: m/z=499.3 (M+H)+; HPLC: 95.03%, rt: 6.16 min.
- Although the present invention has been illustrated by certain of the preceding examples, it is not to be construed as being limited thereby; but rather, the present invention encompasses the generic area as hereinbefore disclosed. Various modifications and embodiments can be made without departing from the spirit and scope thereof. For example, the compounds in the table-4 below which can be prepared by following similar procedure as described in above Schemes/Examples with suitable modifications known to the one ordinary skilled in the art are also included in the scope of the present invention:
- The ability of compounds to inhibit CDK7 kinase activity was tested in a TR-FRET assay using 5 nM of CDK7/CycH/MNAT1 obtained from Invitrogen, USA. Test compounds were pre-incubated with the kinase at room temperature for 60 min. After the incubation, substrate mix [100 nM Ultra-light MBP (Perkin Elmer, USA) and 1 mM ATP (Sigma)] was added. The above reaction was stopped by the addition of 40 mM EDTA after 60 minutes of kinase reaction. 1 nM Eu-labelled antiphospho-MBP antibody [Perkin Elmer, USA] was added, mixed well and the fluorescence emission at 615 nm and 665 nm [excitation at 340 nm] was measured. The final DMSO concentration in the assay was 1%. For IC50 determination, appropriate concentrations were made by ⅓rd serial dilutions of 10 mM DMSO stock solution of test compound. All the fluorescence measurements were made in a Victor 3 Multilabel Counter [Perkin Elmer, USA]. The IC50 was determined by fitting the dose response data to sigmoidal curve fitting equation using GraphPad Prism software V5. To identify compounds that inhibit CDK7 irreversibly, time depended inhibition studies were carried by pre-incubating compound with the enzyme at three time points (20, 60 and 180 min) and carrying out assay as described above.
- The compounds were screened by the above mentioned assay procedure. The % inhibition at 10 μM concentration and the IC50 values of the compounds are summarized in the table-5 below wherein “+++” refers to an IC50 value less than 0.025 μM, “++” refers to IC50 value in range of 0.025 μM to 0.1 μM and “+” refers to an IC50 value greater than 0.1 μM.
-
TABLE 5 % inhibition and IC50 values Compound % inhibition IC50 No. @ 10 μM (μM) 1 92% ++ 2 69% + 3 99% ++ 4 95% + 5 80% + 6 0% − 7 84% + 8 92% + 9 60% + 10 99% +++ 11 75% + 12 98% +++ 13 97% ++ 14 95% + 15 93% +++ 16 95% ++ 17 80% + 18 95% + 19 97% ++ 20 100% +++ 21 89% + 22 97% +++ 23 98% ++ 24 96% ++ 25 97% ++ 26 96% +++ 27 98% +++ 28 96% ++ 29 97% +++ 30 28% + 31 100% +++ 32 100% +++ 33 97% ++ 34 88% + 35 86% + 36 98% +++ 37 67% + 38 94% + 39 84% + 40 100% +++ 41 90% + 42 98% +++ 43 99% +++ 44 99% +++ 45 89% +++ 46 95% +++ 47 91% +++ 48 90% ++ 49 89% +++ 50 94% +++ 51 90% + 52 91% +++ 53 100% +++ 54 78% +++ 55 95% +++ 56 96% +++ 57 98% +++ 58 90% + 59 99% ++ 60 99% ++ 61 92% + 62 81% + 63 98% ++ 64 94% ++ 65 94% + 66 88% + 67 79% + 68 95% +++ 69 87% ++ 70 81% ++ 71 81% + 72 98% +++ 73 91% + 74 79% + 75 78% + 76 98% +++ 77 98% ++ 78 100% ++ 79 102% +++ 80 95% ++ 81 100% ++ 82 99% ++ 83 62% + 84 88% + 85 74% + 86 48% − 87 89% + 88 62% + 89 45% − 90 83% + 91 84% + 92 86% ++ 93 100% +++ 94 85% + 95 71% +
Claims (24)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/496,452 US20230250062A9 (en) | 2015-06-04 | 2021-10-07 | Substituted Heterocyclyl Derivatives as CDK Inhibitors |
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN2803/CHE/2015 | 2015-06-04 | ||
IN2803CH2015 | 2015-06-04 | ||
IN6214CH2015 | 2015-11-18 | ||
IN6214/CHE/2015 | 2015-11-18 | ||
PCT/IB2016/053267 WO2016193939A1 (en) | 2015-06-04 | 2016-06-03 | Substituted heterocyclyl derivatives as cdk inhibitors |
US201715579246A | 2017-12-04 | 2017-12-04 | |
US16/867,761 US11174232B2 (en) | 2015-06-04 | 2020-05-06 | Substituted heterocyclyl derivatives as CDK inhibitors |
US17/496,452 US20230250062A9 (en) | 2015-06-04 | 2021-10-07 | Substituted Heterocyclyl Derivatives as CDK Inhibitors |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/867,761 Continuation US11174232B2 (en) | 2015-06-04 | 2020-05-06 | Substituted heterocyclyl derivatives as CDK inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
US20220098156A1 US20220098156A1 (en) | 2022-03-31 |
US20230250062A9 true US20230250062A9 (en) | 2023-08-10 |
Family
ID=57440798
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/579,246 Active US10689347B2 (en) | 2015-06-04 | 2016-06-03 | Substituted heterocyclyl derivatives as CDK inhibitors |
US16/867,761 Active US11174232B2 (en) | 2015-06-04 | 2020-05-06 | Substituted heterocyclyl derivatives as CDK inhibitors |
US17/496,452 Pending US20230250062A9 (en) | 2015-06-04 | 2021-10-07 | Substituted Heterocyclyl Derivatives as CDK Inhibitors |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/579,246 Active US10689347B2 (en) | 2015-06-04 | 2016-06-03 | Substituted heterocyclyl derivatives as CDK inhibitors |
US16/867,761 Active US11174232B2 (en) | 2015-06-04 | 2020-05-06 | Substituted heterocyclyl derivatives as CDK inhibitors |
Country Status (20)
Country | Link |
---|---|
US (3) | US10689347B2 (en) |
EP (2) | EP4342540A3 (en) |
JP (3) | JP6750806B2 (en) |
KR (1) | KR20180041112A (en) |
CN (2) | CN113773257A (en) |
AU (3) | AU2016272908B2 (en) |
CA (1) | CA2987552A1 (en) |
CU (1) | CU24496B1 (en) |
DK (1) | DK3302448T3 (en) |
EA (1) | EA037236B1 (en) |
FI (1) | FI3302448T3 (en) |
HK (1) | HK1255239A1 (en) |
HR (1) | HRP20240101T1 (en) |
IL (2) | IL255960B (en) |
LT (1) | LT3302448T (en) |
MX (2) | MX2017015521A (en) |
MY (1) | MY190459A (en) |
PH (1) | PH12017502179A1 (en) |
SI (1) | SI3302448T1 (en) |
WO (1) | WO2016193939A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20220281871A1 (en) * | 2015-03-09 | 2022-09-08 | Aurigene Discovery Technologies Limited | Pyrazolo[1,5-A][1,3,5]Triazine and Pyrazolo[1,5-A]Pyrimidine Derivatives as CDK Inhibitors |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CU24496B1 (en) * | 2015-06-04 | 2021-01-12 | Aurigene Discovery Tech Ltd | PIRAZOLE-3-IL-AMINE DERIVATIVES SUBSTITUTED AS CDK INHIBITORS |
GB201617548D0 (en) | 2016-10-17 | 2016-11-30 | Linnane Pharma Ab | Novel biological factor |
TWI703149B (en) | 2017-11-16 | 2020-09-01 | 美商美國禮來大藥廠 | Compounds useful for inhibiting cdk7 |
JP7319977B2 (en) | 2017-12-06 | 2023-08-02 | リン バイオサイエンス,インコーポレイテッド | tubulin inhibitor |
WO2019148244A1 (en) * | 2018-02-01 | 2019-08-08 | The University Of Sydney | Anti-cancer compounds |
CN111918863B (en) * | 2018-03-29 | 2024-01-05 | 武田药品工业株式会社 | Heterocyclic compounds |
EP3774768A4 (en) * | 2018-04-04 | 2022-01-05 | Aurigene Discovery Technologies Limited | Substituted pyrazole derivatives as selective cdk12/13 inhibitors |
EP3787629A4 (en) | 2018-05-02 | 2022-01-05 | Kinnate Biopharma Inc. | Inhibitors of cyclin-dependent kinases |
CN110590747B (en) * | 2018-06-12 | 2022-03-22 | 隆泰申医药科技(南京)有限公司 | Compound, preparation method, pharmaceutical composition and application thereof |
CN112367991A (en) * | 2018-06-25 | 2021-02-12 | 达纳-法伯癌症研究所股份有限公司 | TAIRE family kinase inhibitors and uses thereof |
TW202016094A (en) | 2018-06-29 | 2020-05-01 | 美商奇奈特生物製藥公司 | Inhibitors of cyclin-dependent kinases |
EP3853225B1 (en) * | 2018-09-17 | 2023-11-29 | Yungjin Pharm. Co., Ltd. | N-(5-(3-(1-((thiazol-2-yl)amino)-1-oxopropan-2-yl)phenyl)pyridin-2-yl)acrylamide derivatives as cdk7 inhibitors for the treatment of cancer |
EP3946288A4 (en) * | 2019-04-01 | 2023-01-11 | Aurigene Discovery Technologies Limited | Substituted 5-cyclopropyl-1h-pyrazol-3-yl-amine derivatives as selective cdk12/13 inhibitors |
CN110845474B (en) * | 2019-11-07 | 2021-01-12 | 四川大学 | Target I-type PRMT compound and preparation method and application thereof |
KR20210116325A (en) * | 2020-03-13 | 2021-09-27 | 영진약품 주식회사 | Pharmaceutical composition for preventing or treating cancer comprising thiazole derivatives or pharmaceutically acceptable salts thereof |
KR102335637B1 (en) * | 2020-03-13 | 2021-12-06 | 영진약품 주식회사 | Novel compounds of inhibiting cdk7, and their pharmaceutically acceptable salts |
TWI783480B (en) | 2020-05-27 | 2022-11-11 | 美商美國禮來大藥廠 | Compounds useful for inhibiting cdk7 |
WO2022130304A1 (en) | 2020-12-18 | 2022-06-23 | Aurigene Discovery Technologies Ltd. | Cocrystal of a cdk inhibitor |
CN117693344A (en) * | 2021-04-27 | 2024-03-12 | 奥瑞珍肿瘤有限公司 | Method for preparing CDK inhibitors |
CA3224189A1 (en) * | 2021-06-16 | 2022-12-22 | Blueprint Medicines Corporation | Substituted pyrimidinyl-pyrazoles as cdk2 inhibitors |
CN117897384A (en) | 2021-06-28 | 2024-04-16 | 缆图药品公司 | CDK2 inhibitors |
WO2023107861A1 (en) * | 2021-12-06 | 2023-06-15 | Exelixis, Inc. | Aminopyrazole derivatives as cdk7 inhibitors for use in treating in cancer |
WO2023224961A1 (en) | 2022-05-16 | 2023-11-23 | Exelixis, Inc. | Cancer therapy using a combination of a cdk7 inhibitor with an oral serd |
CN115093397B (en) * | 2022-06-07 | 2023-09-05 | 自贡市第三人民医院 | Compound for treating tumor, synthesis method and application |
WO2024066984A1 (en) * | 2022-09-30 | 2024-04-04 | 楚浦创制(武汉)医药科技有限公司 | Tricyclic derivative, pharmaceutical composition and use |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS57169465A (en) * | 1981-04-13 | 1982-10-19 | Showa Denko Kk | Pyrazole derivative, its preparation and herbicide |
US6399627B1 (en) | 1999-02-11 | 2002-06-04 | Cor Therapeutics, Inc. | Inhibitors of factor Xa |
GEP20053476B (en) | 1999-08-12 | 2005-03-25 | Upjohn Co | 3(5)-Amino-Pyrazole Derivatives, Process for Their Preparation and Their Use as Antitumor Agents |
EP1320531B1 (en) * | 2000-08-10 | 2010-09-08 | Pfizer Italia S.r.l. | Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
US6455559B1 (en) | 2001-07-19 | 2002-09-24 | Pharmacia Italia S.P.A. | Phenylacetamido-pyrazole derivatives, process for their preparation and their use as antitumor agents |
AU2002215053A1 (en) | 2000-11-27 | 2002-06-24 | Pharmacia Italia S.P.A. | Phenylacetamido- pyrazole derivatives and their use as antitumor agents |
DE10148618B4 (en) * | 2001-09-25 | 2007-05-03 | Schering Ag | Substituted N- (1,4,5,6-tetrahydro-cyclopentapyrazol-3-yl) derivatives, their preparation and use as medicaments |
CA2535359A1 (en) | 2003-08-21 | 2005-03-03 | Merck Frosst Canada Ltd. | Cathepsin cysteine protease inhibitors |
AU2005321091B2 (en) * | 2004-12-30 | 2012-04-12 | Astex Therapeutics Limited | Pyrazole compounds that modulate the activity of CDK, GSK and Aurora kinases |
WO2006070198A1 (en) | 2004-12-30 | 2006-07-06 | Astex Therapeutics Limited | Pyrazole derivatives as that modulate the activity of cdk, gsk and aurora kinases |
CN101146533A (en) | 2005-01-21 | 2008-03-19 | 阿斯泰克斯治疗有限公司 | Combinations of pyrazole kinase inhibitors and further antitumor agents |
US8404718B2 (en) | 2005-01-21 | 2013-03-26 | Astex Therapeutics Limited | Combinations of pyrazole kinase inhibitors |
GT200600457A (en) | 2005-10-13 | 2007-04-27 | Aventis Pharma Inc | DIHYDROGEN PHOSPHATE SALT AS ANTAGONIST OF PROSTAGLANDINA D2 RECEPTOR |
US20110269740A1 (en) * | 2008-07-02 | 2011-11-03 | Ambit Biosciences Corporation | Jak kinase modulating compounds and methods of use thereof |
WO2010007537A1 (en) | 2008-07-17 | 2010-01-21 | Koninklijke Philips Electronics N.V. | Nanopore device and a method for nucleic acid analysis |
CN102264737A (en) | 2008-12-23 | 2011-11-30 | 雅培制药有限公司 | Anti-viral compounds |
FR2943058B1 (en) | 2009-03-11 | 2011-06-03 | Centre Nat Rech Scient | DERIVATIVES OF PYRAZOLO® 1,5-A! -1,3,5-TRIAZINES, THEIR PREPARATION AND THEIR USE IN THERAPEUTICS. |
EP2241619A1 (en) * | 2009-04-17 | 2010-10-20 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Development of fluorescently P-loop labeled kinases for screening of inhibitors |
CA2856291C (en) * | 2011-11-17 | 2020-08-11 | Dana-Farber Cancer Institute, Inc. | Inhibitors of c-jun-n-terminal kinase (jnk) |
EP2909194A1 (en) | 2012-10-18 | 2015-08-26 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
WO2014201073A1 (en) | 2013-06-13 | 2014-12-18 | Bristol-Myers Squibb Company | Macrocyclic factor viia inhibitors |
EP3039021A1 (en) | 2013-08-30 | 2016-07-06 | Ambit Biosciences Corporation | Biaryl acetamide compounds and methods of use thereof |
JP6487430B2 (en) | 2013-10-21 | 2019-03-20 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung | Heteroaryl compounds as BTK inhibitors and their use |
WO2015154022A1 (en) | 2014-04-05 | 2015-10-08 | Syros Pharmaceuticals, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
FR3025075A1 (en) * | 2014-08-28 | 2016-03-04 | Oreal | NEW CARE AND / OR MAKE-UP DEVICE COMPRISING A GEL / GEL ARCHITECTURE COMPOSITION |
US10870651B2 (en) | 2014-12-23 | 2020-12-22 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (CDK7) |
CU24496B1 (en) | 2015-06-04 | 2021-01-12 | Aurigene Discovery Tech Ltd | PIRAZOLE-3-IL-AMINE DERIVATIVES SUBSTITUTED AS CDK INHIBITORS |
-
2016
- 2016-06-03 CU CU2017000154A patent/CU24496B1/en unknown
- 2016-06-03 HR HRP20240101TT patent/HRP20240101T1/en unknown
- 2016-06-03 EP EP23203356.3A patent/EP4342540A3/en active Pending
- 2016-06-03 SI SI201631797T patent/SI3302448T1/en unknown
- 2016-06-03 CA CA2987552A patent/CA2987552A1/en active Pending
- 2016-06-03 US US15/579,246 patent/US10689347B2/en active Active
- 2016-06-03 MY MYPI2017001787A patent/MY190459A/en unknown
- 2016-06-03 DK DK16802673.0T patent/DK3302448T3/en active
- 2016-06-03 CN CN202111184551.4A patent/CN113773257A/en active Pending
- 2016-06-03 KR KR1020187000333A patent/KR20180041112A/en active IP Right Grant
- 2016-06-03 LT LTEPPCT/IB2016/053267T patent/LT3302448T/en unknown
- 2016-06-03 AU AU2016272908A patent/AU2016272908B2/en active Active
- 2016-06-03 EA EA201890001A patent/EA037236B1/en unknown
- 2016-06-03 JP JP2017561810A patent/JP6750806B2/en active Active
- 2016-06-03 CN CN201680045348.XA patent/CN108024970B/en active Active
- 2016-06-03 WO PCT/IB2016/053267 patent/WO2016193939A1/en active Application Filing
- 2016-06-03 EP EP16802673.0A patent/EP3302448B1/en active Active
- 2016-06-03 MX MX2017015521A patent/MX2017015521A/en active IP Right Grant
- 2016-06-03 FI FIEP16802673.0T patent/FI3302448T3/en active
-
2017
- 2017-11-28 IL IL255960A patent/IL255960B/en unknown
- 2017-11-29 PH PH12017502179A patent/PH12017502179A1/en unknown
- 2017-12-01 MX MX2020010484A patent/MX2020010484A/en unknown
-
2018
- 2018-11-09 HK HK18114372.9A patent/HK1255239A1/en unknown
-
2020
- 2020-05-06 US US16/867,761 patent/US11174232B2/en active Active
- 2020-08-03 JP JP2020131775A patent/JP7033764B2/en active Active
-
2021
- 2021-08-04 AU AU2021212016A patent/AU2021212016B2/en active Active
- 2021-09-14 IL IL286428A patent/IL286428A/en unknown
- 2021-10-07 US US17/496,452 patent/US20230250062A9/en active Pending
-
2022
- 2022-02-18 JP JP2022024039A patent/JP7482918B2/en active Active
-
2023
- 2023-06-06 AU AU2023203524A patent/AU2023203524A1/en active Pending
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20220281871A1 (en) * | 2015-03-09 | 2022-09-08 | Aurigene Discovery Technologies Limited | Pyrazolo[1,5-A][1,3,5]Triazine and Pyrazolo[1,5-A]Pyrimidine Derivatives as CDK Inhibitors |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11174232B2 (en) | Substituted heterocyclyl derivatives as CDK inhibitors | |
US11993595B2 (en) | Compounds | |
US10577367B2 (en) | IRAK4 inhibiting agents | |
US11186576B2 (en) | Pyrazolo[1,5-A][1,3,5]triazine and pyrazolo[1,5-A]pyrimidine derivatives as CDK inhibitors | |
US10160753B2 (en) | Indazole compounds as IRAK4 inhibitors | |
JP2020143124A (en) | 1-cyano-pyrrolidine compounds as usp30 inhibitors | |
US20220194924A1 (en) | Substituted 5-Cyclopropyl-1H-pyrazole-3-yl-amine Derivatives as Selective CDK12/13 Inhibitors | |
CN115209952A (en) | Substituted pyrazolopyrimidines and use thereof | |
US20220370431A1 (en) | C-myc mrna translation modulators and uses thereof in the treatment of cancer | |
US20220348560A1 (en) | N-(1h-imidazol-2-yl)benzamide compound and pharmaceutical composition comprising the same as active ingredient | |
BR122023020299A2 (en) | COMPOUND, USE OF A COMPOUND, PHARMACEUTICAL COMPOSITION AND PROCESS FOR PREPARING A COMPOUND |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: AURIGENE DISCOVERY TECHNOLOGIES LIMITED, INDIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SAMAJDAR, SUSANTA;PODDUTOORI, RAMULU;PANDIT, CHETAN;AND OTHERS;SIGNING DATES FROM 20160626 TO 20160704;REEL/FRAME:057813/0422 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
AS | Assignment |
Owner name: AURIGENE ONCOLOGY LIMITED, INDIA Free format text: CHANGE OF NAME;ASSIGNOR:AURIGENE DISCOVERY TECHNOLOGIES LIMITED;REEL/FRAME:063312/0927 Effective date: 20221207 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |